Synergistic and dose rate effects in Boron Neutron Capture Therapy by Phoenix, Ben
SYNERGISTIC AND DOSE RATE EFFECTS IN BORON
NEUTRON CAPTURE THERAPY
by
BEN PHOENIX
A thesis submitted to
The University of Birmingham
for the degree of
DOCTOR OF PHILOSOPHY
School of Physics and Astronomy
The University of Birmingham
March 2012
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Abstract
An investigation of the factors aecting the biological eectiveness of neutron beams suitable
for Boron Neutron Capture Therapy (BNCT) has been carried out. This has focused on two
main areas of current uncertainty. The primary experimental work described in this thesis
concerns the degree of interaction, if any, between biological damage caused by low Linear
Energy Transfer(LET) radiation and that caused by high LET radiation. The second area
investigated concerns the biological impact of delivering a BNCT irradiation at diering
dose rates.
Previously published work by McNally et al [1] suggested that the biological eect of
irradiation with photons and alpha particles together may be greater than suggested by
the combined response to the single elds. This would have implications for BNCT as
treatment irradiations are a mix of dierent radiation qualities. Results of extending the
quasi-simultaneous exposures of McNally et al to truly simultaneous exposures with alpha
particles and photons are presented in this thesis.
In mixed 60Co photon and 238Pu alpha particle irradiations, no synergistic eect was
observed above the response from the separate components. Maximum alpha particle doses
delivered were 2.54 Gy. In mixed 250 kVp X-ray and 238Pu alpha particle exposures, no
synergy eect was seen with 2.54 Gy of alpha particles delivered to the cells. At the 3.18Gy
alpha particle dose level, signicantly lower cell survival was observed than would be pre-
dicted from survival in single elds. The mixed eld data was compared to various published
model treatments of synergistic eect. No model was found to t the mixed eld data, either
presented here or by McNally et al, at all alpha particle dose levels.
The second area of experimental work concerned the dose rate eect in BNCT treatment
beams. The principle that low LET radiation delivered at high dose rates is more biologically
eective, for a given dose, than radiation delivered at low dose rates is well established
[2]. How this principle applies to mixed eld irradiations, such as those found in BNCT
treatments, is less clear.
Dose rate experiments on cell survival in the Massachusetts Institute of Technology
(MIT) Fission Converter neutron beam have been carried out. Cells loaded with boric acid
were exposed to the beam inside a water phantom at dose rate diering by a factor of
approximately 15. A dose rate eect was observed at both of the irradiation depths used,
although this was only clearly signicant at 50 mm depth within the phantom. Analysis of
the data demonstrates that the eect observed was too large to explained solely by a dose
rate eect within the photon component.
Following the same protocol as the MIT experiments, cells were also exposed to the
Birmingham accelerator based epithermal neutron beam in the presence of 50 g per gram
concentrations of enriched boric acid. Survival data collected for the Birmingham beam
were in agreement with previously published work by Gabel et al [3], with no account made
for dose rate eects. This suggests that no signicant dose rate eect was observed at this
boron concentration.
The implications of these results are discussed in the context of clinical applications of
BNCT.
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Chapter 1
INTRODUCTION
Radiotherapy is the use of ionising radiation to treat cancerous tumours. Conventional
external beam radiotherapy is performed using photons and electrons, generated by linear
accelerators in all modern facilities. It relies on precise imaging of the tumour volume,
typically via X-ray Computed Tomography (CT) scans. Doses to tumour are maximised,
while minimising doses to surrounding healthy tissue, via multiple overlapping radiation
elds and manipulating the shape of the elds through the use of multileaf collimators [4].
Recently there has been much development of ion beam sources for use in external beam
radiotherapy. The advantage of ion beams is that they have a very sharp Bragg peak, the
position of which can be tuned using accelerator energy adjustments, allowing very precise
delivery of much of the ions energy in a well dened volume. This makes it possible to
deliver very high tumour doses with reduced doses to healthy tissue.
Boron Neutron Capture Therapy (BNCT) is unusual in that it uses an external neutron
beam combined with an internal chemical agent to provide a radiation dose to a tumour.
As the name implies, the internal agent is a compound containing 10B. This has a very high
capture cross-section for neutrons in the thermal and epithermal energy range as shown in
gure 1.1. The details of the boron capture reaction are shown below:
10B + n  !7 Li+4 He (2:79MeV ) (1.0.1)
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Figure 1.1: Neutron capture cross-section for 10B [5]
10B + n  !7 Li +4 He (2:32MeV ) (1.0.2)
Around 94% of the reactions result in the Li being left in the ground state (1.0.2) [5].
This capture reaction has the advantage that its reaction products have extremely high
Linear Energy Transfer (LET) resulting in very short ranges in tissue. This means that
the dose delivered by each reaction is conned to a few cells, allowing large dierentials
in dose between tissue with high boron concentrations and tissue with low concentrations.
Boron has a further advantage in that its atomic mass is similar to carbon allowing it to be
substituted for carbon in a range of organic compounds. It also has a low toxicity [6].
The targeted nature of BNCT means that it is particularly suited to treating some
types of tumour for which existing treatment modalities are problematic. Particularly of
interest is the treatment of Glioblastoma Multiforme (GBM), the most aggressive form
of glioma [7]. The prognosis for patients with GBM is generally very poor, with median
patient survival of around 12 months. This is largely due to the frequency of tumour
recurrence after surgical resection [8]. This recurrence is common because of the inltration
of otherwise healthy tissue by tumour tendrils. Treatment is complicated by the resistance
of the malignant cells to damage, inability of most treatment compounds to cross the blood
brain barrier, the susceptibility of the brain to damage and the poor repair capacity of brain
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tissue. Maximum doses to tumour of 65Gy, delivered in 2Gy fractions, are required for
conventional treatment. [9] This dose is limited by dose to the healthy brain tissue and
associated toxicity.
1.1 History of BNCT for Glioblastoma Multiforme
The rst clinical trial of BNCT was carried out at Brookhaven National Laboratory(BNL).
Ten GBM patients who had previously had their tumours surgically debulked, were irra-
diated using a thermal beam from the reactor. Borax, delivered intravenously at doses of
up to 200 mg/kg, was used as the boron carrying agent. Five patients received a single
radiation dose, and the remaining 5 were given the treatment in 2 to 4 fractions. Results
were disappointing; there were complications with radiation erosion of the patients scalps
and all patients died from 6 to 21 weeks after treatment [10]. This was a typical survival
time for glioblastoma patients in the 1950s regardless of treatment methodology.
A second series, comprising 9 malignant glioma patients, was treated with a less toxic
borate preparation, sodium pentaborate with D-glucose in the molar ratio 2:1.[11] While
survival times were somewhat improved compared to the rst series, with median survival
rising from 97 to 147 days, there were still signicant problems with radiation damage to
the scalp. Attempts to reduce this with the aid of pressure bandages in later patients
were unsuccessful [12]. In the third series of nine patients treated at Brookhaven, in order
to reduce radiation dose to the scalp, the pentaborate solution was delivered directly to
the internal carotid artery of the tumour-bearing hemisphere of the patients. While these
patients showed no signs of severe radiation dermatitis exhibited by previous groups their
median survival was on a par with group one; 96 days.
The second trial was carried out at the Massachusetts Institute of Technology (MIT)'s
reactor, which had just been constructed. To address the issues with scalp damage patients
in the second trial had the scalp and bone aps which were created in their prior surgery
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turned down to expose tumour containing brain directly to the thermal beam. A new
compound, p-carboxyphenylboronic acid, was used as the boron carrier compound in 16 of
the 18 patients treated. The nal two were treated using sodium perhydrodecaborate. Both
compounds were administered intravenously. These were compounds found to have better
tumour:brain boron ratios in animal models [13].
Again, results were disappointing. All patients died 10 days to 11.5 months after irra-
diation. Poor tumour control was shown and extensive necrosis of brain tissue found in a
number of cases [14].
The extremely poor outcomes of these initial trials can be attributed mainly to the
boron compounds used. They had poor tumour specicity which resulted in large doses
to the healthy brain and critically, the vasculature. It is this dose which likely lead to the
extensive necrosis observed. The problem was compounded by the lack of a rapid diagnostic
method to establish boron levels in the blood. The neutron beams used were also far from
optimal, having a thermal spectrum and exhibiting poor penetration into tissue.
Following these initial trials, in 1968, a large series of clinical studies headed by Hiroshi
Hatanaka was begun in Japan. These were initially based at the Hitachi Training Reactor
(HTR) but eventually irradiations took place at a number of reactor sites across the country.
Sulfhydryl borane (BSH) was used as the boron carrying compound administered via a
slow infusion, usually intra-arterially, but in later cases intravenously. All irradiations were
carried out using a thermal beam with scalp and a skull ap removed. In later cases the void
space after tumour resection was maintained by the insertion of an air lled sphere, normally
a ping pong ball. This allowed for greater thermal neutron penetration into deeper regions
of the tumour. The results from 149 patients, 64 with glioblastoma, are presented in [15].
Analysis by Hatanaka and Nakagawa of various patient sub groups showed improved long
term survival rates over patients receiving conventional treatment. Analysis by Laramore et
al of a small sub-group of patients from the United States, treated in Japan, found results
in line with those expected from conventional treatment with no improvement attributable
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to BNCT [16].
Improvements in boron compounds through the 1980's, such as the development of
boronophenylalanine-fructose, spurred further trials worldwide. These new compounds ex-
hibited both low toxicity and high tumour:normal tissue boron ratios [17]. Development of
treatment facilities to deliver neutrons at epithermal (1 eV to 10 keV) energy levels instead
of thermal energy levels was also carried out. This increase in beam energy results in higher
doses at clinically relevant depths in tissue while reducing skin doses.
Between 1994 and 1999 at the Brookhaven National Laboratory (BNL) 53 patients
were treated using a newly epithermal neutron beam. The boron compound used was
BPA-fructose. Treatments with varying numbers of elds and at dierent dose levels were
performed [18]. The initial 37 subjects treated had similar clinical outcomes to historical
controls with minimal side eects [19]. Problems with side eects such as Central Ner-
vous System(CNS) toxicity, increased as the dose was escalated. The time to progression
and survival of subjects in the later protocols, with higher doses and multiple elds, did
not compare favourably with historical controls. This lack of positive correlation between
favourable clinical outcomes and increasing exposure was taken as indirect proof that ben-
ets from BNCT may be realised at low neutron exposures. This study also exposed the
main issue with BPA-fructose; it's poor solubility. This lead to requirements for very large
volumes of uid to patients and some instances of the compound crystallising out of solution
[18]. Over the same time period as the BNL study a phase I trial at MIT, with 22 patients
treated, was carried out. While some toxicity eects were observed results were generally
good. Of the 17 patients for whom Magnetic Resonance Imaging (MRI) follow up studies
were available, 11 exhibited marked reduction in tumour volume [20].
Since 2005 the bar has been signicantly raised when comparing BNCT results to clinical
outcomes from standard treatment. This is due to the widespread adoption of temozolomide
as a chemotherapy agent in the treatment of GBM. Results from Stupp et al [21] compar-
ing temozolomide plus radiotherapy to radiotherapy alone, in a randomised study of 573
5
patients, can be seen in gure 1.2.
Figure 1.2: Clinical trial data for conventional radiotherapy treatment of GBM with and without
temozolomide, taken from [21]
Over the past decade a number of further BNCT for GBM trials have been carried out
worldwide. At the R2-0 research reactor at Studsvik, Sweden 30 patients were irradiated in
a Phase II trial. BPA-fructose was given to patients at higher levels than ever before; doses
of 900 mg kg 1 [22]. Results demonstrate that BNCT oers a treatment that is at least
as eective as conventional radiotherapy alone. Further analysis suggests that for patients
with poor response to telozolomide a possible clinical advantage of BNCT over combined
telozolomide and radiotherapy was suggested [23]. A small phase I study on the LVR-15
reactor in the Czech Republic has been carried out, using BSH as the boron agent and
assessing the limiting toxicity of the BNCT treatment [24]. Five patients received BSH and
were exposed to the epithermal beam. Tolerance appeared good but patient numbers were
not high enough to form denitive conclusions.
Extensive clinical work has been carried out at the FIR-1 reactor in Helsinki, Finland.
BPA-Fructose was used as the boron loading agent and patients were exposed to an ep-
ithermal beam. Initial results from Joensuu et al were presented in [25] and appeared to
demonstrate eectiveness at least equal to conventional treatments. Studies are still ongo-
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ing with the facility treating around 1 patient a week, mainly with head and neck cancer
or recurrent GBM. A number of BNCT clinical projects are still underway in Japan with
recent clinical results being published by Yamamoto et al for irradiations, with BSH, on
the Japan Research Reactor 4 [26]. Outcomes were consistent with those of conventional
radiotherapy treatments. Current work from Yamamoto's group focuses on conventional
photon therapy combined with BNCT. Twenty one newly diagnosed GBM patients have
been treated with BNCT at the Kyoto University Reactor (KUR) utilising a combination
of BPA and BSH as the boron carrying agents. Of the 21, 10 received BNCT alone while
11 received a combination of BNCT and conventional radiation therapy. THe BNCT alone
group had a median survival of 15.6 months. The mixed group had a median survival of
23.5 months [26].
Another current trial is at the recruiting stage in Taiwan. This will be a study treating
recurrent head and neck cancers using BPA and the Tsing Hua Open-Pool Reactor (THOR)
epithermal neutron beam [27]. It is based at the Taipei Veterans General Hospital.
The future of BNCT is reliant on further development of the boron containing com-
pounds. Current clinical work focuses on improving the uptake and retention of these
compounds. Human pharmacokinetic and laboratory base trials at the University Hospital,
Birmingham of BPA with Mannitol, a compound which disrupts the blood-brain barrier,
along with various pre-loading and administration strategies are ongoing and are showing
promising results. Patients in the cohorts receiving an additional mannitol bolus are showing
approximately double the boron levels, in their extra cellular uid of the brain, compared
to the group which did not receive a bolus. The levels in the rst patient to receive the
additional mannitol and have BPA administered interarterially appear to show a further
doubling, that is four times that found in the no bolus and conventionally administered
BPA group [28].
Clinical application will be facilitated by the drive towards suitable accelerator sources
for hospital based treatment. Such accelerators are under development worldwide and some,
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such as the newly completed Cyclotron-Based Epithermal Neutron Source (C-BENS) [29]
are likely to enter the clinical trial phase over the next few years.
1.2 Dose eect uncertainties in BNCT
1.2.1 Beam composition and synergistic eects
All neutron beams, regardless of source, consist of a mix of neutrons with other radiation
types. This includes photons, both from the initial neutron production mechanism and
capture within various materials. There is also likely to be a signicant proton dose from
capture reactions. In the case of BNCT neutrons not captured in the boron also provide
additional dose. These neutrons have a range of energies. The largest capture reaction
contributors to dose are likely to be from nitrogen and hydrogen, both abundant in tissue.
These are detailed below;
1H + n  !2 H +  (2:25MeV )
12N + n  !12 C + p (580keV )
Relative Biological Eectiveness (RBE) factors have been determined, albeit with large
uncertainties, for the individual components [30]. However, these take no account of any
possible interaction between the dierent components, which could result in a greater bio-
logical eect than would be the case for independent action of the dierent radiation types
present. What the eect of such interactions, if any, would be is not clear. Such interactions
would introduce treatment planning complexity and make the comparison of clinical results
between facilities problematic. There have been a number of publications reporting the ef-
fects of mixed radiation elds. Unfortunately the evidence is not clear, with many authors
reporting synergism [31][32][33][34] [35][36][1][37] and others no eect [38][39][40][41]. In
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some cases experimenters have used sequential irradiations, neutrons followed by X-rays for
example, while in just a few cases have experimenters used truly simultaneous irradiations
as would be the case in BNCT. A literature review of work in this area can be found on
page 47.
1.3 Boron Compounds for BNCT
BNCT relies on delivery of boron containing agents to the tumour tissue to be treated; levels
of at least 20 g of boron per g [42] must be achieved. It also requires a clear dierential in
boron levels in tumour vs levels in healthy brain and blood. These levels and ratio of boron
level in tumour to healthy tissue must be maintained over the course of the irradiation. Initial
BNCT clinical trials used sodium tetraborate (borax) as their boron delivery agent [43] [44].
This compound was inexpensive, readily available and had low toxicity. Unfortunately it
had poor tumour targeting and washed out of cells quickly. It is thought that this played
a large role in the unsuccessful outcome of the early trials. Eorts were quickly undertaken
to nd more suitable compounds.
An amino acid, p-boronophenylalanine (BPA), was synthesised in the late 1950's with
BNCT applications in mind [45]. It's structure is shown in gure 1.3. Early compound
screening eorts were concerned with compounds which accumulated in tumours but could
Figure 1.3: The p-boronophenylalanine (BPA) molecule
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not cross the blood brain barrier into normal brain tissue. This lead to BPA being initially
rejected as a therapeutic compound as it readily crossed over. However, the similarity of
BPA to melanin precursors lead to it's application in treatment of melanomas after it was
shown to accumulate preferentially in melanoma cells[46]. Following this work, Coderre and
co-workers demonstrated rstly that BPA was accumulated by non melanoma tumour cells
[47], and subsequently control of gliosarcomas in a rat model [48]. The accumulation of
BPA in the tumour appears to be related to the increased rate of amino acid transport at
the cell membrane. Studies such as [49] demonstrated an incorporation rate in tumour four
times that in healthy tissue. Preferential accumulation was also demonstrated in tumour
cells away from the main tumour body. Accumulation in such inltrating cells is necessary
for successful treatment of tumours such as glioblastoma multiforme and is likely related
to the ability of BPA to cross the blood brain barrier. BPA has since been used in human
clinical trials of BNCT all over the world.
More recent work on BPA has concentrated on the uptake mechanism and implications
this may have in therapeutic applications. A number of researchers [50] [51] [52] have data
that suggest that the BPA uptake is directly related to cell replication, with the quiescent
cell population not actively taking up boron. If this is the case in glioblastoma multiforme
typically only around 10% of the tumour cell population will be in cycle and taking up BPA
[53]. As the boron reaction product range is low, only a small fraction of the tumorous
cells will receive the prescribed dose and treatment is unlikely to be successful. At variance
with this conclusion is a study by Detta and Cruickshank et al [54] at Birmingham. This
work focuses on the role of L-Amino Acid Transporter-1 (LAT-1) in BPA uptake. Cell from
fresh tumour explants were labelled for proliferating cell nuclear antigen (PCNA), which
is an antigen that is expressed in the nuclei of cells during the DNA synthesis phase of
the cell cycle. They were also labelled for LAT-1 expression. It was found that PCNA
expression and LAT-1 expression were independent, with on average 70% of the tumour
cells expressing LAT-1. In addition, it was found that BPA uptake was inhibited by LAT-1
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Figure 1.4: The sulfhydryl borane(BSH) molecule
dependent substrates and known inhibitors. These results indicated that this transporter
plays an important role in BPA uptake in glioma cells. It also demonstrated that, for
successful clinical outcomes, the on average 30% of tumour cells which do not take up
BPA must be targeted using a dierent methodology.
The other boron compound which has seen widespread clinical interest and application
is sulfhydryl borane (BSH), pictured in gure 1.4. Like BPA, BSH was rst considered for
use in BNCT in the 1960's [13]. Unlike BPA, BSH is unable to cross the blood brain barrier.
Accumulation is still possible in intracranial tumours, via diusion from blood, as they lack
a complete blood brain barrier. Tumour to normal blood boron ratios of 1.3:1 to 2:1 have
been demonstrated in patients for BSH [55]. Boron levels in inltrating cells are much lower
than in the main tumour mass.
Future compounds for BNCT are still being actively developed, with the compounds of
most current interest being groups of boron loaded porphyrins and liposomes [56]. These
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have shown large tumour to healthy brain uptake ratios in rat models, 30 or more in some
cases [57]. Development is a long process and potential clinical eectiveness of compounds
is hard to asses without data for distribution of the boron which is taken up, both at a gross
tissue level and on a cellular scale.
Bioavailability of the boron compound used and their half life after delivery is a big
consideration. While this is somewhat dependant on the compound, some work has been
carried out utilising varied delivery mechanisms and blood brain barrier disruptors in order
to maximise the amount of compound available for uptake by tumorous cells [58]. Clinical
work is ongoing in this area at Birmingham [59] with a new BPA-Mannitol formulation, as-
sessing the eects of inter-arterial delivery and giving the compound along with an additional
Mannitol bolus.
It has also been demonstrated in animal tumour cell models [60] that pre-loading with
compounds such as L-tyrosine can stimulate uptake of BPA. An extension of this work, in
explanted human tumours, is currently being undertaken at Birmingham.
In dose response cell biology studies of BNCT the compound of choice is generally boron-
10 enriched boric acid. As the accumulation ratio, the ratio of boron in cells to growth
medium, is unity for boric acid [61] the boron levels inside the cells is easily determined.
This allows the dose from boron capture to be calculated easily. Boric acid was used in all
of the boron loaded cell survival experiments detailed in this report.
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1.4 Neutron Sources for BNCT
In order to deliver the doses required for BNCT over a reasonable time period a high neutron
ux is required; approximately 109ncm 2s. Realistically this restricts the choice of sources
to either a ssion reactor or a high current particle accelerator with a suitable target. The
spectrum of the neutron ux is also a design concern. Thermal neutrons, with an energy of
approximately 0.025 eV, are required at the treatment depths. This requires irradiation with
epithermal neutrons, energy from approximately 1 eV to 10 keV, with the nal moderation
down to thermal energies happening inside tissue. The range of neutron energies in a reactor
is very large. Figure 1.5 shows the prompt ssion spectrum for thermal ssion of uranium-
235, with a probability peak at 0.7 MeV and an average of 2MeV. Other isotopes present
in the reactor have dierent ssion spectra and there are contributions from fast ssion
and delayed neutrons. Typically a BNCT beam will have a combination of lters, which
capture neutrons outside of the desired energy range, and moderating material. A suitable
material for moderation has a very low capture cross section for neutrons, a high scattering
cross section and consists of light nuclei leading to large energy losses in each collision. The
moderator assembly will also contain materials designed to reduce the gamma ray component
of the beam, as large amounts are produced in the reactor core directly from ssion, from
neutron capture reactions and from decay of ssion daughter products.
The BNCT beam at the MITR-II is unusual in that it does not use neutrons directly from
the core. Instead, leakage neutrons from the core are incident on an array of 11 MITR-II
fuel elements held in a tank to one side of the core; see gure 1.6. This assembly is separated
from the core by a system of shutters allowing a beam which is easily switchable without
aecting normal reactor operation. This beam assembly was specically designed for BNCT
and has very low gamma and fast neutron contamination of the beam. It also has a purpose
built patient irradiation room shown in gure 1.7. While this beam was not designed to
have a variable dose rate, it is possible to reduce the dose rate by not fully opening the
shutter. This allows for a change in ux without a change in beam spectra. Due to the
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Figure 1.5: Prompt ssion neutron energy spectrum for thermal ssion of uranium-235 from [62]
Figure 1.6: Isometric view of the MIT BNCT beam facility [63]
Figure 1.7: Inside of the MIT treatment room [64]
14
nature of a low energy neutron beam and the large distance between the shutter and the
beam aperture, the beam prole across the aperture remains at even for a small shutter
opening.
All clinical trials of BNCT carried out so far have used reactors as a source of neutrons.
Reactors can produce extremely large uxes and are very reliable, however they are extremely
expensive, large and have a poor public perception. These factors suggest that accelerators
are more suitable for an in hospital application of BNCT. With the widespread adoption
of linear accelerators for photon therapy, and now synchrotrons and cyclotrons for proton
and carbon ion therapy, there is also greater clinical experience with and acceptance of
accelerators. An accelerator design would use a proton beam onto a light nuclei target
surrounded by an appropriate moderator assembly. Birmingham's Dynamitron accelerator
would be typical of accelerators designed for this application. A 2.8MeV, 1mA proton beam
is used to irradiate a 4cm diameter thick lithium target on a copper backing, which is cooled
by a submerged jet heavy water system. The cooling system is the ultimate limit of beam
power as lithium has very poor thermal properties. Work is ongoing at various sites to
manufacture circulating liquid lithium targets to solve these issues [65]. Birmingham are
currently (March 2012) in the process of testing a potential upgrade to their target cooling
system to cope with loads of 15 kW+ utilising a novel `binary ice cooling system'. This makes
use of a suspension of ice crystals of tens of m in volume, suspended in water containing a
freezing point depressant.
Neutrons are generated by the Li(p,n) reaction. Neutron energies are dictated by the
kinematics of the neutron source reaction and are therefore known; 820 keV at 90 and
1.2 MeV at 0. This low peak neutron energy allows for an extremely compact moderator
and lter assembly when compared to a reactor beam. There is also intrinsically a much
lower gamma component to the beam. The moderator assembly is pictured in gure 1.8;
the assembly is an approximately 75 cm cube.
While the dose rates of the Birmingham and MIT beam are dierent by a factor of
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Figure 1.8: Schematic of the Birmingham lter-moderator assembly [66]
15 or more, the dose components delivered to tumour are similar as both are close to the
ideal for BNCT, that is, maximum epithermal neutron delivery while minimising all other
components. This is illustrated by gure 1.9.
A dierent approach to accelerator based BNCT is being pioneered by Kyoto University
and Sumitomo Heavy Industries in Japan. Rather than a dynamitron, a 30 MeV cyclotron
with a water cooled beryllium target is being utilised. Commissioning is complete and initial
radiobiology studies are in progress [67].
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Figure 1.9: Dose proles for MIT and Birmingham treatment beams. Boron values are 15 g
per g and 52.5 g per g in normal and tumour tissues, respectively. Birmingham prole from [66],
MIT from [64]
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1.5 Scope of this thesis
While considerable progress has been made in the clinical application of BNCT the number
of patients irradiated at any one site, with an identical beam, has remained relatively small.
The complex biological eect of a mixed eld beam makes direct intercomparison of these
results dicult. This also hampers the application of lessons learned at one BNCT facility to
others. It is clear that further work on the fundamental biology which dictates the response
to a given BNCT treatment beam is required.
The two major uncertainties that remain when considering doses delivered in BNCT are
the inuence of the dose rate eect and any synergistic interaction between dierent beam
components.
Currently dose rate eect is solely accounted for by an estimated `Dose Reduction Factor'
applied to the gamma ray proportion of the beam. This is factor that weights the gamma
fraction of the beam, typically by 0.5-0.7 [27] [68] [69] to account for the reduction in eect
by giving the gamma rays at a low dose rate. The dose rate is substantially lower in most
cases than the 5Gy min 1 used in modern x-ray radiotherapy. This magnitude of this dose
rate factor is derived by considering the response of cell lines, such as HeLa, to dierent
dose rates of photons [70].
A direct dose rate eectiveness comparison for all combined beam components has not
been carried out. This study attempts to address this, presenting the results of a measure-
ment campaign carried out at the MIT reactor at two dose rates.
The power of the MIT Fission Converter Beam (FCB) can be varied by adjusting the
position of a beam shutter. This allows the beam dose rate to be varied while leaving the
other beam characteristics the same, something which would not necessarily be the case if
the beam power was altered by controlling the power level of the reactor itself. The potential
to vary the dose rate in this manner makes it unique among reactor based BNCT beams.
V79 cells were irradiated, in the presence of boric acid, at full beam dose rate and a rate of
approximately 1/15th of the full dose rate. The details of this experiment are described in
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chapter 4. In addition to the MIT data, the result of cell irradiations using the Birmingham
Dynamitron accelerator beam are also presented.
The work of McNally et al [1] and others suggests that when alpha particles and photons
are delivered together the resulting biological eect is greater than might be expected from
the two radiations delivered separately. This has implications for clinical BNCT, where a
large fraction of the dose is delivered by alpha particles combined with photons. Relative
biological weighting factors for beam components have been derived assuming no interaction
between the dierent radiation qualities. Using a unique irradiation set-up at the Medical
Research Council, cell survival experiments with controlled doses of photons and alpha
particles delivered truly simultaneously have been carried out for the rst time. The results
will be presented here and discussed in the context of BNCT.
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Chapter 2
BASIC RADIOBIOLOGY CONCEPTS AND
METHODOLOGY
2.1 Biological Eect of Ionising Radiation
As the name suggests, ionising radiation is radiation which is capable of forming ions within
the material being studied. The various types of radiation encountered in radiotherapy and
radiobiology interact with tissue and lead to ionisation events in dierent ways.
Photons interact with matter via a number of dierent mechanisms dependant on their
incident energy. At low energies, the photoelectric eect is dominant. The incident photon
is absorbed by an atom and an energetic photo-electron is ejected. This electron will have
an energy equal to the dierence between the energy of the incident photon and the binding
energy of the electron in its original shell. For high enough energy electrons the most
probable origin for photo-electrons is the most tightly bound shells, the K shell of the
atom. As the absorber atom is now in an ionised state with a vacancy in a bound shell,
which is lled via absorption of a free electron and/or rearrangement of electrons within the
shells, photoelectric absorption can lead to the emission of further photons in the form of
characteristic X-rays.
At higher energies Compton scattering is the dominant mechanism. This interaction
takes place between the incident photon and an electron of the material it is incident upon.
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Figure 2.1: Compton scattering (from [71])
The gamma ray is deected through some angle, , with respect to its original direction and
transfers some of its energy to the electron. As any scattering angle is possible, the energy
transfer can be anything from zero to a large proportion of the original gamma ray energy.
The two extreme scattering cases are at  = 0, where very little of the gamma ray
energy is transferred, and  =  where the gamma ray is backscattered and the maximum
energy possible in a single interaction is transferred (gure 2.1). Normally all scattering
angles are possible and a continuum of energy transfer ranging from zero to this maximum
is observable.
Electrons ejected in the various photon interactions can themselves lead to further ioni-
sation events.
Charged particles travelling through a medium primarily interact via Coulomb scattering
with orbital electrons. In the case of light particles such as electrons, these interactions can
cause large deections in the path of the particle and large losses of kinetic energy by the
incident electron.
Using a conservation of energy/momentum argument it can be demonstrated that, in a
head-on elastic collision between a heavy particle, such as an alpha, and an electron, the
proportion of kinetic energy lost by the heavy particle is small. For a 5 MeV alpha particle
it is 2.7 keV ([5]). It follows that many such collisions are required to slow the heavy particle
signicantly. In a glancing collision the heavy particle will only be deected by a very small
amount. This means that heavy particles tend to follow more or less straight paths.
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Figure 2.2: Energy loss of 1.46 MeV alpha particles with distance in water. Calculated in
SRIM[72]
As the means of interaction of charged particles is the Coulomb force, which has an
innite range, the particles interact simultaneously and continuously with many electrons
along their path. This leads to charged particles having a well dened mean range. In
BNCT this is particularly important as it means that the alpha particle and lithium nucleus
produced in the boron capture reaction have a short, well dened range of a few cell diameters
at most and produce many ionisation events along their short track.
How the energy is deposited along the track is important; higher amounts of energy
deposited are equivalent to higher numbers of ionisation events. As the interaction cross
section rises as energy decreases, large proportions of the particles energy are deposited
towards the end of it's path. This can be seen clearly in a plot of energy loss with distance,
or Bragg curve, as in gure 2.2.
As they are uncharged, neutrons interact with the nuclei of material directly via a series
of elastic scattering reactions. Energy is lost by the incident neutron in each collision, with
energy transferred depending on the mass of the scattering nucleus and calculable through
simple conservation of momentum. As the velocity of the neutrons reduces to thermal levels
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(0.025 eV), capture reactions become dominant. The products of these capture reactions
cause further ionisation events.
2.1.1 Linear Energy Transfer (LET)
Linear energy transfer is dened as the average energy deposited by a particle per unit length
of its track in a given material. High LET particles have tracks with more densely clustered
ionisation events and cause damage which is harder for cells to repair; see gure 2.3.
Figure 2.3: Ionisation events across a DNA double helix, low vs high LET [73]
In reality LET is an average value and particles with a given LET have a wide range of
energies.
2.1.2 Relative Biological Eectiveness (RBE)
Relative biological eectiveness is a measure of the eect on a biological system of a type
of radiation, relative to some reference radiation. It is always given for a specic endpoint
(eect). Normally, the reference radiation used is 250 kV X-rays.
RBE =
Dose of reference radiation
Dose of test radiation
(2.1.1)
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Figure 2.4: Measured RBE compared with particle LET in V79, CHO and T1 cell lines. Taken
from [74]
RBE tends to increase with LET. This is to be expected as low LET, sparsely ionising,
radiation produces damage which is more readily repaired. However there is a peak value of
LET above which RBE no longer increases; above this value each cell exposed is experiencing
more ionisation events than are required to bring about cell death. This can be seen clearly
in gure 2.4 which compares particle LET with a wide range of experimentally determined
RBE's.
As it is derived from a set of experimental results it is important to dene exactly the
doses, end point used and all other experimental factors when using a given RBE [75].
A calculated RBE only applies at the dose point it was calculated at; RBE tends to
decrease with increasing dose. This is illustrated for typical alpha particle survival responses
in gure 2.5.
This can be particularly important in all areas of high LET radiotherapy, with doses
delivered in a number of fractions, particularly when the dose per fraction is varied, as
a naive application of RBE can lead to patients receiving a higher equivalent dose than
intended. In order to account for this eect and allow biologically meaningful calculations
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Figure 2.5: Variation of RBE with alpha particle dose. Calculated for the alpha particle / X-ray
data presented in reference [1]
to be made the concepts of RBEmax and RBEmin have been introduced [76].
RBE of a high LET irradiation is derived from the dose to produce a given biological
eect, compared to a low LET irradiation. For a single dose;
LdLLd
2
L = HdHHd
2
H (2.1.2)
Where d is dose, alpha and beta are constants and the H and L subscripts refer to high
and low LET radiations respectively. RBE is at a maximum when dose is close to zero and
the quadratic terms become negligible;
LdL = HdH (2.1.3)
RBE ! RBEmax = dL=dH = H=L (2.1.4)
RBE is at a minimum when doses are large, and the quadratic terms dominate;
Ld
2
L = Hd
2
H (2.1.5)
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RBE ! RBEmin = dL=dH =
p
H=L (2.1.6)
The assumption of the Theory of Dual Radiation Action (TRDA)[77] is that  is con-
stant with LET and that RBEMin is therefore unity for all radiation types. This has been
challenged via analysis of various cell survival experiments [78] [79] but the generalised trend
of RBEmin with LET is not yet clear.
2.1.3 Compound Biological Eectiveness (CBE)
The concept of RBE is valid only when the quantity absorbed dose can be dened, that is
when the averaging implied by energy deposited per unit mass is applicable. For the boron
dose in BNCT the concept of absorbed dose is not valid because of the inhomogeneous
distribution of the boron compounds and the short range of the boron capture reaction
products. Therefore the RBE cannot be dened and the inuence of an inhomogeneous
distribution of the boron atoms cannot be determined.
Only the product of two components, RBE and boron distribution, can be assessed for
a given experimental system. It is therefore standard to refer to `Compound Biological
Eectiveness' (CBE) [80] when discussing weighted doses in BNCT. This is dened as the
true, geometry-independent, RBE for the boron capture particles multiplied by some factor
unique to a given tissue type and boron compound. Given CBE's relationship to RBE, CBE
values also vary with dose.
To date all clinical BNCT treatments have been given in small numbers of large, high
dose, fractions and have used xed values of CBE in their treatment plans.
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2.2 Dose rate eects
Low LET radiation that is delivered at high dose rates has a larger biological eect than the
same low LET radiation delivered at lower dose rates. There are two separate mechanisms
responsible for this eect. The classical dose rate eect is the result of sub-lethal radiation
damage being repaired over the course of a long irradiation. The second potential dose rate
eect mechanism is due to cell proliferation over the course of the radiation exposure. If the
exposure is long relative to the length of the mitotic cycle cell births may partly cancel out
cell deaths. The dose rate eect is illustrated in gure 2.6, with the same cell line exhibiting
markedly dierent responses to the same dose delivered at diering rates.
The magnitude of the dose rate eect varies with cell line. This can be understood with
reference to the Linear-Quadratic model of cell survival discussed in section 2.3.2. For single
event killing, represented by e D in the linear quadratic model, no repair is possible. In
the case of two event killing, initial sub-lethal damage is compounded into lethal damage by
a second ionising event. As the initial damage is repairable the amount of lethal two event
damage is dictated by the frequency of ionising events in some critical volume. This implies
that cells with small  /  ratios will exhibit more of a dose rate response than cells with
large  /  ratios.
Dose rate eects in tumour tissue tend to be much smaller than that exhibited in healthy
tissue. Tumours normally have high  /  ratios in the range 6-14 Gy while low  /  values
of 1.5-5 Gy have been observed for late responding normal tissues [82]. A tumour line with
minimal dose rate response is shown in gure 2.7
No dose rate eect is seen with high LET radiation; it is normally assumed that there is
minimal sub-lethal damage to repair. However, this is an oversimplication. Hill et al [84]
demonstrated that alpha particles are more eective per unit dose than X-rays even in repair
decient cells. They also demonstrated that cells, which shared the same parent line, with
diering repair pathway deciencies exhibited diering degrees of alpha particle sensitivity.
This implies that there is signicant repair of high LET, alpha particle induced damage.
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Figure 2.6: Survival curves for CHL-F cells exposed to 60Co gamma rays at varying dose rates
in vitro. Taken from [81]
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Figure 2.7: Survival curves for cells from the KHT sarcoma in mice, irradiated in situ and
introduced into recipient mice. Replotted from [83]
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In BNCT, at high boron concentrations, the majority of the dose is delivered by high
LET components. The precise fraction varies with the treatment beam parameters but in
the Birmingham epithermal beam, at levels of 50 g/g of boron-10, approximately 85% of
the dose is delivered by the high LET boron capture products. It might be expected that,
at high boron concentrations, there is minimal dose rate eect in BNCT. However, there is
a lack of in vitro and in vivo data to support this assumption. This study was aimed to
address this issue.
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2.3 Practical biology common to both studies
The mixed eld irradiation study and the BNCT beam dose rate study shared common
methodology. Both were clonogenic survival studies, using the same cell line and similar
handling techniques. With this in mind, common elements to both studies are described
here instead of repetition within the appropriate chapters.
2.3.1 Cell Survival Studies
Biological assays are always carried out with reference to some carefully dened endpoint.
In the context of survival studies, this is normally the ability to reproduce for a number
of generations after exposure to the compound or radiation being investigated. Choosing
continued clonogenic reproductive ability as the endpoint provides a way of quantifying
the response of a cell line to the radiation dose delivered in the laboratory. In practice
this is performed by introducing known numbers of cells to a suitable growth medium post
exposure. The cells are then left for long enough for visible colonies of greater than 50
cells to form, these are counted and then compared to the number of cells introduced. The
survival fraction calculated by this method is then adjusted by the plating eciency, the
fraction of cells forming colonies in unirradiated controls.
In all cases where cells were irradiated as single cell layers, cells were left for 2 hours
post-irradiation. This was to allow time for all repair of sub-lethal damage to be completed
before cells were processed. This time period can be justied with reference to the work
of Reddy et al [85]. Their experimental work involved irradiating V79 cells with 250 kV
X-rays, incubating the cells in medium then replacing the medium with hypertonic saline
at dierent time intervals. Hypertonic saline had previously been demonstrated to x, that
is make permanent, unrepaired damage in cells [86] [87]. Their data is shown in gure 2.8.
They derived an expression for repair time, or time to reach a plateau of cell survival, for
log-phase V79 cells;
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tR = (6:04 0:3)D (2.3.1)
Where D was x-ray dose and tR, time to reach plateau.
In all studies presented in this report, cells post-irradiation were introduced into 90 mm
Petri dishes at densities calculated to give approximately 200 colonies per dish. Five dishes
were used per dose point. Where the expected survival was not well known cells were plated
out at a range of densities.
This methodology requires cell numbers to be known with a good degree of precision.
Cells in suspension were counted using a Coulter Counter. This device pushes a sample
through an aperture and measures resistance change allowing particle size to be calculated
[88]. It then records the number of particles above some preset threshold. With V79 cells
this was set to 8 m. To obtain an accurate count it was important to obtain a single cell
suspension, avoiding clumping. Counts were periodically checked via a manual count using
a haemocytometer.
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Figure 2.8: Kinetics of recovery under growth conditions measured by treating cells with 0.5 M
saline at various repair intervals after irradiation with X-rays. The number next to each curve
represents the dose in Gy. Taken from [85]
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2.3.2 Survival Curves
The conventional way to present survival study data of this type is a log-linear plot of cell
survival fraction against dose as shown in gure 2.9. Normally, as shown, curves of this type
are tted with a linear quadratic model. This model assumes that cell death is brought
about either by a single lethal event or the accumulation of damage from sub lethal events.
If these are independent then, S = S1S2 when S1 is single event killing, e
 D and S2 is two
event killing e D
2
. Hence, S = e (D+D
2) where S is the surviving fraction after a dose of
D has been delivered, alpha and beta are constants.
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Figure 2.9: Example cell survival curve. Experimental data for V79 cells exposed to 250kVp
X-rays. Fitted linear quadratic function with  =0.259  0.03Gy 1 and  =0.03  0.003Gy 2
Extensions of this theory to apply to mixed eld irradiations separate the alpha and beta
constants of the high and low LET radiation and attempt to describe any synergistic eects
seen. Early work was published by Zaider and Rossi [89]. The model presented in this paper
introduced terms into the survival curve tting equations to explicitly account for temporal
eects such as repair of sub-lethal damage and interaction between sub-lethal damage from
dierent radiations. This model and others are discussed in more detail and compared to
experimental results on page 93.
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Compound Lonza Catalogue number Percentage of complete medium
DMEM BE12-614F 87.635
L-Glutamine 200mM in 0.85 % NaCl BE17-605E 1.753
Gentamicin sulphate 50 g per ml BE17-5187 0.096
Non-Essensial Amino Acids(NEAA) BE13-114E 0.876
Foetal Bovine Serum DE14-801F 9.640
Table 2.1: Complete cell growth medium constituents
2.3.3 Cell Culture Consumables
When grown in vitro a growth medium is used to provide water, salts, glucose, amino
acids and other essentials for cell growth. Practically this involves a prepared solution
to which perishable elements are added immediately prior to use in culture. The culture
medium used throughout the cell survival experiments detailed in this report was Dulbeccos
Modied Eagle's Medium (DMEM). This is a standard, widely used medium. The DMEM
used was purchased from Lonza bioscience as were all other liquid consumables. Various
other compounds are added to the base medium, as detailed in table 2.1. These are growth
essentials along with an antibiotic to help suppress infections of the cell population.
Foetal Bovine Serum (FBS) is the portion of plasma remaining after coagulation of blood.
As an extracted biological product it can demonstrate signicant variation in composition
between dierent suppliers and even between dierent batches from the same supplier. It is
normal practice to use the same batch of FBS throughout a series of cell experiments. This
was the case for all of the experiments carried out at the Medical Research Council (MRC)
described later in this report.
Unfortunately restrictions on the import and export of products derived from cattle
meant that this was not possible for the biological comparison of the treatment beams at
Birmingham and MIT, detailed in chapter 4. Fortunately the V79 cell line used did not
appear particularly sensitive to small changes in medium composition. Plating eciency at
Birmingham was 0.515  0.06 while at MIT it was 0.494  0.04. These plating eciencies
were both somewhat lower than is usual for V79 cells with > 0.8 regularly observed in
other experiments by the author. The lower plating eciency was thought to be due to the
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presence of boric acid in the medium.
2.3.4 Cell Line
For all experiments described in this report the cell line used was V79-4. This is a sub
line of the V79 cell line. V79's were rst developed in 1958 from the lung tissue of a male
Chinese hamster. V79-4's were isolated in 1966. They have a very high plating eciency,
typically greater than 80%, and a short doubling time of around 12 hours [90]. They are
very robust cells and routine handling of them is very straightforward. This cell line has
been used extensively in radiobiology work.
Stocks of V79 cells for the mixed eld experiments described from page 71 onwards,
were obtained from stocks held at the Medical Research Council laboratories. A single vial
of approximately 3106 cells was thawed and cultured. The resulting cell population was
placed into culture medium containing dimethyl sulfoxide (DMSO) and divided into vials.
These vials were then slow frozen and stored at liquid nitrogen temperatures until required.
The V79 cells used for the dose rate comparison study, described in chapter 4, were
obtained from professor Jacqueline Yanch's group at MIT. A single vial of approximately
1106 cells was thawed and cultured. Cells from this culture were then used immediately in
the MIT irradiations. A ask of viable cells was then transported back to the UK, further
cultured, and vials frozen for use in the Birmingham series of irradiations.
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2.4 Weighted Doses in BNCT
As discussed on page 20, Relative Biological Eectiveness is an important concept in ra-
diobiology. As traditionally formulated however, it is only a function of radiation LET. In
BNCT treatment situations it is more useful to refer to Compound Biological Eectiveness
(CBE) [91]. This concept was introduced as the eect of a BNCT irradiation is strongly
dominated by the accumulation of boron in the cells being irradiated. In addition to the
gross tissue/tumour boron uptake ratios, microdistribution within the cells is extremely
important. Simulations have shown that irradiations with boron in the nucleus are more
damaging than the same amount of boron universally distributed [92]. CBE is calculated in
the same way as RBE in that it is a ratio of doses to produce some given end point, with
reference to a 250 kV photon dose. It has the further qualication that it is specic to a
given boron compound.
RBE varies with dose but BNCT treatment plans have historically applied a single, xed,
RBE/CBE value for each dose component when calculating equivalent doses. This has been
justied with reference to the fact that BNCT is typically delivered in a single large dose
[30]. If a dierent clinical strategy is adopted for BNCT, and a series of small dose fractions
are delivered, then consideration will need to be given to how best apply CBE's and RBE's
derived from large single dose exposures.
2.4.1 In Tumour
A number of studies have determined CBE factors in cell lines in vitro. Initial studies
irradiated cells in attachment. Davis et al [93] irradiated HeLa cells, incubated in varying
concentrations of boric acid, using the MIT reactor thermal neutron beam. Their results are
shown in gure 2.10. A CBE factor of 3.7 was calculated. Dose deposited by the capture
reaction in the cells was calculated via a computer program which was complicated by the
non-spherical nature of the attached cells and various assumptions were made. Specically
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in vitro in vivo
Irradiation SF=0.1 SF=0.01 SF=0.001 SF=0.1 SF=0.01 SF=0.001
Thermal beam 2.6 2.6 2.6 2.1 2.3 2.5
Thermal beam minus photons 3.7 3.7 3.8 2.8 3.2 3.5
BPA 9.8 7.8 6.7 4 3.8 3.6
BSH 3.1 2.9 2.8 - - -
Boric acid 3.4 3.4 3.3 - - -
Table 2.2: CBE factors for 9L gliosarcoma cells, gures from [48]. CBE change with dose was
small, as the corresponding X-ray curve was nearly linear in this region; corresponding X-ray doses
were > 10 Gy ( in vitro) and >8Gy ( in vivo).
the assumption that all borated media was removed and capture could only take place
within the cells themselves. As a layer of a few tens of microns eectively represents an
innite borated layer, due to the short range of the reaction products, the assumption of no
boronated medium surrounding the cells may not have been correct.
Gabel et al [3] used V79 cells in suspension, loaded with enriched boric acid at varying
concentrations and irradiated with thermal neutrons using the Medical Research Reactor
at Brookhaven. Their results are shown in gure 2.11. By comparing the boron loaded
results to the survival without boron present, RBE values at dierent survival levels could
be derived and a calculated V79 survival curve produced as shown in gure 2.12. A combined
RBE factor of 2.3  0.3 at low survival was calculated for the boron reaction products. An
extension of this work was derivation of CBE factors for boric acid, BPA and BSH in rat
9L gliosarcoma cells. Cells were irradiated both in vitro and in vivo using the Brookhaven
thermal beam [48]. This comprehensive study attempted to derive RBE factors for all BNCT
beam components. Results are shown in gures 2.13 and 2.14. Calculated values for CBE
are shown in table 2.2.
The CBE factors for boric acid and BSH were similar to those stated in other published
work [3] but were found to be extremely high for BPA. These factors assumed that the
amount of boron inside the cells was equal to the concentration in the medium. This was
shown to be an unwarranted assumption by Capala et al [61]. This work used a rapid
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Figure 2.10: HeLa cells irradiated at MIT in a thermal neutron beam, in the presence of boric
acid, at varying concentrations, replotted from [93]
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Figure 2.11: V79 irradiated at Brookhaven, using a thermal neutron beam, in the presence of
boric acid at varying concentrations. Taken from [3].
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Figure 2.12: Calculated V79 survival curve for the 10B(n,)7Li reaction. Replotted from [3].
Function is S = e 1:5D.
centrifuge ltration technique to strip away medium containing boron and allow direct mea-
surement of only intracellular levels. The results are shown in gure 2.15. When the doses
used in [48] are adjusted to account for the 3 times higher boron doses the average CBE
factor for BPA reduced to 3.8 [91].
The factor of 3.8 for boron dose, with BPA, in tumour tissue has been widely adopted in
the BNCT community and used in treatment planning in clinical trials all over the world.
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Figure 2.13: Clonogenic survival of 9L gliosarcoma cells as a function of dose following in vitro
irradiation with 250 kVp X-rays, BMRR thermal neutron beam alone, or BMRR thermal neutron
beam combined with the boron compounds. Taken from [94].
Figure 2.14: Clonogenic cell survival determined in vitro following irradiation of tumours in vivo.
Intracerebral 9L gliosarcomas were irradiated with either 250 kVp X-rays, BMRR thermal neutron
beam alone, or BMRR thermal neutron beam following administration of either BPA or BSSB.
Taken from [94].
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Figure 2.15: Boron concentration in cells after incubation in various compounds, from [61]
2.4.2 In Skin
The tolerance limit for skin is generally taken as 18 Gy photon-equivalent delivered in a single
fraction [95] [96]. Above this level permanent damage to the underlying dermis results and
leads to necrosis. There have been a number of in vivo studies which attempt to quantify
RBE or CBE, in skin, for a number of end points. A summary of the calculated factors is
shown in table 2.3. It is clear that the CBE factor is strongly dependant on the endpoint
used and other experimental conditions. It is also apparent that the CBE in humans [97]
and the CBE in rats [98] is dierent, even with the same compound and beam conditions.
It has been suggested that this could be due to the structural dierences in vascular supply
[91].
Skin is not a limiting factor in BNCT treatment, with epithermal beams and BPA or
BSH. The dose required to create signicant skin damage, as indicated in dog experiments,
exceeds the dose required to cause serious central nervous system damage [102]. This is
almost certainly due to the characteristics of the neutron beam; provided it is epithermal it
delivers peak dose 20+ mm below the skin.
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2.4.3 In Central Nervous System (CNS)
Damage to the Central Nervous System (CNS) is normally quantied by damage to spe-
cic cell populations, the functioning of which can be assessed by various functional and
histopathological tests [91]. There have been conicting reports on which of these popu-
lations is of the most importance in terms of damage delivered during BNCT treatment;
elements of the bulk CNS tissue or the vascular system.
Morris et al [103] exploited the fact that BSH is excluded from bulk CNS tissue and
conned to the vascular system by the blood brain barrier to selectively irradiate the CNS
vascular system of healthy Fischer rats. The histopathological results from this selective
thermal neutron plus BSH irradiation were compared to the results from irradiations with
thermal neutrons alone or thermal neutrons plus BPA. Results were similar in all three cases,
suggesting that vasculature and the endothelial cells in particular are the critical target. The
results also mirror damage found in conventional photon radiotherapy. This is supported
by more recent work specically undertaken to compare the importance of glial stem cell
damage to vascular endothelial damage in white matter necrosis by Coderre et al [107].
A result of the domination of vascular system damage in BNCT is the relatively low
RBE values for CNS, in BSH loaded irradiations, as seen in table 2.4. This can be explained
by considering the geometry of the brain capillary system. The smallest capillaries are 8m
with a wall thickness of 0.1 to 0.3 m. The range of the boron capture products means that
some capture events within the capillaries will deposit the majority of their energy outside.
Rydin et al demonstrated that the fraction of the dose received by the blood vessel wall was
one-third to one-fth that delivered to an innite pool of blood, depending on the diameter
of the vessel [108]. For BPA loaded systems there is a contribution to this dose from capture
in the surrounding tissue.
It is clear from the varying CBE values in table 2.4 that the CBE is strongly dependent
on experimental conditions. Based on the work in [103] a brain tissue CBE of 1.3 was used
in planning for clinical trials at Brookhaven, MIT and elsewhere [109] [110].
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The variance between various experimental results shows that relative biological eective-
ness and compound biological eectiveness in BNCT are not simple quantities to evaluate.
Values derived in all tissues seem to depend strongly on the beam used and, more signi-
cantly, on the distribution of the boron compounds used. It is obvious that caution needs to
be exercised when comparing biological and clinical results obtained under dierent beam
conditions.
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Chapter 3
MIXED FIELD IRRADIATIONS
3.1 Previously Published Work
There have been a number of investigations involving irradiation of cell cultures with mixed
high and low LET elds. In the case of mixed elds of neutrons and photons there have been
a large number of publications, in part due to clinical interest in fast neutron therapy. Work
by Ngo et al [31], using 25 MeV fast neutrons and 250 kVp X-rays with the V79 cell line,
showed lower survival level when the fractions were given immediately following each other
compared to allowing repair post neutron irradiation, see gure 3.1. In the `immediate' case
cells were kept on ice in between the fractions to minimise repair.
This work supported the earlier ndings of Railton et al [37], who found a similar eect
when irradiating Chinese Hamster Ovary (CHO) cells with deuterium-tritium fusion neu-
trons and cobalt-60 gamma rays. The synergism was also demonstrated in V79 cells, again
with Deuterium-Tritium fusion neutrons and Cobalt-60 gamma rays, by Higgins et al [32]
[33]. A further study using V79's by McNally et al [34] showed that the synergistic eect
was present for a range of neutron priming doses.
In support of the evidence of an eect in vitro is a study by Joiner et al [35] which
demonstrated a synergistic interaction between 140 kVp X-rays and 3 MeV neutrons given
simultaneously in vivo. The model used was appearance of visible skin eects in mouse feet.
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Figure 3.1: Single-dose and fractionated-dose survival curves of V79-AL162 Chinese hamster
cells obtained with JANUS neutrons and X-rays. Replotted from [31]
Figure 3.2: Eects of combined  and X-ray radiation. Taken from [38]. Curve 1: 0.5 Gy  plus
0, 1, 1.5, 2, 3 and 5 Gy of X-ray. Curve 2: 1 Gy  plus 0, 1, 1.5, 2, 3 and 5 Gy of X-ray. Curve
3: 3 Gy of X-ray plus 0, 0.5 and 1 Gy of . Curve 4: 5gy of X-ray plus 0, 0.5 and 1 Gy of .
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From these studies the evidence seems consistent that there is an interaction between
the damage delivered by fast neutrons and photons. In the case of mixed elds of photons
and alpha particles, or other heavy ions, the picture is much less clear.
Early work by Barendsen et al [38] in the 1960's showed that for sequential irradiation
with polonium-210 alpha particles and 200 kVp X-rays there was no deviance from the
survival results predicted by giving the fractions individually (gure 3.2). The cells used
were human origin kidney cells, irradiated while attached to thin based dishes.
This work was taken as supporting evidence that, in an exponential cell survival situation
such as that given by a high LET alpha particle beam, there is no sub-lethal damage in the
survivors. Without such damage there is no mechanism for synergistic interaction between
the high and low LET components.
Work by Bird et al [39] sequentially exposed V79 cells to 50 kV X-rays and either
deuterons or 3He ions. A synergistic eect was found, with lower cell survival in the mixed
irradiations than would be expected from the individual fractions. This eect was present
for all of the dierent high LET fractions tested and increased in magnitude with dosage of
the high LET fraction. Example data is shown in gure 3.3
In addition to these mammalian cell data, Murthy et al [36] found that in diploid yeast
cells there was a synergistic eect when cobalt-60 gamma rays and polonium alpha particles
were given together.
The most comprehensive mixed alpha particle and photon investigation to date is perhaps
found in McNally et al (1988) [1], the method and results are worth examining in some
detail. The motivation for the study was to repeat the work mentioned earlier [38] with
the high LET component making up a higher fraction of the total dose delivered. Previous
studies with neutrons [34] had suggested that the doses employed were too low to show the
synergistic eect. The cells used were the V79 line, cultured in standard complete growth
medium. The cells were plated out in appropriate numbers, given expected survival, into
dishes several hours before irradiation. Doses of 0.5, 2 or 2.5 Gy of alpha particles were
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Figure 3.3: Survival data for late-S V79 cells irradiated with 50 keV per m LET deuterons
alone (black squares), or with graded doses of X-rays after a 2-Gy dose of deuteron ions (black
diamonds). The continuous line is the X-ray only survival curve and the dashed line shows the
predicted mixed eld survival from the separate components. [39]
given alone, and combined with a range of X-ray doses. The combination was not truly
simultaneous; the `priming' alpha particle dose was delivered followed by the X-rays several
minutes later. Alpha particles were delivered by a plutonium-238 source as described in
[111] and X-rays by a 250 kV machine with a hardening lter. Their results are shown in
gure 3.4. The implications are clearer when normalised results are shown, as in gure 3.5.
This gure shows the mixed dose survival data adjusted with the alpha particle only data. If
there was no synergistic eect the curves would overlap each other and the X-ray only curve,
within uncertainties. It is obvious that a synergistic eect is visible in the 2 Gy and 2.5 Gy
alpha priming dose data which is more pronounced at higher doses. The authors conclude
that alpha particles can cause damage that interacts with X-ray damage leading to a lower
survival in the mixed case than would be expected from the fractions given separately.
Recently, there has been renewed interest in the eect of mixed-eld irradiations as they
may be of interest in the rapidly expanding clinical eld of carbon ion therapy which utilises
high LET particles. Combining this therapy with traditional photon radiotherapy may
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Figure 3.4: Survival curves for V79 cells exposed to a-particles, X-rays, or X-rays after priming
a-particle doses of 0.5, 2 or 2.5 Gy. Taken from [1]
Figure 3.5: Survival curves for cells exposed to alpha particles, X-rays, or X-rays after priming a-
particle doses of 0.5, 2 or 2.5 Gy. The X-ray plus alpha data is normalised - the surviving fraction
at each point is divided by the surviving fraction of the appropriate alpha only data. Re-plotted
from data in [1]
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produce complicated treatment planning scenarios if a synergistic eect is seen. Demizu et
al [40] irradiated human salivary gland (HSG) cancer cells with a mix of 320 MeV carbon ions
and 4 MeV X-rays. It was found that the two radiation qualities acted in a simple additive
fashion and no synergistic eect was seen. Furusawa et al [41] exposed V79 cells to X-rays
combined with various heavy ions; 40Ar, 28Si and 56Fe. Unlike many previous investigations
their irradiations were truly simultaneous, with high LET dose rates matched to their X-ray
dose rates. No synergistic eect was seen with the 40Ar or 28Si ions. A statistically signicant
synergistic eect was seen with the very high LET 56Fe ions. However, the authors noted
that this eect was very small and strongly depended on the tting functions used. A
summary of the various photon-ion simultaneous exposures, with mammalian cell lines, is
given in table 3.1.
It is assumed by theoretical explanations of the synergistic eect observed by McNally
et al [1] and others that the lowered cell survival is the result of interactions between sub
lethal lesions produced by the two radiation qualities [112]. The threshold for observing an
eect, observed by McNally et al, and proposed as an explanation for Barendsen et al not
observing a synergistic interaction suggests that the level of eect is small and dicult to
observe at higher cell survival levels. A series of experiments have been carried out to clarify
the question of synergism between alpha particles and photons, particularly in the case of
truly simultaneous irradiation. They will be described in the rest of this chapter.
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3.2 Radiation Sources and Set-up
The initial experiments detailed in this report were carried out at the Medical Research
Council (MRC) at Harwell. They utilised one of the facility's cobalt 60 sources in conjunction
with a plutonium 238 alpha particle irradiator. The cobalt sources are pencil style sources
attached to Teleex for handling, which allows them to be inserted into the xed irradiation
position, inside the irradiation cells, remotely. In the case of these experiments a rig was
assembled which positioned the source approximately 300 mm above the cell layer to be
irradiated, as seen in gure 3.6. When in position the cobalt source used provides a dose
rate of 2.6 Gy per minute. There was a small amount of transit dose, at a much lower dose
rate, as the source moved on the Teleex from the shielded bunker to the lighthouse. This
dose was included in the total dose delivered to the cells and was less than 0.1 Gy in all
cases.
Photon dosimetry was carried out with the assistance of James Thompson at the MRC.
Gamma dosimetry was provided by a Thermo Scientic NE2670 Farmer dosimeter using
a model 2581A ionisation chamber. This is a standard 0.6 cm3 `thimble' type, cylindrical
graphite chamber as described by Aird and Farmer [113] and shown in gure 3.7. Temper-
ature and pressure compensation were built into the dosimeter. Dose rate was checked at
the start and end of each day of irradiations. The dosimeter used is regularly calibrated
and checked as part of the MRCs normal auditing procedures. For dose measurements the
ionisation chamber is held in a dummy cell dish lled with an appropriate amount of distilled
water to simulate the cell growth medium. This allowed a direct measure of dose rate at
the cell layer in identical conditions to the cell irradiations themselves. The positioning of
the chamber and design of the shutter jig ensured that dose from scattered X-rays measured
in the chamber set-up was the same as that in the cell irradiation set-up. The jig, with
ionisation chamber, is shown schematically in gure 3.8.
Actual dose delivered to the cells was calculated from the measured dose rate and time
of exposure. This exposure time was electronically controlled by a purpose built micro-
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Figure 3.6: Photograph of the mixed alpha particle and gamma ray setup
Figure 3.7: Schematic of a Farmer type ionisation chamber. Taken from [113]
55
Figure 3.8: CAD drawing of the jig used to position 250kV X-ray irradiation head for cell dish
irradiations
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controller with a timing error of less than ten milliseconds.
The plutonium irradiator used was the setup described in Goodhead et al [114] as shown
in gure 3.9. It consists of a plutonium coated platinum disk held inside a helium atmosphere.
Distance from the source to the cell layer is variable. This changes the path length within
the helium and consequently allows the energy of the alpha particles, at the cell layer, to be
varied as described by the Bethe-Bloch formula (equation 3.2.1).
dE
dx
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4
mec2
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2
2
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e2
4"0
2


ln

2mec
22
I  (1  2)

  2

(3.2.1)
Where;
 = v=c
v velocity of the particle
E energy of the particle
x distance travelled by the particle
c speed of light
z particle charge
e charge of the electron
me rest mass of the electron
n electron density of the target
I mean excitation potential of the target
e0 vacuum permittivity
There is also a variable diameter aperture positioned above the source and various sector
plates that can be positioned below the cell layer. The aperture allows the dose rate to be
lowered while the sector plate allows for uniform irradiation when a rotating sample wheel is
tted. For these irradiations the largest aperture was used, with no sector plate, in all cases.
This source has been used extensively at the MRC and its characteristics are well known. In
it's standard conguration the source is positioned 65 mm below the chamber window. After
traversing 65 mm of helium, 3 mm of air and two 0.35 mg cm 2 mylar windows the alpha
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Figure 3.9: Schematic of the MRC Plutonium irradiator
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Figure 3.10: Energy spectrum of alpha particles in the position of the irradiated cells, as measured
with a silicon detector masked with a 0.9 mm diameter aperture. Taken from [115]
particles have a measured mean spectral energy of 3.15 MeV and with spectrum peak energy
of 3.23 MeV as shown in gure 3.10. These measurements, taken with a silicon detector, are
detailed by Thacker et al in reference [115]. A conversion of this energy spectrum to LET
in water gives an average, at the cell layer, of 127 keV m 1.
A modication to the set-up was made specically for these experiments; a fast shutter
was added between the source and the cell layer. The gap between the shutter and the top
of the existing setup was continually ushed with helium over the course of the irradiation.
As this set-up was a minor modication from the usual conguration of this source, it was
modelled using the TRIM [72] code to check that the LET of the alpha particles at the cell
layer was similar to that used in previous work. This code modelled the transport of the
alpha particles through 65mm of helium, 2.5 m of mylar, 5mm of helium then a nal 2.5
m of mylar. The LET as the alpha particle traverses the dierent layers is shown in gure
3.12. The cell layer in this case is modelled as a layer of water 7 m thick.
The average LET across the cell layer was calculated as 123 keV m 1. This small
dierence in LET is not expected to make a signicant dierence to the biological eect of
the alpha particles [74]. This is illustrated by gure 2.4 on page 24. An attempt to quantify
the dierence in biological eect was made by tting a log-normal distribution to the peak
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Figure 3.11: Pooled data for particle LET vs RBE in V79 CHO and T1 cell lines. Replotted from
data in [74]. Fitted line is a log-normal curve generated in Origin.
in the pooled RBE-LET data using Origin, as shown in gure 3.11. This is not presented as
having any relationship to the physical RBE-LET relation; it is just a convenient function
to t the data in the region of interest. This suggests a shift from a predicted RBE of 3.61
to 3.60 for a change in LET from 127 keV m 1 to 123 keV m 1.
An appropriate number of open vs closed cycles of the shutter were used in each experi-
ment to ensure that the prescribed alpha particle dose in the experiment was delivered over
the same time period as the gamma ray dose. Alpha particle dose rate was measured using
CR39 lm held in a dummy cell dish. Several lms were irradiated over the course of each
day of experiments to provide an accurate measure of the dose rate being delivered.
All alpha dosimetry was carried out by James Thompson at the MRC. He followed the
CR39 methodology described by Cartright et al in reference [116]. Discs of CR39 were
placed in a dish identical to those used for the cell irradiations before being exposed to
the alpha particles. Tracks created by the ions were enlarged by etching in 40% NaOH for
4 hours so that they were visible under a microscope. The number of tracks in a given
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Figure 3.12: LET across the cell monolayer in a hostaphan dish for the MRC alpha particle
source. Calculated with TRIM [72]
area were then electronically counted using an ImageJ macro. Some dose points were also
counted manually and compared to the electronic results; agreement within 1.1% was found.
A example microscope image of CR39 tracks, with highlighting from ImageJ, is shown in
gure 3.13. Dose in Gray was calculated from this counted track density per unit area and a
calibration factor as described in equation 3.2.2. This is a dosimetry method used routinely
at the MRC.
Dose =
19:424 Track count
Area of region counted
(3.2.2)
One drawback of the CR39 dosimetry method is that, at high doses, tracks can overlap.
This could produce an underestimate of dose delivered. All dosimetry was carried out with
maximum doses of approximately 0.7 Gy to eliminate this eect. As with the photons, doses
in cell irradiations were calculated from the measured dose rate along with the irradiation
time.
Initially it was believed that the dose delivered during the shutters open and close cycle
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Figure 3.13: Example image of CR39 alpha particle tracks after etching. Red highlighting is a
feature of the ImageJ track counting algorithm.
time would not be signicant and dose planning was carried out under this assumption.
Reviewing the CR39 dosimetry data demonstrated that this was not the case, with an
additional dose of approximately 8x10 3 Gy per shutter cycle. This equated to a 27% rise
in average dose from initial estimates. This also introduced a variation in dose across the
dish. With square shutter leaves this variation would be present in one direction, y, but not
in the other, x. With an iris mechanism shutter the variation would be equal in all radial
directions. In reality the shutter leaves are curved and the dose variation lies somewhere in
between the two extremes, with the variation in dose along x being somewhat lower than
the variation across y. This dose variation, for an example irradiation with 0.7 Gy, is
illustrated in gure 3.14
This variation factor introduced some additional uncertainty in the dose across the dish.
Taking just the x variation, maximum dose in the central region was 6% higher than the
average with a corresponding drop in the dose at the edges of the dish. Averaging both
X and y variation, the maximum dose was 5% higher. As stated, due to the shape of the
shutter, the actual variation from the average lies somewhere between these two values.
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Figure 3.14: Alpha particle dose variation, measured by CR39 track counting, across a hostaphan
dish.
The second series of experiments described in this report utilised the same alpha particle
source as described above. The gamma ray source was replaced with a 250 kVp X-ray
set with a hardening lter consisting of 0.6 mm of tin, 0.25 mm of copper and 1.0 mm of
aluminium. With this lter in place the dose rate at the cell layer was 1.49 Gy/min at
15 mA. The irradiation head was positioned above the cell layer, see gure 3.15. X-ray
dosimetry was again provided by the Farmer dosimeter and alpha dosimetry by CR39 discs.
While a detailed spectrum of this X-ray source was not recorded, the half value layer was
measured as 2.8 mm of copper.
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Figure 3.15: Photograph of the mixed alpha particle and X-ray setup
64
3.3 Cell Protocol
The protocol in each set of experiments was similar. Cell culture dishes were prepared
40-48 hours prior to irradiation. 2  105 cells were plated out into each dish in 2 ml of
complete growth medium. The dishes used consist of a glass ring with a layer of polyethylene
terephthalate (Mylar), serving as a base, attached with epoxy resin as in gure 3.16. The
cell layer is grown directly on the Mylar.
Immediately prior to irradiation several dishes were selected randomly, the cells stained
with a uorescent dye and viewed using a confocal microscope. This allowed a check on how
uniform a monolayer has formed, with stacks of cells being clearly visible. An example image
is shown in gure 3.17. This is important as the alpha particles deposit a large fraction of
their energy in the rst cell they interact with. Cells above the rst layer would receive
a much reduced alpha particle dose. After examination under the microscope the stained
dishes were discarded.
Ideally all cell cultures irradiated would be a monolayer to avoid any dose reduction
eects. Unfortunately this requirement is in conict with the requirement to have enough
cells per irradiation to provide the required seeding for colony assays. The propensity for
V79's to stack up even at relatively low densities was also an issue. With this in mind, cells
were seeded at varying densities and observed 48 hours later. From these observations the
Figure 3.16: Thin based Mylar dish
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Figure 3.17: Confocal microscope image of V79 cells stained with uorescent dye
density of 2  105 cells seeded was chosen as it provided sucient cells for the subsequent
experimental work with minimal stacking.
Cell dishes were removed from the incubator immediately prior to irradiations. The
control dishes were removed for a similar time period to that needed for the irradiations.
Post-irradiation the dishes are returned to the incubator for 2 hours prior to processing. Cells
from the edges of the dish were discarded, due to possible alpha particle dose uncertainties.
This was accomplished by cutting out the centre of the Mylar using a specially designed
cutter; see gure 3.18. These Mylar disks were then placed in trypsin to remove the cells,
which were then handled as described in the clonogenic cell survival study section on page
30.
In the case of the gamma ray experiments, the cells were handled in triplets comprised
of cells exposed to gamma rays only, alpha particles only and a mix of alpha particles and
gammas. An unirradiated control was used with each triplet. In the X-ray experiments the
cells were handled in quartets with the order during the day and the grouping randomised.
Two unirradiated controls were used and handled at dierent points during the day.
In order to provide the required gamma ray build up in the cobalt-60 exposures, 24 hours
prior to irradiation an additional 2 ml of complete cell growth medium was added to the cell
66
Figure 3.18: Cutter for removing the centre section of irradiated Mylar dishes
dishes.
There was no provision for incubation of cells in situ so temperature of the medium, and
cell layer, was not controlled during the experiment. As temperature can have a signicant
eect on cell repair rate [117] [118] an experiment to quantify the temperature drop over
the course of the irradiations was carried out. In the case of cobalt exposures, there was
also a signicant delay between removal of cultures from the incubator and the irradiation
commencing due to the distance from the culture lab to the cobalt source. Attempts were
also made to simulate this.
Dummy dishes containing 2ml or 4ml of distilled water and a K-type thermocouple (RS
part number 444-1247) were prepared and preheated in an incubator to 37 ℃. To simulate
the Cobalt-60 irradiations, dishes containing 4ml were removed from the incubator and left
at room temperature for ten minutes before being placed in an insulated box held at 10 ℃.
Temperature measurements were then made. To simulate the X-ray irradiation conditions
the dishes containing 2ml were removed from the incubator and held at room temperature,
with temperature measurements beginning two minutes after removal. Temperatures were
logged using a National Instruments NI9213 thermocouple module and a simple data logging
application written in Labview. Results are shown in gure 3.19. As expected, a marked
dierence in cooling rates due to the diering temperature of the surroundings is observed.
67
0 1000 2000 3000 4000 5000
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
Te
m
pe
ra
tu
re
 
(D
e
gr
e
e
s 
Ce
lc
iu
s)
Elapsed Time (Seconds)
 Simulated X-ray exposure
 Simulated gamma ray exposure
Figure 3.19: Temperature of mylar based cell dishes over irradiation time in mixed alpha, photon
cell survival experiments. A dierence in cooling rate is observed as the X-ray exposures were
carried out in a 20 degree Celsius environment, as opposed to 10 degrees for the cobalt exposures.
The longest irradiation time in the case of the gamma ray exposures was less than ten
minutes. According to the data shown in 3.19, this corresponds to a lowest temperature at
the end of irradiation of 21.4 ℃. In the X-ray case, the longest irradiations were less than
fteen minutes corresponding to a lowest temperature at the end of irradiation of 23.6 ℃.
Even when such a temperature drop is maintained for 24 hours or more post exposure,
little dierence in cell response is seen [119]. In the context of an experiment including a
2 hour post irradiation incubation it was not expected to have had an observable eect on
cell repair.
3.4 Calculation of Uncertainties
In all results presented in this report, cell survival uncertainties shown are calculated as one
Standard Error, taken as the Standard Deviation in the survival measurements divided by
the square root of the number of independent survival measurements.
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SE =
SDp
N
(3.4.1)
Each independent measurement is the mean number of colonies in the ve dishes plated
per dose value.
Uncertainty in photon doses are calculated by multiplying the uncertainty in irradiation
time by the dose rate. These errors, when combined with the uncertainty in the dose rate
itself, are typically small enough not to be visible on plots. In the case of the irradiations
using cobalt-60 sources the additional uncertainty in dose from the transit time of the source
is also incorporated. Errors in alpha particle doses are the combination of error introduced
by irradiation time plus dose rate uncertainty, as with the photon doses, and the error due to
shutter cycle time. The error from the shutter cycle time could not be calculated precisely.
Plotted values are the calculated dish average dose  6%. This is likely to represent the
extremes of dish centre dose vs dish edge dose in the worst case of square edged shutters.
Uncertainties in calculated values are based on the uncertainties in the values which were
used in the function to calculate them. Normal error propagation rules were followed [120].
3.5 Curve tting
Unless stated otherwise, all survival curves plotted in this report were tted using Origin
6.1 or OriginPro 8 from OriginLab[121]. Origin minimises the dierence between the ex-
perimental observations and the curve generated by a theoretical, user supplied, function.
This is referred to as a chi squared minimisation t. Chi squared is calculated as shown in
equation 3.5.1.
2 = wi
X
i = 1nyi   ytih (3.5.1)
yi is the observed value, yt is associated theoretical value and wi the weighting factor.
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Generally, the survival curve tted followed the linear-quadratic model;
S = e (D+D
2) (3.5.2)
Minimising 2 requires iteration of the free parameters in the theoretical tting function,
in this case  and . Such an optimising iteration is not as straightforward as it might appear
as there are potential pitfalls such as local minimums of the 2 function. Origin utilises the
Levenberg-Marquardt algorithm as described in reference [122].
A check of Origins tting methodology was carried out using both Excels `Solver function-
ality and an independent FORTRAN program. Excel uses a Generalized Reduced Gradient
(GRG2) algorithm for its minima search as described by Lasdon [123]. The FORTRAN pro-
gram implemented a more straightforward algorithm to solve for a minimum of a parabolic
function, as described in [124]. This program can be found in appendix 1. In all cases tested
it was found that all three independent methods, when given the same data, arrived at the
same tting function. This indicated that the ts provided by Origin were reliable.
Stated uncertainties in tted parameters were provided by Origin and are derived from
the sum of the squares of the deviations from each data point to the tted line. Details of
the calculation can be found in the Origin user manual [125].
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3.6 Results and Discussion
3.6.1 Single Field Exposures
Alpha Particles
A comparison of single eld alpha particle exposures with previously published data is shown
in gure 3.20. The data show slightly lower survival at all levels than previously published
data from Thacker et al [111], McNally et al [1] and Folkard et al [126] as shown in gure
3.20 and table 3.2. However, this is somewhat exaggerated by the levelling o of cell survival
at higher doses and the resulting eect on the survival curves. A plot of the data sets for
doses under 3.5Gy is shown in gure 3.21, with tting parameters in table 3.3. Within
the 95% condence intervals the tted curves for the current study, McNally et al 's and
Folkard at al 's data all overlap. All three data sets show lower survival than that observed
by Thacker et al [111].
The observed agreement at low dose with the two published data sets, but disagreement
when higher dose responses are included suggest that cell handling techniques may account
for the dierence. McNally et al exposed their cells at low concentrations, then cultured the
cells in the same dishes for their colony assay without discarding cells at the periphery. Any
shielding eect at the edges of the dish would have therefore resulted in a small population
receiving a reduced dose. Barendsen et al [38] noted a `levelling o' eect at high alpha
particle doses which they attributed to cells improperly attached to dish bases receiving a
lower dose. This is another possible explanation for the observed dierence, with the single
eld experiment described here not producing low enough survival levels for the eect to be
observed. Better agreement is seen with the data of Hill et al [84]. An expanded comparison
is shown in gure 3.22. This alpha particle data was generated using the same mylar based
dish system as the current study, with the same source. While this data shows slightly lower
survival at higher doses, the uncertainties in the ts overlap with uncertainties in the current
data.
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Figure 3.20: V79 cell survival after irradiation with alpha particles compared with historic data
from Thacker et al [111], McNally et al [1], Hill et al[84] and Folkard et al [126]
Alpha (Gy  1) Beta (Gy  2)
Current Study 1.2486  0.101 0.0487  0.0015
Thacker et al 1.2  0.0256 -
McNally et al 1.106  0.1963 -
Folkard et al 1.3105  0.097 0.0001  0.0206
Hill et al 1.5548  0.15 -
Table 3.2: V79 survival when exposed to alpha particles. Fitted values of alpha and beta for gure
3.20, values for published data taken from the appropriate papers.
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Figure 3.21: Comparison of v79 cell survival after alpha particle irradiation, at doses under
3.5Gy, with historic data from McNally et al [1] and Folkard et al [126]. Solid lines are Origins
t lines to the data while dotted lines indicate 95% condence levels for the t lines of the same
colour.
Alpha (Gy  1) Beta (Gy  2)
Current Study 1.2486  0.101 0.0487  0.0015
Thacker et al 0.9855  0.0574 0.030470.026
McNally et al 1.243  0.007 -
Folkard et al 1.3105  0.097 0.0001  0.0206
Table 3.3: Fit parameters for gure 3.21. Irradiation of V79 cells with alpha particles, doses of
less than 3.5Gy
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Figure 3.22: Comparison of alpha particle survival with historic data from Hill et al [84]. Solid
lines indicate linear quadratic ts to the data of the same colour, dashed lines the 95% condence
intervals of the associated t. Fit to Hill et al data has coecients =1.545  0.039 and =0.
Fit to the current study with parameters as in table 3.2.
Gamma Rays
Results of single eld gamma ray irradiation is shown in gure 3.23. These data also show a
lower survival fraction than presented in some previous published work [32] [127], as shown
in gure 3.23. While this dierence from the low dose rate exposures in [32] is expected,
due to the dose rate eect, the reason for the dierence from published exposures at similar
dose rates by Mitchell et al [127] and Girigoswami et al [128] is not clear. Better agreement
is shown with the data of Winzel et al [129] and Schalla et al [130].
It has been demonstrated that V79 cells radiosensitivity can be aected by a variety
of cell culture factors and their morphology during irradiation. A number of authors have
reported that V79 cells grown in suspension and irradiated as clusters have a greater capacity
for repair, and lower radiosensitivity, than cells grown and irradiated as a monolayer or
single cells [131] [132] [133]. It has also been reported that sensitivity to DNA denaturation
74
in V79 is related to cell shape by Olive et al [134]. Reddy et al [135] reported diering
radiosensitivity with serum concentration in medium, and also with cells exposed to trypsin,
and related the observed dierence between spheroids and monolayers to this.
While cell conditions in the experiments detailed here were similar to some literature
exposures, and nominally identical to others, it is inevitable that factors such as small
dierences in medium composition exist between laboratories. Cells in this experiment were
also, unusually, cultivated and exposed on mylar as opposed to a more conventional cell
culture substrate.
As the mechanisms aecting radiosensitivity are thought to be repair related, dierences
in response are expressed more clearly in the low LET data than the high LET.
While doses are, in theory, intercomparable between the various experiments dosimetry
techniques and gamma ray build up are often not fully documented for published work.
There may therefore be some dierences in actual gamma ray dose delivered to the cell level
between the studies, at a given reported dose. Such dierences, however, are likely to be
small and probably do not account for variation observed.
Irradiating at low temperature produces similar eects to irradiating at a very large dose
rate and can produce greater cell kill than an identical irradiation at room temperature.
The irradiation room itself was at 10 ℃. While an experiment was carried out to quantify
temperature drop in the cell dish being irradiated, as described in section 3.3, this may have
underestimated the true temperature drop which was not directly measured. This suspicion
is given some weight by the fact that the historic irradiations which most closely matched
this experiments survival levels, for a given dose, (Winzel et al [129]) were carried out with
the cells on ice at 4 ℃.
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Figure 3.23: Comparison of V79 cell survival, when exposed to gamma rays, with historic data
from Higgins et al [32], Winzel et el [129], Schalla et al [130], Girigoswami et al [128] and Mitchell
et al [127].
Alpha (Gy  1) Beta (Gy  2)
Current Study 0.2332  0.0040 0.0180  0.0008
Higgins et al 0.0955  0.0173 0.0046  0.0011
Mitchell et al 0.1231  0.0034 0.0109  0.0002
Schalla et al 0.2150  0.0031 0.0252  0.0009
Winzel et al 0.1380  0.0138 0.0096  0.0025
Girigoswami et al 0.1543  0.2171 0.0074  0.0220
Table 3.4: Values of alpha and beta for gure 3.23. V79 survival when exposed to 60Co gamma
rays. Values taken from published papers for historic data. Fits to the experimental data presented
here were calculated in Origin, along with the associated uncertainties.
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X-rays
A comparison between the X-ray survival data and some previously published work with
V79 cells is shown in gure 3.24. Although the survival appears somewhat lower than that
reported by McNally et al [1], the tted alpha parameter is the same, within the calculated
error bounds, as shown in table 3.5. There is a small dierence in beta. The observed
dierence in beta is clearly visible in gure 3.25 with the 95% uncertainty bounds of the
tted lines overlapping at lower doses and diverging at high dose. Both sets of data show
lower survival than that reported by a number of other authors.
As with the single eld gamma ray data, the reason for the dierence in observed sur-
vival from some values presented in the literature is not entirely clear. Dierences in beam
hardness between the experiments are small, and X-ray dosimetry techniques are routine,
leaving cell handling and culture protocols as the most likely explanation. The data pre-
sented from Gabel et al [55], Folkard et al [126] and Chapman et al [136] are for v79s grown
and irradiated in conventional tissue culture conditions. The current study and two others
where the v79 cells were irradiated and/or cultured on mylar bases, Belli et al [137] and
McNally et al [1], show better agreement. This may indicate that the growing conditions in
these experiments aected their response to irradiation. At odds with this conclusion is the
data from Thacker et al [111] for cells also grown on mylar. However, these data have large
published uncertainties.
Temperature was unlikely to be a factor in these exposures, as the irradiation room was
at 20 degrees Celsius or higher.
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Figure 3.24: Comparison of V79 cell survival after exposure to x-rays with historic data from
Thacker et al [111], McNally et al [1], Belli et al[137], Gabel et al[3], Chapman et al[136] and
Folkard et al [126]
Alpha (Gy  1) Beta (Gy  2)
Current Study 0.2587 0.0309 0.0307 0.0032
Thacker et al [111] 0.0789 0.0467 0.0373 0.0092
McNally et al [1] 0.2801 0.0286 0.0194 0.0025
Folkard et al [126] 0.1100 0.032 0.0270 0.0058
Belli et al [137] 0.1248 0.0156 0.0448 0.0035
Chapman et al [136] 0.1582 0.0236 0.0297 0.0029
Gabel et al [3] 0.0763 0.0474 0.03432 0.0047
Table 3.5: Fit parameters for gure 3.24. Cell survival after exposure to X-rays. Values taken
from published papers for historic data. Fits to the experimental data presented here were calculated
in Origin, along with the associated uncertainties.
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Figure 3.25: Comparison of V79 survival response with the work of McNally et al[1]. Fitted line
parameters as shown in table 3.5, condence bounds calculated in Origin.
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3.6.2 Mixed Field Exposures
Gamma Rays and Alpha Particles
The results of the combined gamma ray and alpha particle irradiations are shown in gure
3.26. For this series of irradiations the corresponding doses of high and low LET radiations
were chosen to give approximate identical eects (surviving fraction), based on previous
work. These doses were chosen as a starting point due to the fact that in healthy tissue in
BNCT, with a boron concentration of 15 ppm, receives approximately half of it's weighted
dose from alpha particles.
Each of the points on the graph represents between 3 and 5 individual experimental de-
terminations, which were carried out over a 5 week period. As described in the experimental
protocol, the cells were incubated for 2 hours post irradiation to allow for repair processes
to complete.
Figure 3.27 shows a comparison between the mixed eld experimental data and calculated
values which correspond to the eect of the two radiation qualities behaving in a strictly
additive fashion. `Additive' here, and in this rest of this document, is used in the same sense
as used by Suzuki [138] in his mixed eld work; the additive values were calculated from
(alpha particle only surviving fraction)  (gamma ray surviving fraction) at each point.
Comparing the two data sets of data points shows no signicant dierences. This is also the
case when comparing the t parameters, as shown in table 3.6.
Alpha (Gy  1) Beta (Gy  2)
Mixed alpha and gamma 0.3672  0.0345 0.02543  0.0041
Expected mixed eld (no synergy) 0.3748  0.0491 0.0213  0.005
Alpha only 1.2486  0.101 0.0487  0.0015
Gamma only 0.2332  0.004 0.018  0.0008
Table 3.6: Fit parameters for curves shown in 3.26 and 3.27. Fits to V79 cell survival in alpha
particle, gamma ray and mixed elds calculated in Origin.
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Figure 3.26: Survival data for mixed gamma ray and alpha particle irradiations
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Figure 3.27: Comparison between experimental mixed gamma ray and alpha particle irradiation
data and additive response from the elds given separately
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X-Rays and Alpha Particles
The results of the combined 250 kV X-ray and alpha particle irradiations are shown in
gure 3.28. Each of these data points represents the mean of between 5 and 13 experimental
determinations. In order to make any variance from the expected, additive behaviour clear
the data is replotted in gure 3.29. In this plot the mixed eld data sets have been divided
by the appropriate alpha particle only survival value, as calculated from the tted curve.
This allows any synergistic behaviour to be seen as a deviation from the X-ray only curve.
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Figure 3.28: V79 cell survival in mixed LET elds. Fitted lines are linear-quadratic functions.
Alpha (Gy  1) Beta (Gy  2)
X-ray only 0.2587  0.0309 0.03070.0032
X-ray with 2.54Gy alpha 0.4480  0.0214 -
X-ray with 3.18Gy alpha 0.6383  0.0390 -
Table 3.7: Fitted values of alpha and beta for the curves in gures 3.28 and 3.29. Survival data
for v79 cells. V79 survival after exposure to mixed X-ray and alpha particle elds. Mixed curves
adjusted by dividing by the alpha particle only response. Values derived from a weighted chi squared
t of the linear quadratic function.
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Figure 3.29: Re-plot of mixed X-ray and alpha particle irradiations to show synergistic eect.
V79 cell survival in mixed LET elds. Fitted lines are linear-quadratic functions. Mixed curves
adjusted by dividing by the alpha particle only response.
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Figure 3.30: Re-plot of mixed gamma ray and alpha particle irradiations to show synergistic eect.
Mixed curves adjusted by dividing by the alpha particle only response. Fit lines from unweighted
chi squared minimisation.
Alpha (Gy  1) Beta (Gy  2)
X-ray only 0.2294  0.0125 0.0357  0.0037
X-ray with 2.54Gy alpha 0.1756  0.0323 0.0393  0.0093
X-ray with 3.18Gy alpha 0.3520  0.0534 0.0891  0.0232
Table 3.8: Fitted values of alpha and beta for the curves in gure 3.30. Values derived from an
unweighted chi squared t of the linear quadratic function. Mixed curves adjusted by dividing by
the alpha particle only response.
It appears from the plot in gure 3.29 that the mixed irradiation, with a 3.18 Gy dose of
alphas, shows a strong synergistic eect. There appears to be no signicant synergistic eect
for the mixed eld with 2.54 Gy of alphas. However, comparing the tted curve parameters
(table 3.7) suggests that there is a synergistic eect in both cases. Some caution is required
when interpreting these ts as the parameters are strongly dependent on the way the data
is weighted in the tting calculation. Re-tting the data without error weighting, as shown
in gure 3.30 and table 3.8, produces ts which are not signicantly dierent for the X-ray
only and 2.54 Gy alphas with X-rays. The t to 3.18 Gy mixed data remains signicantly
dierent.
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Figure 3.31: Re-plot of cell survival data for human kidney cells of human origin irradiated with
alpha particles taken from [38].
Results are complicated further by the fact that at the lowest survival levels there appears
to be some `levelling o' of the survival curve. As mentioned in section 3.6.1, a similar eect
was noted by Barendsen et al [38] when carrying out their alpha particle irradiations at doses
greater than 3.5 Gy. Part of their data has been reproduced in gure 3.31. Their proposed
explanation was a small sub population of cells, which did not adhere to the base of their
dishes, and received a much reduced alpha particle dose. A similar eect may be visible in the
data presented in this report, although with a much smaller population than was observed
by Barrendson et al. The data for the mixed irradiation, with 3.18Gy of alpha particles,
was retted with the lowest survival data point excluded from the tting calculation. The
results are shown in gure 3.32. It is clear, from referring to the t parameters in table 3.9,
that excluding the last point does not have a signicant eect on the t.
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Figure 3.32: Re-plot of mixed gamma ray and 3.18 Gy alpha particle irradiations to show syner-
gistic eect. V79 survival data. Fit lines from weighted and unweighted chi squared minimisation
with the lowest survival point excluded from the tting calculation.
Alpha (Gy  2) Beta (Gy  2)
Weighted 0.6772  0.0557 -
Unweighted 0.3510  0.0536 0.0896  0.0233
Table 3.9: Fitted values of alpha and beta for the curves in gure 3.32. Fit lines from weighted
and unweighted chi squared minimisation with the lowest survival point excluded from the tting
calculation.
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3.6.3 Statistical Comparison of Data
Each of the groups of independent measurements corresponding to the mixed 2.54Gy and
3.18Gy alpha plus X-ray curves has been compared to the equivalent expected `additive'
result using a t-test. The t statistic was calculated form the dierence between the two
group means, divided by the standard error of the dierence from the means;
t =
xT   xC
SE(xT   xC) (3.6.1)
From the values in table 3.10 it is apparent that there is no statistically signicant
dierence between the expected response to the mixed eld data, with 2.54 Gy of alpha
particles, and the experimental data.
X-ray dose (Gy) Alpha dose (Gy) t DOF value for 95/% condence
2 2.54 -0.493 13 1.771
4 2.54 -0.755 15 1.753
6 2.54 -0.641 11 1.796
8 2.54 0.988 15 1.753
10 2.54 1.640 15 1.753
2 3.18 -1.128 12 1.782
4 3.18 -2.978 14 1.761
6 3.18 -1.846 10 1.812
8 3.18 -0.796 15 1.753
Table 3.10: t-test results for mixed eld data
In the case of the mixed eld data with 3.18 Gy of alpha particles there is a signicant
dierence from the expected response with both 4 Gy and 6 Gy of X-rays. The lack of
signicance at 8 Gy, and the marginal signicance at 6 Gy, is likely an artifact of the
levelling of the survival curve discussed earlier.
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3.7 Comparison of Mixed Field Results with Published
Data
A plot of the X-ray mixed eld data presented in this report, along with the results published
by McNally et al can be seen in gure 3.33. While the survival levels in the McNally et al
2.5 Gy data and the 2.54 Gy exposure presented in this report are similar, in the region
of doses explored in the McNally experiment, the tted lines diverge at higher doses. The
dierence in survival seen in the single eld exposures between the two studies also leads
to a large dierence in the expected mixed eld survivals and therefore in the magnitude of
the observed synergistic eect.
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Figure 3.33: Comparison of v79 cell survival in mixed x-ray/alpha particle elds with previously
published work by McNally et al[1].
McNally et al observed a synergistic eect at two of their alpha particle dose points, 2Gy
and 2.5Gy (gure 3.5 on page 52). Synergy leading to higher than anticipated cell kill was
only seen at 3.18Gy and not at 2.54Gy of alphas in our recent work (gure 3.29 on page 83).
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Figure 3.34: Comparison of tted x-ray survival curves with tted mixed eld survival curves.
Data for the mixed eld case was generated by dividing the experimental mixed eld data by the
appropriate single eld alpha survival value.
The level of synergistic eect can be seen in gure 3.34. This is a plot of the curves tted
to the X-ray response in each study along with a plot of a linear quadratic t to (the mixed
eld survival)/(single eld alpha survival).
The change in response in McNally et al 's 2.5Gy and the current 3.18Gy exposure was
similar in that both showed a purely exponential response to the mixed eld exposure. This
diers from what would be expected from a simplistic multiplication; (single eld alpha
survival)  (single eld X-ray response) for a single alpha particle dose, as this function
leads to a shouldered curve. The level of synergistic eect therefore varies over the x-ray
dose range. A comparison of synergistic eect, or `additional cell kill', is shown in gure
3.35, calculated from the curves in gure 3.34. This curve is a plot of dierence between the
observed mixed eld response, divided by the appropriate alpha survival, and the single eld
x-ray data. The dierence is plotted as a fraction of x-ray response so 1 corresponds to the
X-ray survival level, 2 to half the x-ray survival level and so on. Finding the maximum value
of the functions in Mathematica gives a low LET fraction of 0.67 for the data presented here
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Figure 3.35: Plot of observed synergistic eect against low LET fraction for v79 cell exposures.
Data generated from tted curves to X-ray single eld data and to the tted mixed eld curves from
3.34
and 0.77 for McNally et als work. These correspond to X-ray doses of 6.36 Gy and 6.76 Gy.
The reason for the dierences in which alpha particle doses exhibited a synergistic eect,
and the level of synergistic eect, between the two studies is not clear. There were some
dierences in experimental protocol between the studies. Perhaps the most obvious is the
truly simultaneous nature of the more recent irradiations. McNally et al performed a quasi-
simultaneous irradiation where one radiation quality was delivered, the cells were maintained
at 4 C for a brief period before exposure to the second radiation type.
There were a number of dierences in cell handling technique. Rather than irradiating
a cell monolayer and diluting the cells for colony growth, McNally et al introduced an
appropriate number of cells into the dishes pre-irradiation and the colonies were grown in
the irradiated dishes. This could have introduced a reduction in true alpha particle dose
delivered, through a shielding eect at the dish edges. Examination of the single eld alpha
particle doses suggests that this eect, if present, is small at the alpha particle doses of
interest ( 2.5 Gy).
The technique of plating the cells into mylar based dishes 48hr prior to exposure adopted
in this study was based on experience at the MRC with this methodology and published
work which used the same technique [111][139]. There is some suggestion in these papers by
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Thacker et al and Raju et al that V79 cells grown on mylar take signicant amounts time
to assume the `attened' morphology of cells attached to a surface. McNally et al plated
their cells onto mylar four to six hours prior to alpha particle irradiation. If the cells were
not at at the time of irradiation the path length of the alpha particles through the cells,
and consequently the dose delivered for a given ux, would be higher than that for at cells.
Again, examination of single eld alpha survival suggests that this eect would not explain
the dierence observed in the dual eld cases.
Dose rates were dierent between the two studies. McNally et al delivered the photon
dose at 3 Gy min 1 as opposed to 1 Gy min 1 in the recent work. Alpha particles were
delivered at 0.3 Gy min 1. The alpha dose rate in the recent work varied, as the alpha
irradiation time was matched to the photon irradiation time. The maximum was 1.59
Gy min 1 and the minimum 0.254 Gy min 1. The longest exposures were 12 minutes,
the shortest 2 minutes. These dose rate dierences would not normally be expected to
produce signicantly dierences in survival in single eld experiments as they would both
be considered `acute'. Ling et al have demonstrated that some dose rate eect is present
above 1 Gy min 1, with a dierence observed between 10 Gy min 1 and 1 Gy min 1 at the
same dose. The eect observed was small, 1% or less at the photon dose levels considered
in the current work [140].
Frank et al [141] demonstrated that cells with diering morphologies, spheroids or mono-
layers, expressed diering degrees of dose rate eect. They postulated that the spheroid
status confers greater protection against lesion xation or misrepair. If the synergistic eect
is more sensitive to dose rate than single eld photon exposures and if, as suspected, the
morphology of the cells between the two studies was somewhat dierent then this may pro-
vide some explanations for the diering levels of synergy seen. Further studies at varying
dose rates are required for greater understanding of the eect.
This potential dierence in repair between the two studies is reected in the diering
alpha/beta ratios seen in the single eld X-ray exposures. McNally et al obtained a value
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of 14.4  2.4 Gy compared to a value of 8.4  1.3 Gy in our more recent work. This
ratio indicates the dose where alpha mediated cell kill is equal to beta mediated cell kill.
Lower ratios therefore indicate a survival response with a larger contribution from multiple
event, potentially repairable, damage. If the synergistic eect is repair dependant then the
conditions responsible for this dierence, seen in the single elds, could also account for the
dierences seen in mixed eld responses.
Uncertainties over the origin of the synergistic eect make drawing denitive conclusions
dicult. Further discussion of potential synergistic mechanisms can be found it section 3.9.
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3.8 Comparison with Theoretical Predictions
3.8.1 Linear-Quadratic Based
There have been a number of attempts to treat the proposed synergistic interaction between
dierent radiation qualities theoretically. Zaider and Rossi [89] used The Theory of Dual
Radiation Action (TDRA) [142] as a starting point. The base assumption of the TDRA is
that ionizing radiation produces `sub-lesions' at a rate proportional to the specic energy, z.
Pairs of these sub-lesions produce lesions and the number of lesions is proportional to the
observed colonogenic survival.
Following the approach presented in [112], the yield of sublesions is cz where c is a
constant. Taking A as the probability of interaction between two sublesions, the yield of
lesions is therefore;
(z) = Ac2z2 = kz2 (3.8.1)
where k = Ac2.
The specic energy is a stochastic quantity and for an absorbed dose of D the average
number of lesions can be expressed as;
(D) =
Z
(z)f(z;D)dz (3.8.2)
f(z;D)dz is the probability, dependent on dose, that the specic energy lies between z
and z + dz. It is dened so that;
Z
f(z;D)dz = 1;
Z
zf(z;D)dz = D (3.8.3)
It was shown by Kellerer and Rossi in [143] that (D) can be expressed as;
(D) = k(D +D2) (3.8.4)
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 is the dose mean of the specic energy deposited in single events.
Choosing an appropriate constant k such that;
 = k;  = k (3.8.5)
allows survival fractions to be calculated from;
S = e D D
2
(3.8.6)
With two doses of radiation, D1 and D2, with specic energies z1 and z2 the yield of
sublesions is c1z1 and c2z2. Equation 3.8.2 can then be rewritten to give the yield of lesions
in the two dose case;
(z1; z2) = A(c1z1 + c2z2)
2 = (k
1=2
1 z1 + k
1=2
2 z2)
2 (3.8.7)
(D1; D2) =
Z Z
(z1; z2)f(z1; z2;D1; D2)dz1dz2 (3.8.8)
As z1 and z2 are independent scholastic variables the probability function can be written
as;
f(z1; z2;D1; D2) = f1(z1;D)f2(z2;D2) (3.8.9)
Using 3.8.3 and 3.8.4 this gives;
D1; D2 = k11D1 + k22D2 + (k
1=2
1 D1 + k
1=2
2 D2)
2 (3.8.10)
and the surviving fraction can be calculated from
S = e (1D1+1D
2
1+2D2+2D
2
2+2(12)
1=2D1D2) (3.8.11)
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The expected synergistic eect is reected in the dierence between equations 3.8.6 and
3.8.11; the 2(12)
1=2D1D2 term. Zaider and Rossi referred to this as the interference term.
It suggests that an interaction between the sub-lesions produced by each radiation type
interact, to produce more lethal damage than would be expected from the two irradiations
given separately.
This treatment of sequential irradiations implies that the order in which the two irradia-
tions are given is irrelevant. This is in agreement with the experimental ndings of McNally
et al [34] [144] with neutrons and X-rays. No signicant dierence in survival was found be-
tween X-rays followed by neutrons, neutrons followed by x-rays or both given simultaneously.
Similar results were shown by Suzuki [145].
The theoretical predictions of equation 3.8.11 can be compared to experimental mixed
eld data through obtaining values for the 1; 2; 1 and 2 constants from single eld
irradiations. Using the alpha and beta values arrived at using weighted chi squared tting
(table 3.7) modelled vs experimental results for 2.54 Gy of alpha particles plus photons and
3.18 Gy of alpha particles plus photons are shown in gures 3.36 and 3.37 respectively.
It is clear that the Zaider-Rossi model is an excellent t to the mixed eld survival data
with 3.18Gy of alpha particles. For the 2.54 Gy of alpha particles the model predicts lower
survival than was observed experimentally. Uncertainties in these Zaider-Rossi plots and all
further model plots were calculated from the uncertainties in the single eld alpha and beta
values.
Suzuki [145][146] modied the Zaider and Rossi model to apply to various mixed eld
irradiation regimes. They also presented experimental data to demonstrate that the order
of irradiation in sequential mixed eld exposures is not signicant. The model presented
in the paper included terms to account for cell recovery during the course of irradiation.
This extension allowed them to explain the variation in observation of synergistic eects
between Higgins et al [147] and McNally et al [144], with neutron-photon mixed elds, as
due to dierences in dose rates. The model, as derived in [145] is;
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Figure 3.36: Comparison of experimental mixed eld results for 2.54Gy of alpha particles plus
photons with the Zaider Rossi model. Parameters for the Zaider-Rossi model were taken from the
ts shown in table 3.8
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Figure 3.37: Comparison of experimental mixed eld results for 3.18Gy of alpha particles plus
photons with the Zaider Rossi model. Parameters for the Zaider Rossi model were taken from the
ts shown in table 3.8
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S = exp [ ( 1a1D
a1 + a2
+
2a2D
a1 + a2
+
q11a
2
1D
2
(a1 + a2)2
+
q22a
2
2D
2
(a1 + a2)2
+ 2q12(D;T )
p
12
a1a2D
2
(a1 + a2)2
)]
(3.8.12)
Where D is total dose, a1 and a2 are the relative dose rates of the two radiation types.
1,2,1 and 2 are the constants determined by tting curves to the single eld irradi-
ation data.
q1,q2 and q12 are cell repair related reduction factors. In the special case of simultaneous
irradiation q1 = q2 = q12 and is given by;
q12 = (
t0
t
)2[exp (
t
t0
)(1  exp ( t
t0
))2 + exp ( t
t0
)  exp ( t
t0
) +
2t
t0
] (3.8.13)
t is the irradiation time.
t0 is referred to, somewhat confusingly, by Suzuki as the `time constant for recovery'.
This formulation of cell recovery is based on the work of Kellerer and Rossi, in `The theory
of dual radiation action' [148], who refer to the same factor as recovery time.
Kellerer and Rossi's treatment of dose rate dependent recovery introduces a reduction
factor applied to the  term in their linear-quadratic formula. A function (t) was in-
troduced, which determines the interaction probability as a function of the time interval
between the formation of two sublesions. This is assumed to be exponential, that is;
(t) = e
( t
t0
)
(3.8.14)
Their formula for a reduction factor q(T), derived in reference [148], for a continuous
irradiation of duration T and dose D can be written;
q(T ) =
2t0
T
  (2t
2
0(1  eT=t0)
T 2
)D2 (3.8.15)
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Figure 3.38: Plot of reduction factor of the beta term as a function of irradiation time T and
recovery time t0[148]
The function for cell survival therefore becomes;
S = e (D+q(T )D
2) (3.8.16)
A plot of reduction factor against the ratio of exposure time to recovery time is shown
in gure 3.38. At the limit of T/t0 ! 0 equation 3.8.16 reduces to the standard linear
quadratic function. At the limit where T/t0 ! 1 the beta term is insignicant and the
survival function is reduced to a simple exponential. This eect of the beta component
tending to zero has been observed in cell experiments, as illustrated in gure 3.39.
Zaider and Brenner arrive at a value of t0 for V79 cells of 78.6 minutes [150]. This is a
value obtained by by tting a survival function, which accounts for repair in the intertrack
(beta) term, to single eld photon exposures at diering dose rates R;
S(D) = exp (D + q(D;R)D2) (3.8.17)
q(D;R) = 2t0R=D   2(t0R=D)2[1  exp( D=t0R)] (3.8.18)
A comparison of the `Extended Zaider-Rossi model' to the experimental data presented
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Figure 3.39: Plot of survival response of V79 cells to varying 250 kV X-ray dose rates. The
low dose rate has an exponential response, with tted constants in the linear quadratic function of
 = 0:07940:002 and negligible . Fitted constants for the acute exposure were  = 0:16870:0119
and  = 0:0093 0:002. Data replotted from [149].
in this report is shown in 3.40 and 3.41. Values of 1; 2; 1 and 2 were obtained by tting
the single eld data. A t0 of 78.6 was used.
There are no large dierences in survival levels predicted by the extended Zaider-Rossi
compared to the standard Zaider-Rossi model for the dose rates utilised in the irradiations
detailed in this report or in the work presented in [1]. The irradiation time is small compared
to the recovery time. It is likely that Suzuki's treatment of repair is something of an
oversimplication for all dose rates, as it is assumed that the repair is LET independent.
This has been disproved experimentally by Belli et al [151] and others; see gure 3.42.
There is instead signicant evidence that the level of repairable damage is related to the
complexity of the damage, which is in turn related to the ionisation track structure of the
radiation inducing it. This is discussed further in section 3.9.
The statistical approach of the TDRA, on which the Zaider-Rossi model is based, implies
that the biological eect is expressed immediately after dose deposition and disregards cell
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Figure 3.40: Comparison of experimental mixed eld results for 2.54 Gy of alpha particles plus
photons with the Extended Zaider-Rossi model. Parameters for the Zaider-Rossi model were taken
from the ts shown in table 3.8 on page 84 along with the associated uncertainties. Doses are total
dose delivered to the cells.
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Figure 3.41: Comparison of experimental mixed eld results for 3.18 Gy of alpha particles plus
photons with the Extended Zaider-Rossi model. Parameters for the Zaider-Rossi model were taken
from the ts shown in table 3.8 on page 84 along with the associated uncertainties. Doses are total
dose delivered to the cells.
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Figure 3.42: Repair of double strand breaks with time vs LET, in V79 cells. Taken from [151]
repair kinetics. More recent models of cell survival such as the Microdosimetric-Kinetic
(MK) model proposed by Hawkins [152] attempt to combine more sophisticated modelling of
repair and injury processes with a microdosimetric description of radiation energy deposition.
These models have been further extended in various ways [153] [154] to attempt account
for the repair mechanisms dependance on LET. Ultimately these models are limited in
their usefulness due to the large number of parameters which are dicult to determine
experimentally.
The Zaider-Rossi approach may overemphasise the non zero beta constant in the t to
the single eld alpha particle data presented in this report. It is often assumed that a high
LET alpha particle survival curve is exponential with a beta value of zero. Retting the
alpha particle data with beta constrained to zero, as shown in gure 3.43, gave an alpha
value of 1.356  0.012 Gy 1. The quality of t is reduced from the unconstrained case,
with a reduced 2 of 0.2382 vs 0.0014 for the unconstrained case. The reduction is not
signicant as both ts are within experimental uncertainty. Re-plots of the Zaider-Rossi
model with this revised value can be seen in 3.44 and 3.45. The model is a good match for
the 2.54 Gy data but predicts higher survival than is seen experimentally in the 3.18 Gy
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Figure 3.43: Comparison of unconstrained linear quandratic t and constrained t to single eld
alpha particle survival data. Constrained t parameters were =1.356, =0 with beta xed
alpha mixed eld data. This is to be expected as with a zero 2 term the interference term
in the Zaider-Rossi model is zero, no synergistic eect is predicted and the model reduces
to the two single eld curve results multiplied together.
The reduction to zero of the interference term in the Zaider-Rossi, and extended Zaider-
Rossi, model for zero  is the explanation for the lack of agreement at higher alpha particle
dose levels with the work of McNally et al. The Zaider-Rossi model, using the parameters
from the single eld data in [1], predicts a response with no large synergistic eect at a
dose of 2.5 Gy or 3 Gy of alpha particles. This at variance with the experimental results
presented by McNally et al. A comparison between the data presented by McNally et al
and the Zaider-Rossi model at this level can be seen in gure 3.46.
In the tted models presented so far the values of the coecients in the linear quadratic
function have been derived from tting both  and  to single eld data. This has yielded
values of  High,High from the alpha particle irradiations and Low,Low from the X-ray
irradiations. However, the TDRA predicts that high LET radiation increases the linear, ,
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Figure 3.44: Comparison of experimental mixed eld results for 2.54 Gy of alpha particles plus
photons with the Zaider-Rossi model. Parameters for the Zaider-Rossi model were taken from the
X-ray ts shown in table 3.8 on page 84. Single eld alpha particle parameters were =1.356, =0
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Figure 3.45: Comparison of experimental mixed eld results for 3.18 Gy of alpha particles plus
photons with the Zaider-Rossi model. Parameters for the Zaider-Rossi model were taken from the
X-ray ts shown in table 3.8 on page 84. Single eld alpha particle parameters were =1.356, =0
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Figure 3.46: Comparison of experimental mixed eld results for 2.5Gy of alpha particles plus
photons with the Zaider Rossi model. Experimental data replotted from gures presented in [1] and
model parameters were taken from ts to the single eld data in the same reference.
component of radiation damage without changing the quadratic term,  [142] [76]. This
implies survival in the high-LET case can be predicted by;
SHigh = e
 (HighDHigh+LowD2High) (3.8.19)
Where SHigh is cell survival, High is the linear coecient for high LET, Low is the
quadratic coecient found at low LET and D High is dose of high LET radiation delivered.
To determine High for the alpha particles, used in both the current study and the work
of McNally et al, the single eld data was re-tted with beta constrained to the value of Low.
The results are shown in table 3.11. The extended Zaider-Rossi model was recalculated for
each mixed eld case, using these values. Results for the current study are shown in gure
3.47. It is clear that this methodology produces a predicted response much closer to that
which was observed by McNally at lower alpha particle doses. The model still under predicts
cell kill for the highest alpha particle dose delivered by McNally et al (2.5 Gy).
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Alpha (Gy  1) Beta(Gy  2)
Current study 1.2876 0.0307
McNally et al 1.1111 0.0194
Table 3.11: Fit parameters for single eld alpha particle survival data when beta is constrained
to the value of Low
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Figure 3.47: Comparison of the Zaider-Rossi model with experimental mixed eld results for
irradiation with alpha particles plus photons. Co-ecients for the model are as stated in table 3.11
Similar model predictions for the irradiations presented in this report are found using
Low for both levels of LET instead of Low and high. Both approaches predict lower cell
survival in the 2.54Gy alpha mixed case than is observed experimentally while being in good
agreement for the 3.18Gy of alpha particles dose level.
There is some suggestion from re-analysis of historic fast neutron survival data that
rather than being xed with LET the beta constant may actually increase with increasing
LET [78]. If this was the case in the mixed eld exposures then model comparisons with
McNally et al 's higher alpha dose, mixed eld, data would be improved.
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Figure 3.48: Comparison of the Zaider-Rossi model with experimental mixed eld results taken
from [1]. Plotted points are the experimental data and lines are the associated model. Numbers
indicated the alpha particle dose delivered in addition to the photons. Coecients for the model
areas are as stated in table 3.11.
3.8.2 Lesion Additivity Model
A dierent approach to predicting survival in a mixed eld irradiation to that of Zaider
and Rossi was introduced by Lam [155]. This model has as it's central assumption some
intermediate stage in the cell inactivation path, where dierent types of lesion precursors
produced by dierent radiations become indistinguishable and therefore additive. It also
assumed that precursors competing to produce lesions have equal probabilities and that
lesion precursors reach the intermediate stage concurrently if delivered within a suciently
short time [156]. The model derived in [155] can be stated as;
RBEmix =
X
i
fiRBEi (3.8.20)
where fi is the fraction of radiation, with an RBE of RBEi at the eect level being
considered. Predicted cell survival curves can be constructed by calculating RBEmix across
a range of doses.
106
0 2 4 6 8 10 12 14
1E-6
1E-5
1E-4
1E-3
0.01
0.1
1
 Experimental
 Lam model
S
ur
vi
vi
ng
 F
ra
ct
io
n
Total Dose (Gy)
Figure 3.49: Comparison of the Lam et al lesion model[155] with survival data from mixed X-ray
/ 2.54 Gy alpha particle exposures
Figures 3.49 and 3.50 show a comparison between predicted survival values calculated
with the Lam model and experimental work. As with the Zaider-Rossi models good agree-
ment is seen for the data with 3.18Gy of alpha particles, at lower x-ray doses, and poor
agreement at 2.54 Gy. To produce the model ts an alpha particle RBE was calculated
at each survival level based on the linear-quadratic ts to the single eld X-ray and alpha
particle data. Poorer agreement is seen at higher doses in the 3.18 Gy of alpha particles case
than was seen with the Zaider-Rossi model. This was due to the model predicting a larger
degree of curvature than the purely exponential response of the Zaider-Rossi prediction.
This similarity between predictions of the Lam model and the ZR model found here was
also reported by Tilly et al when comparing them to combined gamma ray, nitrogen ion
exposures [156].
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Figure 3.50: Comparison of the Lam et al lesion model[155] with survival data from mixed x-ray
/ 3.18 Gy alpha particle exposures
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3.9 Mechanism of Synergy
There are several mechanisms which could conceptually lead to a synergistic survival re-
sponse in cells exposed to two radiation elds. Possibilities could include an overall increase
in the level of damage, an interaction between existing damage resulting in damage more
eective at causing cell death and an impairment or prevention of damage repair.
As the level of damage is proportional to absorbed dose in a cell, it is hard to see how
a mixed eld would introduce any `extra' damage which could account for synergy. The
amount of DNA damage has been observed to be proportional to the energy deposited.
However, here is signicant evidence that it is not the absolute level of damage but rather
the local complexity of damage which dictates a cells response. The ionisation track struc-
ture is thought therefore to account for the dierence in biological eect, for a given dose,
seen between high LET ions and low LET photons [157]. High LET radiation deposits most
of its energy in the form of relatively small numbers of densely ionising tracks through a
cell compared to much more sparsely ionising electron tracks, produced in large numbers by
X-rays, and distributed randomly throughout a cell. These dierent energy depositions are
reected in the distributions of DNA damage [158]. Thanks to modern antibody staining
techniques, the dierences in density of DNA damage can now be directly observed. Phos-
phorylation of histone protein H2AX on serine 139 occurs at sites anking Double Strand
Breaks (DSB) and can provide a measure of the number of DSBs within a cell [159]. It also
provides an informative visualisation of the location of the damage sites [160]. An example
of images produced using this technique and an illustration of the track dierences between
radiation of diering qualities can be seen in gure 3.51.
The idea that damage from low and high LET tracks could interact, increasing local
complexity of damage and producing more damage clusters, is an appealing explanation for
synergy. However, this is unlikely. The complexity in question, which dictates the likelihood
of a DSB being repairable, involves additional damage within a few DNA base pairs of a
DSB. Monte Carlo track structure models suggest that this additional damage is present in
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Figure 3.51: Formation of uorescent -H2AX clusters in irradiated human broblasts, at 10
min post-irradiation, with (A) 2 Gy of g rays, (B) 0.5 Gy of 54 keV/mm silicon ions, or (C) 0.5
Gy of 176 keV/mm iron ions. Each panel shows the DAPI-stained nucleus(blue)and anti-g-H2AX
antibody (green) [161].
Energy SSB/DSB SSB complex/simple DSB complex/simple
Electrons 0.3 keV 11 0.12 0.28
Electrons 1keV 13 0.11 0.32
Electrons 10 keV 30 0.05 0.23
Electrons 100keV 30 0.04 0.2
 particles 2 MeV 2 0.27 0.73
 particles 4 MeV 3 0.23 0.61
Table 3.12: Clustered DNA damage from dierent radiation qualities. Complex SSB are dened
as single-strand breaks with additional break(s) on the same strand. Complex DSB are double-strand
breaks with additional break(s) on one or both strands. The values for electrons are for full slowing
down tracks of the stated starting energy; the values for alpha particles are for track segments of
the stated energy/. From [162].
approximately 20% of higher energy X-ray DSB's and 60% or more of high LET  DSB's -
see table 3.12. The small dimensions of these clusters leads to the conclusion that clustered
damage is produced almost exclusively within single tracks. The probability of separate
tracks overlapping within the nanometre scale in question is negligible even at very high
doses [162].
Interference with normal cell repair processes has long been proposed as a mechanism for
synergy. While some eorts have been made to investigate this, with delayed cell plating and
separation of the two dose components in time [31][34], little insight into the mechanism has
been gained. It was demonstrated that with a separation of several hours between irradiation
qualities independent action was observed. This lead to a suggestion that there was some
element of interactive damage, which was itself repairable [31].
A recent study by Sta et al [163] applied -H2AX staining assays to mixed eld ex-
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Figure 3.52: Original uorescence microscope images and program output images for -H2AX
labelled VH10 cells irradiated with X-rays (A and D), alpha particles (B and E) and a mixture (C
and F). Top row are original images and the bottom row program output. Red dots in the program
output indicate small foci, green indicate large. From [163].
posures. They exposed VH10 human broblast cells to 190kV X-rays and 241Am alpha
particles, with an LET entering the cell layer ranging from 100 keVm to 172 keVm.
Doses used were 0.13, 0.27 and 0.32 Gy alpha particles, 0.20, 0.40 and 0.80 Gy X rays and
0.27, 0.53 and 0.80 Gy mixed beams, with 25% of the dose contributed by alpha particles.
The alpha irradiation was delivered perpendicularly to the cell layer so, after staining, alpha
particle cell traversals were visible as single large gamma-H2A X Ionising Radiation Induced
Foci (IRIF). Small individual IRIF's were not distinguishable within the track. Previous
results using 3D analysis of carbon ion tracks found approximately 15 IRIF's within each
of these large foci. Therefore, to avoid under-counting IRIF's and facilitate analysis, IRIF's
within their results were classied automatically in software into small foci (SF) or large
foci (LF) groups, depending on area. Numbers of large foci were well matched to number
of cell traversals, calculated from uence and cell area, indicating that each LF in the alpha
case corresponded to a single alpha track. Sample images, along with classication program
output can be seen in gure 3.52.
In analysis of their mixed eld data Staaf et al 's [163] most signicant ndings were
related to repair kinetics. They found that, for large foci, signicant dierences between ex-
perimental responses to the mixed eld and predictions from single eld data were observed.
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Figure 3.53: Dose response and repair kinetics for summarised gamma-H2AX foci number and
total area per nucleus for VH10 cells. Cells were exposed to 0.27 Gy alpha particles, 0.8 Gy X-rays
and 0.13 + 0.40 Gy mixed beams of alpha particles and X-rays. Taken from [163].
Figure 3.54: Dose response and repair kinetics for summarised gamma-H2AX foci number and
total area per nucleus for VH10 cells. Large gamma-H2AX foci data replotted as a percentage of
total gamma-H2AX foci. Cells were exposed to 0.13 +0.40 Gy mixed beams of alpha particles and
X-rays. * = signicant, p0.05. *** = signicant, p0.001. Taken from [163].
The frequency and area of large foci were initially lower than predicted and increased during
the rst 3 hours of repair, at variance with predictions. Response had returned to expected
levels after 24 hours. This data can be seen in gure 3.53. The same data is replotted, with
number of large foci as a percentage of total IRIF, in gure 3.54.
It was concluded that the repair kinetics of large foci, indicative of complex damage
sites, in cells irradiated with a mixed beam of alpha particles and X-rays was signicantly
dierent from predictions based on the eect of the single dose components. The initial
phosphorylation of the damage, indicated by area of visible foci, along particle tracks was
slower than expected. This was taken as an indication that the presence of low LET damage
delayed the DNA damage response to high LET damage.
These results are interesting and seem to conrm that the mechanism of synergy is related
to interference in the repair of DSB's. This is the rst study directly investigating DNA
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damage and repair after mixed beam exposure so it is likely that, in the coming years, similar
DNA damage assay studies will provide a wealth of useful data to help fully understand the
synergistic interaction.
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3.10 Summary
It is clear that, in some dose regimes, damage from high and low LET radiation does interact
in a way that produces higher levels of biological eect than might be expected from single
eld exposures. The mechanism of interaction is less clear. When considering the data
presented by McNally et al [1] and that which is presented in this report, it appears that
the level of synergistic eect is very sensitive to the experimental conditions.
To fully explore the mechanism which leads to increased cell kill in mixed eld exposures
more data are required. As the work of Staaf et al [163] seems to indicate that the synergy
mechanism changes the repair response, further repair related investigations would seem to
be warranted. An experiment, such as that carried out by Nandanuri et al [85] with photons,
where cell repair is eectively stopped at dierent time points after irradiation could yield
valuable information about the synergistic eect. Experiments with wider spreads of dose
rate, in both radiation qualities, may also yield interesting results. Development of the
irradiation rig described in section 3.2 is underway to allow for incubation of cells in situ,
allowing for the possibility of long exposure times. Similarly experiments such as those
performed by Hill et al [84] with alpha particles, using cells with the same parent line but
dierent repair deciencies, would help shed light on which specic DNA repair mechanisms
are involved.
Regardless of the physical basis of the synergy, use can still be made of models when
considering the biological eect of doses from mixed high and low LET elds. The Zaider
Rossi formulation is particularly useful as / ratios are widely available for many tissues
of clinical interest. The Linear Quadratic equation is used in a similar manner, as the basis
for determining the eect of elongation or fractionation of radiation therapy [164], despite
debate over it's physical origins. Caution has to be exercised as, while the Zaider-Rossi
model ts some data sets well, there is signicant disagreement with other experimentally
observed results. Again, further work is required to understand these ndings.
More complex track structure models such as the Local Eect Model (LEM) are nding
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use in treatment planning for carbon ion therapy. The current iteration (LEM III) has
introduced DNA damage clustering to improve tting to experimental data. It is possible
that, in the future, similar computational models can be extended to include the synergistic
eect.
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Chapter 4
EPITHERMAL NEUTRON BEAMS
4.1 Neutron Dosimetry
4.2 General Methodology
Dosimetry in BNCT is not straight forward. There are four major contributions to dose in
a BNCT treatment [165];
1. Boron dose. This is the dose arising from the 10B(n; )7Li reaction. The mean
energy deposited is approximately 2.33 MeV. The 477 keV gamma ray produced by
the de-excitation of the 7Li in the majority of the reactions is not considered as part
of the dose component.
2. Photon dose. The majority of the photon dose arises from the capture of thermal
neutrons in tissue. The 1H(n; )2H reaction emits a 2.2 MeV gamma ray. Further
contributions are from neutron capture in other materials and non-nuclear processes
such as Compton scattering.
3. Neutron dose. Neutrons of epithermal or higher energies scattering from hydro-
gen, result in recoiling hydrogen nuclei. Energy from these `recoil protons' and other
neutron induced reactions which deposit their energy locally, such as the 12C(n; )
reaction, are included in this dose component.
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4. Nitrogen dose. Thermal neutron capture in 14N produces the 14N(n; p)14C reaction.
Dose results from the energy deposited by the proton and the recoiling 14C.
It is not possible to measure all of these dose components directly. The approach taken
is to determine the thermal neutron ux experimentally and derive the other related and
dependant doses from known factors and a computational model. Practically this generally
involves irradiating a series of metal foils and measuring the resulting activity using a gamma
ray detector. These are the most precise dosimetry measurements available in BNCT. Direct
fast neutron and gamma ray doses are generally derived from measurements with the paired
ionisation chamber technique. The results from this are subject to large uncertainties [166].
The interaction rate of a neutron with energy E with an atom is equal to the product of
uence rate (E) and cross-section (E). The reaction rate per atom of such a process is
this product integrated over the full energy range, as shown in equation 4.2.1.
R =
Z
(E)(E)dE (4.2.1)
Thermal uence rate is dened as shown in equation 4.2.2, that is the neutron reaction
rate that produces the reaction rate R when multiplied by the cross section for neutrons of
speed 2200 m=s;
R = 00 (4.2.2)
The dosimetry used in this report used reaction rates induced in gold and manganese
foils as a measurement technique. Dilute foils are used to minimise self-shielding eects.
Reaction rates in these foils can be approximated as shown in equations 4.2.3 and 4.2.4
[165].
RMn = 00;Mn + epiIMn (4.2.3)
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RAu = 00;Au + epiIAu (4.2.4)
Where I is the resonance integral dened as shown in equation 4.2.5.
I =
Z 1
0:55eV
(E)
E
dE (4.2.5)
Solving equations 4.2.3 and 4.2.4 allows thermal and epithermal uence rates to be
calculated.
0 =
IAuRMn   IMnRAu
IAu0;Mn   IMn0;Au (4.2.6)
epi =
0;MnRAu   0;AuRMn
IAu0;Mn   IMn0;Au (4.2.7)
When a complete simulation of uence at dierent depths is available the above approx-
imations do not need to be used. Instead measured values for reaction rate can be used to
scale the theoretical uences appropriately.
A secondary measure of thermal neutron uence can be arrived at using the cadmium
dierence method as described in Rogus et al [167]. This involves exposing gold foils and
gold foils with cadmium covers to separate the activation of gold induced by thermal and
epithermal neutrons. The reaction rate of a gold detector with cadmium cover can be
expressed as shown in equation 4.2.8. FCd is a correction factor for absorption of epithermal
neutrons in cadmium, equal to 1 as a rst approximation.
(RAu)Cd = FCdepiIAu (4.2.8)
0 = [RAu   (RAu)Cd)]0;Au] (4.2.9)
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4.3 Dosimetry for this Report
All experimental and theoretical dosimetry was carried out by Zamir Ghani. A comprehen-
sive description of the work undertaken can be found in his PhD thesis [168]. A summary
is presented here.
4.3.1 Dosimetry in the Large Water Phantom
The majority of the neutron exposures described in this report were carried out in the
'Large water phantom' shown in gure 4.1. The beam enters the phantom through the area
of reduced thickness Perspex which is slightly larger than the area of the beam port.
To derive the doses used in the cell survival experiments, using the Birmingham dyna-
mitron, which are described in this report a Monte Carlo N Particle (MCNP) model was
used. This model incorporated the geometry of the target and its surroundings including
the beam moderator and the water phantom; see gure 4.2. The initial neutron spectra
produced in the lithium target was represented by a source denition originally produced
by Z. Ghani[169]. Fluence at a number of depths in the water phantom was tallied. This
uence was then converted to dose using the energy dependant kerma factors published by
Goorley et al [170].
To provide empirical scaling factors pairs of dilute (1% by weight, in aluminium) man-
ganese and gold foils were xed at a range of depths within the same water phantom being
used for the cell measurements. A perspex jig ensured repeatability of positioning within
1mm. This assembly was then irradiated using the dynamitron beam.
Post irradiation activity in the foils was measured using a high purity germanium detector
(HPGe). Photo peak eciency of the detector was calculated by measuring eciency for
a set of calibration sources, of known activity, and interpolating to give the eciency at
the energy of the characteristic gold and manganese photo peaks. These are 411 keV and
847 keV respectively. Measured gold and manganese activities were then used to calculate
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Figure 4.1: Large water phantom. 40 cm  43 cm  20cm (WHL). D=15cm with a thickness
of 5mm
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Figure 4.2: Output of MCNP le geometry used for dose calculations with the Birmingham BNCT
beam.
14N reaction rates using the approach developed by Freudenreich [171] and described in
`Recommendations for the Dosimetry of Boron Neutron Capture Therapy (BNCT)' [165];
R(14N) = [ 6 10 4  R(Au)
R(Mn)
+ 0:141]R(Mn) (4.3.1)
Dose rate values, at 935 A, derived from foil measurements for a nitrogen fraction of
1.1% are shown in table 4.1. Uncertainties in the calculated reaction rates derive from
uncertainties in the gamma ray counts, taken as
p
N where N is the total number of counts
and from uncertainties in the eciency calculation. A long enough counting time was used
in each case to reduce this error to 5% of the total. Uncertainties in the dose rate were
calculated from these values. A comparison between the MCNP simulated thermal dose and
the measured values at the same beam current is shown in gure 4.3. The simulated dose
has been scaled by a factor of 0.4 but the shape of the curve is in good agreement.
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Figure 4.3: 14N depth dose curve for thermal neutrons in the Birmingham dynamitron BNCT
beam. Dilute foil activation measurements compared to MNCP simulation. Simulated results have
been scaled by a factor of 0.4
Practically, dose rates for cell irradiations in both beams are scaled to a reference neutron
count rate rather than time. At Birmingham this is provided by a U235 ssion chamber
located in the front of the dynamitron beam shaping assembly. This is chosen as scaling
reference for several reasons. Firstly dynamitron proton current is not reliably reproducible
and secondly target neutron yield, the number of neutrons produced per incident proton, can
vary between exposures. Using a neutron count reference as opposed to absolute time avoids
any uncertainties introduced by these factors. Similarly dose rates at MIT were scaled to one
of the FCB's monitoring ssion counters. A dose per monitor unit value is therefore arrived
at and multiplied by the recorded monitoring units during the cell radiation exposures.
The MCNP simulation is based on the theoretical yield for the Li(p,n) reaction for a
given proton current. The size of the scaling factor to experimental values is determined by
a number of factors which modify this yield. The target itself consists of a 40 mm diameter
lithium disk on a copper backing. Proton current onto this target is measured by a Keith-
ley electrometer. It was originally envisioned that collimation would constrain the proton
beam to the lithium region and that all current measured would therefore represent protons
impacting the lithium. This has proved not to be the case and often a signicant portion of
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the proton current is wasted on bare copper regions. This was readily observable on a tar-
get removed from the machine. Tests comparing an unrastered beam at low beam currents
showed that yields of  0.07 ssion neutron counts per recorded proton were achievable
compared to typical values of 0.04 for high current, rastered beams. Deterioration of the
lithium target layer is another factor which may account for lower observed experimental
neutron doses. Visual inspection of used targets suggests that this is a small factor with
little observable degradation.
A further independent check of the Birmingham dosimetry has been provided by direct
measurement of the gamma dose component using a Magnesium-Argon ionisation chamber.
This was carried out as a summer project by Turki Alzahrani assisted by Zamir Ghani,
Cecile Wojnecki and the author. Full details are available in Turki Alzahranis's MSc thesis
[172]. Results are shown in gure 4.4 compared to the scaled MCNP predicted values. The
scaling factor was somewhat dierent in this case as these measurements were carried out
after some changes had been made to beam alignment, with a new target. As with the foil
irradiation work there is good agreement between the shape of the experimental gamma
depth dose curve and the MCNP prediction.
The source denition and precise MCNP geometry input deck were unavailable for the
MIT Fission Converter Beam. Instead published results for were used for comparison with
experimental measurements carried out in conjunction will cell measurements. The values
used were presented by Riley et al in reference [173]. The same foil irradiation protocol was
followed as in the Birmingham BNCT beam. Results of the comparison, for an assumed
nitrogen content of 3.4%, are shown in gure 4.5. This value for nitrogen content, equivalent
to muscle [174], was used to match the published MIT calculations. The foil, and cell,
irradiations used for dosimetry in this report were carried out at 3.5 MWt. This is due to the
fact that the irradiations were carried out in the summer, with high ambient temperatures,
and the reactor power was limited by the capacity of its heat exchangers. Two scaling
methods for the 5 MWt reference doses are shown. One was scaled by a simple 3:5
5
factor.
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Figure 4.4: Comparison of gamma ray measurements using a MgAr ionisation chamber with
MCNP predicted values in the BIrmingham BNCT beam. MCNP results are scaled by a factor of
0.68
The other is scaled by comparing the monitoring ssion chamber counts in the two cases. The
dierences can be explained by several factors. The MIT reactor was refuelled, increasing
uxes by 20%, and the FCB beam line was extended by 1cm to allow tment of an
optional Lithium lter [175]. The additional ux from new fuel would be observable in the
ssion monitoring chambers but the reduction in ux at the beam port, from the increased
distance from the source, would not.
A comparison between doses measured independently by the cadmium dierence foil
activation method and the Freudenreich method [171] are shown in gure 4.6. The dose
rates measured by the two methodologies agree within 5% at all depths. Details of the
Freudenreich method are provided in the previous section (page 116 onwards). The cadmium
dierence method relies on measuring neutron activation in gold foils with and without
cadmium shields. The cadmium absorbs neutrons below about 0.5 eV, the two data sets
therefore allow thermal neutron activation to be distinguished from activation by higher
energies.
The beam from the FCB was used at two dose rates for cell irradiations. This was not
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Figure 4.5: 14N depth dose curve for thermal neutrons in the MIT FCB. Dilute foil activation
measurements compared to historical MIT measurements. Historical measurements are scaled to
account for diering reactor power levels
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Figure 4.6: Comparison between 14N depth dose curves measured by two dierent foil activation
methodologies in the MIT FCB beam
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Figure 4.7: Comparison between 14N depth dose curves measured at two dose rates in the MIT
FCB beam. Doses were measured by the Freudenreich method of foil activation. Low dose rate data
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expected to change the ratio of dose components. This was due to the fact that apparent
power of the FCB was controlled via the position of a shutter rather than by directly varying
the reactor power. The equivalence of the thermal dose was checked with a further foil
activation experiment using the Freudenreich method [171]. A comparison between the low
and high dose exposures is shown in gure 4.7. The low dose rate activities were scaled
up by a factor of 13.44, calculated from the ratio of the ssion chamber monitoring counts
recorded for each case. There was excellent agreement between the two experimental data
sets.
Some further correction factors in the calculated dose values to cells were required. All
doses considered so far were calculated and measured by foils at the centre point of the beam
output port. The beam prole at both Birmingham and MIT is not at across the port and
reduces towards the periphery; see gure 4.8 for an illustration of the eect. With 50 mm
width cell growth asks and a 1 2cm beam aperture the non-uniformity is not negligible. In
addition, when considering cells irradiated in asks, the eect of the boronated cell medium
on the neutron ux has to be considered. For the Birmingham beam a modied MCNP le
including the ask geometry was constructed to quantify these eects. The resulting scaling
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Figure 4.8: Collimator cross-plane prole measured for the MIT FCB using a small volume ssion
counter in air. Power levels refer to FCB power; 80kW is equivalent to a reactor power of 4.8MWt.
Data is normalised to 1 at maximum observed intensity in each case. Taken from reference [173].
factors can be seen in table 4.2. In the case of MIT a correction factor for the beam non
uniformity was calculated using the o axis foil activation measurements presented in [173].
Boron perturbation factors were assumed to be the same as in the Birmingham beam.
To derive total doses to cells levels of various neutron capture agents need to be known
in order to scale the thermal neutron dose. In cell culture experiments there is some un-
certainty in the nitrogen, 14N(n; p)14C, contribution. In brain the nitrogen content is well
established at 2.2% [174] . The value for cell lines is less well known. Gabel et al [3] estab-
lished the nitrogen content of V79 cells as 1.7% by weight. DMEM cell culture medium is
approximately 0.9% by weight without additives. The nitrogen content of FBS is unknown
and is likely to vary between batches. There is a further complication in that the range of
the released proton, which delivers the majority of the dose, is 12.8 m or of the order of
one cell diameter in water. This means that the dose to a cell is due both to the nitrogen
inside and in the medium surrounding it. As the nitrogen content of these two regions is
not the same, charged particle equilibrium can not be assumed and accurate determination
of the dose would require a complex microdosimetry calculation. Following the approach of
Mason [73] Gabel et al 's [92] value of 1.7% by weight for V79's was used and an average
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nitrogen content overall of 1.1% was used for dosimetry purposes.
As identical cells were handled similarly at both MIT and Birmingham an exact nitrogen
concentration is not necessarily required for a comparison provided that the same assumed
concentration and methodology is used for both beams. In any case, for cells loaded with
50 ppm 10B, the nitrogen dose is a small contribution to the total at the depths considered.
It is calculated, via the scaled MCNP results, to be less than 3% in all cases.
Typical dose rates per second for each dose component, calculated from scaled MCNP
simulations, in both epithermal beams are shown in table 4.3.
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4.3.2 Monolayer Correction Factors
A further correction factor is required due to irradiating the cells while they are attached
to a surface. As this surface does not contain boron the dose from boron capture reactions
is reduced, something which is not accounted for in a simple uence to boron dose calcula-
tion. Cells in suspension also adopt a dierent shape from cells attached to a surface, with
markedly dierent nuclear areas and thicknesses for ions to traverse.
Experimental and theoretical work in this area has been carried out by Charlton et
al [176]. In their paper they present survival data for V79 cells in both attachment and
suspension surrounded by growth medium containing an alpha emitter (212Bi) in varying
concentrations. This data is replotted in gure 4.9. A model for calculating cell survival,
from previously obtained D0, values is also presented in the paper.
The Charlton et al model [176] relies on a Monte Carlo simulation of alpha particle
traversals of the nucleus to determine a distribution of doses delivered and corresponding
LET's. A look up table of D0 vs LET constructed from historic V79 alpha particle experi-
mental data is then used to determine expected survival.
A similar Monte Carlo model has been implemented in MatLab, by Zamir Ghani, for
boron neutron capture events. Cell size and nuclear area distributions, as shown in gure
4.10, were taken from the work of Hill et al [84]. For these simulations the distributions were
randomly sampled via a table lookup method. Again based on the work of Hill et al, cell
nuclei were taken to have a mean nuclear thickness to cell thickness ration of 0.8; a typical
cell cross section is shown in 4.11.
The Boron capture cross-section is peaked at a very low neutron energy (less than
0.5eV[5]). This means that the initial neutron energy contributes little to the nal en-
ergy of the reaction products, which carry a combined kinetic energy of 2.79 MeV or 2.31
MeV depending on decay mode. This means that, to simplify the calculation, both particles
can be assumed to be emitted 'back to back' and the resulting pair of ion tracks treated as
a single track with varying LET along it's length. This is illustrated in gure 4.12 where
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Figure 4.9: Comparison of cell survival for cells in attachment and suspension in medium con-
taining 212Bi. Data replotted from values in [176]. Fit lines are exponential ts taken from the
paper.
Figure 4.10: Cell area and thickness distributions for attached V79 cells obtained from confocal
microscope images. From reference [84]
Figure 4.11: Electron Microscope image of a sectioned V79 cell from [84]
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Figure 4.12: Back to back particle LET as a function of distance from the boron capture event.
Taken from [168].
tracks of the individual ions have been simulated in TRIM then combined.
To perform dose calculations, random populations of ion tracks are created. Each of
these ion tracks is checked for intersection with simulated cells. The chord length of these
intersections, across the cell nucleus, is calculated. An integral lookup up function is then
used to obtain a value for energy deposited in the cell traversal. The lookup function
consists of the integral of the LET/stopping power distribution of the two particles over
their combined range. The dierence between the entrance and exit `lookup' is equal to the
energy deposited in the cell.
Example results of a simulation comparing absorbed doses in a suspended cell to doses
in one attached to a non-boron containing boundary can be seen in 4.13. The boundary
was dened such that the cell nucleus sat with it's surface 10% of the total cell height away
from the boundary (approximately 0.3 m). The results can be seen converging on a stable
solution as the number of particle histories increases. By comparing the ratio of absorbed
doses with cells attached to a surface and one with cells in suspension a scaling factor for
the boron dose of 0.77  0.05 was derived.
The quoted uncertainty was a statistical error calculated from the Monte Carlo simu-
lation. Further detailed discussions of possible sources of error in these calculations, more
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Figure 4.13: Tally results for mean energy deposited per source particle in two dierent cell
systems. Replotted from [168]
details of the algorithms used and the results of extensive code validation tests can be found
in Chapter 7 of Zamir Ghani's thesis [168].
Direct experimental investigations of these simulations can be found in section 4.7.1 on
page 168.
4.3.3 Dosimetry in the `Radiobiology Phantom'
All cell survival measurements carried out by Anna Mason took place in a non-standard
water phantom [73]. Cell survival measurements for comparison against this work were
carried out in the same phantom. Again, doses to cells were determined by scaling MCNP
values to foil measurements. As irradiations were carried out in small vials, on-axis, no
o-axis or perturbation corrections were used. Conversion factors are shown in 4.4.
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Figure 4.14: Birmingham's Radiobiology phantom
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4.4 Initial Cell Survival Experiments at Birmingham
Initial irradiations using the Birmingham dynamitron were an attempt to reproduce and
expand on work by Anna Mason [73]. Irradiations were carried out inside the `Radiobiology
Phantom' which is unique to Birmingham; see gure 4.14 on page 137. This phantom has
a central rod into which 1.5 ml vials can be inserted at xed depths. This central rod is
rotated via an electric motor, ensuring that cells in solution do not settle and receive an
even dose. The phantom is water lled and has connections for an external circulating water
bath, allowing temperature to be selected across a wide range.
Irradiation takes place through the end of the phantom with the beam orientated along
the long axis. The lines visible in 4.14 are for aligning with the dynamitron beam port.
4.4.1 Comparison With Historic Data
Following the technique described in Anna Mason's thesis [73], V79 cells were introduced
into vials at a concentration of 5105 cells per ml immediately prior to irradiations. They
were then inserted into the RadB phantom. The cells were held at 4C throughout the
irradiations by chilling the water inside the phantom. Post-irradiation the cells were handled
as described in the Cell Survival Studies section on page 30. Results for irradiations at the
3 depths within the phantom are shown in gures 4.15, 4.16 and 4.17. The two data sets
are in good agreement, within experimental uncertainties.
In order for dose rate eects to be seen clearly, it was desirable for irradiations to take
place at 37 C to allow for cell repair during the course of the irradiation. There were
concerns that this would require modication of the irradiation technique. At 4 C there
is very little, or no, cell proliferation but this is clearly not the case at 37 C. To address
concerns that this may cause problems with cells in suspension at high concentrations, a
survival study with unirradiated cells plated out at dierent time intervals was carried out.
This data is presented in gure 4.18.
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Figure 4.15: V79 cell survival at 4C, 20 mm depth in the RadB phantom. 2003 data from [73].
Fitted with the linear quadratic function; values of alpha and beta can be found in table 4.5.
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Figure 4.16: V79 cell survival at 4C, 35 mm depth in the RadB phantom. 2003 data from [73].
Fitted with the linear quadratic function; values of alpha and beta can be found in table 4.5.
It is clear that high concentrations of cells left for long time periods in the irradiation vials
have their survival adversely aected. This is likely due to the cells inability to regulate the
pH of their surroundings and depletion of various vital survival elements within the media.
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Figure 4.17: V79 cell survival at 4C, 50 mm depth in the RadB phantom. 2003 data from [73].
Fitted with the linear quadratic function; values of alpha and beta can be found in table 4.5.
Alpha (Gy 1) Beta (Gy 2
2007 data (this report)
20mm 0.3046  0.0169 -
35mm 0.1898  0.09 0.0275  0.0230
50mm 0.0624  0.093 0.3951  0.0306
2005 data from [73]
20mm 0.1810  0.0278 0.0517  0.0052
35mm 0.1782  0.0275 0.03571  0.0051
50mm 0.1335  0.0334 0.0374  0.0075
Table 4.5: Fitted values in the linear quadratic function for gures 4.15, 4.16 and 4.17. Data
tted is for V79 cells, irradiated at 4 ℃, in the `RadB' phantom using the Birmingham BNCT
beam
With this in mind it was decided that any irradiations at 37 C in this system should
be at a maximum cell concentration of 1105 cells per ml and limited to less than 5 hours
duration.
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Figure 4.18: Survival over time of cells held in suspension in 1.5ml vials. Cells held in normal
growth medium
4.4.2 New Irradiation Phantom Design
It was evident that the previously described Radiobiology Phantom (RadB) had a number of
aws. The limit on cell concentration with the phantom at 37 C, as discussed in the previous
section, imposed a limit on the lowest realistic survival levels which could be investigated.
There is also a signicant dose uncertainty, linked to the position uncertainty of the cells.
This arose both due to the movement of the cells in suspension, across a 5mm diameter
vial, and poor tolerances in the rod holding the vials. As can be seen in gure 4.19 relatively
small changes in cell position can lead to large changes in ux and consequently dose.
In addition to the intrinsic dose uncertainty it introduces, the RadB phantom had a num-
ber of other practical experimental issues. Changeover of cell vials between irradiation runs
was time consuming as it required removal of the bolted on phantom end cap. Inadvertant
damage to, or contamination of, the cell vials was common during changeover due to the
design of the rod retaining them. The phantom was also unique to the Birmingham facility.
With these aws in mind, and the desire to create a simple biological protocol for the inter-
comparison of BNCT facilities, a new cell irradiation set up was designed and constructed.
Rather than a specialised, unique, phantom it was decided that the more standard large
water phantom should be utilised. As pictured in gure 4.1, on page 120, this phantom is a
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Figure 4.19: Thermal and epithermal neutron ux variation with dose in the RadB phantom [169]
large rectangular box constructed of 12 mm perspex, with a thin 5mm thick front window
which matches up with the beam port. This is the phantom design specied in the Petten
dosimetry methods report, followed by many BNCT centres worldwide[165]. It is therefore
likely that most, if not all, BNCT facilities will posses a similar phantom used for beam
dosimetry. Rather than irradiate in vials it was decided to use 25cm2 culture asks. These
allowed for irradiation of a monolayer, not a suspension, and allowed a sucient volume of
medium for the cells to remain healthy over extended time periods. To hold the asks in
position in the phantom a perspex jig was constructed. This was designed to allow quick
changeover of asks between irradiations, allow for irradiation at any depth and to be easily
replicable at any BNCT site. This jig is shown in gure 4.20. This design was proposed as
a suitable design for use in biology intercomparions, by the author, at the 13th International
Congress On Neutron Capture Therapy in 2009.
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Figure 4.20: Jig to hold asks in position inside the large water phantom
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4.5 Biological Comparison of MIT and Birmingham
Treatment Beams
4.5.1 Cell Preparation and Irradiation
The cell preparation prior to irradiation was identical at both sites. Stock V79 cells were
thawed and cultured for a number of days. 48 hours prior to irradiation, 5 x 105 cells in 5 ml
of medium were introduced into standard Corning T25 asks. These were then cultured in a
5% CO2, humid atmosphere at 37
C. 16 hours prior to irradiation the medium was removed
and replaced with medium loaded with 50 ppm 10B using enriched boric acid. Immediately
prior to irradiation the asks were completely lled with this boron loaded medium and the
ask tops replaced with non-lter caps. Two controls for each day of experiments were used
and treated identically to all other dose points. After irradiation the cells were incubated
for 2 hours to allow for repair prior to processing. Flasks were irradiated at two distances
from the beam port simultaneously using the jig shown in gure 4.20. The lowest depth was
selected as it is close to the ideal peak clinical treatment depth. Originally it was intended
that all irradiations would be carried out at 37℃with temperature in the phantom controlled
by an aquarium heater linked to a digital temperature controller. Due to a failure of the
original heating element, the water phantom irradiations were carried out at 34C instead of
37C. The eect on cell repair of this dierence over the course of the irradiations is believed
to be minor. Dose delivered was controlled on a time basis during irradiations and exact
dose calculated later from recorded ssion chamber counts.
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4.6 Results of Biology Comparison
4.6.1 Birmingham
Results of irradiations using the epithermal beam from Birmingham's dynamitron accelera-
tor are shown in gure 4.21. Each point represents a single evaluation, with mean survival
calculated from 5 Petri dishes. Evaluations from the same exposure plated at dierent den-
sities are shown as separate points. Mean total physical dose rate, before o axis corrections,
for these exposures was 0.042 Gy min 1 at 20 mm depth.
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Figure 4.21: V79 cell survival, in the large rectangular phantom, in Birmingham's epithermal
beam. Cells loaded with 50 g per g boric acid. Fit parameters can be found in table 4.6
20mm 50mm
Alpha (Gy 1) 1.226  0.08 1.277  0.10
Beta (Gy 2) - -
Table 4.6: Fit parameters for gure 4.21. V79 survival, loaded with 50 ppm boron, irradiated in
the Birmingham epithermal beam. Fitted with the linear quadratic function
As might be expected from the similar dose component mixes at these depths the survival
response is very similar at both 20 mm and 50 mm. Gabel et al [3] presented survival data
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Alpha (Gy 1) Beta (Gy 2)
Boron capture 1.5  0.15 -
Nitrogen capture 1.29  0.23 -
Photon 0.2332  0.004 0.018  0.0008
Fast neutron 1.18  0.2 -
Table 4.7: Summary of constants used with equation 4.6.1 to produce predicted survival data for
V79 cells in a BNCT beam. Taken from ts to data presented in references [3] and [34]
for V79 cells exposed to various elements of a typical BNCT beam. This data, data from
photon exposures presented in this report and fast neutron survival data from [34] was used
to calculate expected survival using the following equation;
SF = e (pDp+pD
2
p)e (nDn+nD
2
n)e (tDt+tD
2
t )e (BDB+BD
2
B) (4.6.1)
The subscripts refer to the various dose components. p is photon, n is fast neutron, t
is thermal neutron (Nitrogen capture) and B is the dose from the boron capture reaction.
The various constants used are summarised in table 4.7.
A comparison using this methodology is shown in gure 4.22. The survival predicted
from Gabel et al 's work is an excellent match to the 20mm depth data, with the prediction
overlaying the linear quadratic t to the data. The predicted 50mm survival is somewhat
higher than was observed experimentally.
When appropriate fractional doses, from table 4.3 on page 131, and tted constants from
table 4.7 are substituted into equation 4.6.1 it reduces to a linear-quadratic. Values of alpha
and beta for this function are shown in table 4.8.
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Alpha (Gy 1) Beta (Gy 2)
20mm 1.21452  0.11 0.00026  0.0002
50mm 1.13  0.1 0.00246  0.0003
Table 4.8: Values of constants in the linear-quadractic function in mixed elds at two depths, in
the large water phantom, in Birmingham's epithermal beam. Values and uncertainties calculated
from the constants in table 4.7.
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Figure 4.22: V79 cell survival, in the large rectangular phantom, in Birmingham's epithermal
beam. Cells loaded with 50g per g boric acid. Experimental results compared with predictions from
previously published RBE values. Constants used are shown in table 4.7
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Figure 4.23: Comparison of predicted cell kill in Birminghams epithermal beam, with diering
tted values for the photon component. Photon data taken from reference 2.6
The constants for the photon component of the beam, in table 4.7, are taken from cobalt-
60 exposures detailed earlier in this report (Chapter 3). These values are likely to be an
overestimate of cell kill by the photons, as the dose rate the irradiation were delivered at
was 1 Gy min 1 compared to approximately 0.01 Gy min 1 for the photon component in
the epithermal beam. The result of using t parameters from a lower photon dose rate to
predict response is shown in gure 4.23. In this case the photon constants used were taken
from an experiment which exposed V79 cells to 250 kV X-rays at 0.01 Gy min 1 [149]. Due
to the small contribution to total cell kill from the photon component at this boron fraction,
little dierence is seen in overall predicted biological eect.
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4.6.2 MIT
Results of irradiations using the MIT Fission Converter Beam at full output are shown in
gure 4.24. Mean total dose rate, before o axis corrections, at 20 mm depth for these
exposures was 1.788 Gy min 1. Exposures using the MIT FCB at reduced dose rate, of
0.135 Gy min 1 at 20 mm, are shown in gure 4.25.
It is clear that the survival levels are much higher than would be expected for the stated
doses, with RBE's of less than 1 when compared to 250 kV X-rays. This is illustrated
in gure 4.26 where the tted lines from gures 4.24 and 4.25 are plotted alongside 250
kV X-ray survival data. The 50 mm high dose rate data shows the lowest survival of the
groups studied; RBE's for this data are shown in table 4.10. This response suggests a large
systematic error in either the stated doses or the levels of cell survival.
As the plating eciency was low in these experiments, compared to the authors other
work with V79's, this was considered as a possibility to explain this result. It is clear
that it some cases the low plating eciency results in articially high survival, >1 in one
case. Figure 4.27 shows a comparison between two sets of data at the same dose rate and
depth, with dierent plating eciencies. These were 0.27 and 0.56 respectively. Survival is
plotted against irradiation time allowing a comparison regardless of total dose delivered. The
similarity of the two data sets, despite the approximate factor of two dierence in plating
eciency, suggests that plating eciency alone is not responsible for the high survival levels.
Similar results were found comparing plating eciencies within the other data sets.
Incident neutron uxes from the reactor were monitored by a number of independent
ssion counters which, as may be expected in a reactor facility, are frequently checked and
20mm 50mm 20mm low dose rate 50mm low dose rate
Alpha (Gy 1) 0.3090  0.0233 0.3385  0.0270 0.2114  0.0863 0.1539  0.0556
Beta (Gy 2) - 0.0010  0.0060 0.00081  0.0060
Table 4.9: Fitting factors for gures 4.24 and 4.25. Fitted linear quadratic function to survival
data for V79. Doses based on cells loaded with 50ppm boric acid. Irradiations carried out in the
large water phantom.
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Figure 4.24: V79 cell survival, at 20mm depth in the large rectangular phantom, in MIT's ep-
ithermal neutron beam at varying dose rates. Doses based on cells loaded with 50ppm boric acid.
Fit parameters can be found in table 4.9.
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Figure 4.25: V79 cell survival, at 50mm depth in the large rectangular phantom, in MIT's ep-
ithermal neutron beam at varying dose rates. Doses based on cells loaded with 50ppm boric acid.
Fit parameters can be found in table 4.9.
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Figure 4.26: Comparison of 250kV X-ray survival data with ts to experimental data from MIT's
epithermal beam exposures. The 250kV experimental system is detailed in the previous chapter.
MIT ts as in table 4.9
Survival level X-ray dose 50mm, high dose rate dose RBE
0.1 5.42 6.80 0.80
0.01 8.74 13.60 0.64
0.001 11.37 20.41 0.56
Table 4.10: Calculated RBE's for exposures in the MIT epithermal beam, at high dose rate. 50
ppm boron level assumed. Doses calculated from tted curve data presented in table 4.9 and X-ray
curve from table 3.5 on page 78.
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Figure 4.27: V79 cell survival in the large rectangular phantom in MIT's epithermal beam at full
dose rate. Comparison of two data sets with dierent plating eciencies
calibrated. Thermal neutron doses were measured using two standard techniques which, as
described in section 4.3, were in good agreement with each other and showed only minor
dierences from MIT's reference dosimetry.
The most likely explanation for the results therefore lies in the calculated dose values,
specically the dose from boron capture products. Due to export restrictions a dierent
supply of 10B enriched boric acid was used at MIT than at Birmingham and a new stock
solution was prepared in saline. The boric acid dilution is straightforward. 3.08 g of 99%
enriched boric acid, H3BO3, is added to 500 ml of saline to give a 1000 g ml
 1 stock solution.
This is then diluted at 20:1 in complete cell growth medium for use in experiments. It has
hard to see how a dilution error could be introduced. The most likely explanation is thought
to be that the boric acid supplied at MIT was not enriched and instead had the natural
isotope ratio of 19.9% 10B with 80.1% 11B. Unfortunately boron analysis for the cell solutions
was unavailable. All cells were incubated using the same stock solution and therefore can
be assumed to have had the same boron levels. Consequently, all cells would receive the
same physical dose for a given thermal neutron ux. With this in mind the two dose rates
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can still be usefully compared despite the uncertainty over absolute dose levels. Plots of
the data with two axis, representing the two assumed boron concentrations, can be found
in gures 4.28 and 4.29.
A comparison of the survival data, assuming 10 ppm boron, with the published work of
Gabel et al [3] is shown in gures 4.30 and 4.31. Dose rates at this boron level were 0.911
Gy min 1 and 0.067 Gy min 1. Fitted values for this data can be found in table 4.11. As
described in the preceding section, the predicted curves are produced using equation 4.6.1
with values of the constants from table 4.7 on page 146.
4.6.3 Comparison of Data Sets for Diering Dose Rates
To establish if the dierences between survival at the high and low dose rates in the MIT
beam were statistically signicant they were compared using an f-test.
An f-test is normally used to compare two dierent models tted to one data set. The two
models are tted and goodness of t is quantied as the sum of squares of the deviations
of the data points from the model. Complexity of the model is quantied by degrees of
freedom; the number of data points minus the number of parameters t by the model. If
the alternative, more complicated, model is correct the increase in the sum of squares going
from the complex to the simple model is greater than the relative increase in the degrees of
freedom.
In this case the f-test is used to see if the dierences between two sets of data are
statistically signicant. The two data sets and the data combined into a single set are all
tted with the same model. Hence the null hypothesis is that there is no signicant dierence
between the two data sets. The degrees of freedom and sum of squares of the two separate
ts and the combined t are compared as in equation 4.6.2 taken from [122]. This f-test
value, along with the appropriate degrees of freedom, was used to look up a p-value using
Microsoft Excels FDIST command. The resulting values are shown in table 4.12.
This result suggests that there is a signicant dose rate eect at both depths.
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Figure 4.28: V79 cell survival, at 20 mm depth in the large rectangular phantom, in MIT's
epithermal neutron beam at varying dose rates. Doses for two assumed boron levels are shown.
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Figure 4.29: V79 cell survival, at 50 mm depth in the large rectangular phantom, in MIT's
epithermal neutron beam at varying dose rates. Doses for two assumed boron levels are shown.
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Figure 4.30: Comparison between experimental results and calculated values from Gabel et al [3].
10 ppm boron is assumed. Cell data from 20 mm depth in the large water phantom, irradiated
in the FCB. Fitting factors can be found in table 4.11; solid lines indicate weighted ts, dashed
unweighted.
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Figure 4.31: Comparison between experimental results and calculated values from Gabel et al [3].
10 ppm boron is assumed. Cell data from 50 mm depth in the large water phantom, irradiated
in the FCB. Fitting factors can be found in table 4.11; solid lines indicate weighted ts, dashed
unweighted.
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20mm Depth
Alpha (Gy  1) Beta (Gy  2)
Weighted
High dose rate 0.5750  0.0032 0.0448  0.0017
Low dose rate 0.4539  0.2432 0.0132  0.0394
Combined 0.6176  0.1090 0.0156  0.0589
Unweighted
High dose rate 0.8633  0.0032 -
Low dose rate 0.7176  0.0596 -
Combined 0.6480  0.0395 -
50mm Depth
Alpha (Gy  1) Beta (Gy  2)
Weighted
High dose rate 0.7705  0.1468 -
Low dose rate 0.4288  0.0052 -
Combined 0.6176  0.1090 0.0156  0.0589
Unweighted
High dose rate 0.6049  0.2026 0.1055  0.1519
Low dose rate 0.3640  0.1310 0.0040  0.0332
Combined 0.5553  0.1520
Table 4.11: Fitted values to V79 survival data irradiated in the large water phantom using the
MIT FCB. 10ppm boron assumed.
F =
(SSCombined SSSeparate)
(DFCombined DFSeparate)
SSSeparate
DFSeparate
(4.6.2)
Weighted t Unweighted t
20mm 1.22E-04 7.92E-04
50mm 7.54E-05 1.20E-03
Table 4.12: p-values from an f-test comparing the ts to independent high and low dose rate sets
to a t to the pooled data set. The null hypothesis was that there is no signicant dierence between
the ts.
As discussed earlier in this report all curves plotted in this report were tted to the data
sets using OriginPro from OriginLab. In addition to producing a best t, Origin is capable
of calculating condence bands for the t at any given point. A value y, for a condence
level , condence intervals are;
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y^  t
2
(Estimated standard error of y^) (4.6.3)
t
2
is the critical value of the t-distribution.
For a chosen condence level, the condence bands show the limits of all possible tted
lines for the given data. For example, for a chosen 95% level it is possible to say that there
is 95% condence that the best-t line lies within the condence bands[125].
Plots of data from both depths in the phantom is plotted with tted lines and associated
condence intervals in gures 4.32 and 4.33. The 50 mm data shows a signicant dierence
between the two dierent dose rates; the 95% condence intervals do not overlap. The 20
mm data shows no signicant dierence between the tted lines.
The diering conclusions of the two methods of comparing the data sets may be due to
the inuence of `outliers' within the data. With small data sets, the F-test calculation is
very sensitive to such points. As an F test compares the dierence in sum-of-squares with
the dierence expected by chance, it can be skewed if one or both tted data sets have large
dierences from the predicted values for some points. Figure 4.34 shows a plot illustrating
the dierence between observed experimental values and the weighted t value as a fraction
of the observed value. The data shows a number of points where the deviation from the
model is large compared to the recorded experimental errors.
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Figure 4.32: V79 cell survival, at 20 mm depth in the large rectangular phantom, in MIT's
epithermal neutron beam at varying dose rates. 10ppm boron assumed. Solid lines indicate tted
linear quadratic functions; constants as in table 4.11. Dotted lines indicate 95% condence intervals
in the ts.
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Figure 4.33: V79 cell survival, at 50 mm depth in the large rectangular phantom, in MIT's
epithermal neutron beam at varying dose rates. 10ppm boron assumed. Solid lines indicate tted
linear quadratic functions; constants as in table 4.11. Dotted lines indicate 95% condence intervals
in the ts.
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Figure 4.34: Comparison of values predicted by tted linear quadratic functions with experimental
data, at varying depth and dose rate. Survival data for V79 cells irradiated in the MIT epithermal
beam.
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Photon Thermal Neutron Fast Neutron Boron
20mm depth 52.33% 3.63% 4.06% 39.98%
50mm depth 61.38% 3.08% 1.59% 33.95%
Table 4.13: Fractional contributions to physical dose, in the FCB, at 10ppm boron. Percentages
calculated as described in section 4.3 on page 119, from data provided by Zamir Ghani[168]
4.6.4 Comparison With Published V79 Dose Rate Data
V79 cells have a large `shoulder' region in their survival curves when exposed to X-ray
radiation and show a large dose rate eect.
In the classic dose rate eect diering survival levels with dose rate, at a given dose,
are assumed to result from longer irradiation times allowing more sub-lethal damage to be
repaired over the course of the irradiation. High LET radiation is assumed to show no dose
rate eect, as cell kill is dominated by unrepairable damage [177]. In a mixed eld such as
that found in BNCT it may therefore be expected that any dose rate eect is due only to
repair of the photon component. Proportions of the dierent dose fractions are shown in
table 4.13.
As seen in the previous section in gures 4.30 and 4.30 on page 155, the high dose rate
survival data is a good match, when uncertainties are considered, to predictions made from
previously published data when using an acute (1 Gy Min 1) dose rate photon component.
Actual photon dose rates in the FCB were 0.0340.001 Gy Min 1 and 0.45 0.1 Gy Min 1
for the low and high dose rates respectively. Bedford et al [149] presented data for V79 cells
irradiated with cesium-137 gamma rays (661.7 keV) at a wide range of dose rates. Their
data are replotted in gure 4.35.
Predictions of cell survival using ts to Bedford et al 's 0.026 GyMin 1 and 14.2 GyMin 1
data are shown in gures 4.36 and 4.37. All other beam components were modelled using
the constants in table 4.7 on page 146. Modelling methodology was the same as described in
section 4.6.1. As with the higher dose rate photon data, predicted survival is similar to that
observer in the higher dose rate exposures but lower than observed at the low dose rate.
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Figure 4.35: Survival data for V79 cells exposed to gamma rays at varying dose rate. Replotted
from reference [149], ts generated in Origin. Fitted parameters can be found in table 4.14.
Dose/min (Gy) Alpha (Gy  1) Beta (Gy  2)
0.006 0.0794  0.0057 -
0.012 0.1361  0.0077 0.0018  0.003
0.018 0.1327  0.0079 0.0030  0.003
0.026 0.1410  0.0063 0.0038  0.0002
0.045 0.1629  0.0039 0.0039  0.0001
14.2 0.2315  0.0211 0.0068  0.0011
Table 4.14: Parameters tted to the gamma ray survival data of Bedford et al[149], plotted in
gure 4.35
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Figure 4.36: Comparison between experimental results and calculated values. 10 ppm boron is
assumed. Cell data from 20 mm depth in the large water phantom, irradiated in the FCB. Fitting
factors can be found in table 4.11; solid lines indicate weighted ts, dashed unweighted. High and
low dose rate predictions based on combination of photon data from Bedford et al[149] and factors
from table 4.7
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Figure 4.37: Comparison between experimental results and calculated values. 10 ppm boron is
assumed. Cell data from 50 mm depth in the large water phantom, irradiated in the FCB. Fitting
factors can be found in table 4.11; solid lines indicate weighted ts, dashed unweighted. High and
low dose rate predictions based on combination of photon data from Bedford et al[149] and factors
from table 4.7
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20mm Depth
SF 0.37 0.1 0.01
High dose rate 1.54  0.01 Gy 3.20  0.02 Gy 5.58  0.05 Gy
Low dose rate 2.07  1.00 Gy 4.50  2.30 Gy 8.20  4.60 Gy
Ratio 0.74  0.34 0.71  0.35 0.68  0.36
50mm Depth
SF 0.37 0.1 0.01
High dose rate 1.29  0.24 Gy 2.99  0.56 Gy 6.00  1.10 Gy
Low dose rate 2.46  0.02 Gy 5.37  0.07 Gy 10.74  0.13 Gy
Ratio 0.524  0.10 0.56  0.10 Gy 0.56  0.1
Table 4.15: Dose values to produce dierent levels of survival. Calculated from weighted ts to
V79 survival data with 10ppm boron, in the large water phantom, in the MIT FCB
A further comparison can be made to published data by considering the ratio of doses
required to produce a given biological eect between the two dose rates. Table 4.15 shows
the results of this calculation for the MIT FCB exposures. Table 4.16 shows a similar
calculation for the data of Bedford et al. Ratios of (Dose Required)/(Acute Dose Required)
are tabulated to allow comparison between the two dose rate experiments.
These calculations of eect vs dose show clearly that the observed dose rate eect at
20 mm is insignicant; a ratio of (Dose Required)/(Acute Dose Required) of 1 within the
uncertainties at the 95% level. The data from 50 mm depth shows a signicant, and large,
dose rate eect. The photon component has dose rates of 0.034  0.001 Gy Min 1 and 0.45
0.1 Gy Min 1 at this boron level. Comparing the observed eect with that of the photon
dose rate eect quantied by Bedford et al, the reduction in cell kill at low dose rate is
greater than would be expected even if all of the physical dose components were repairable
to the same degree as photons.
A nal useful comparison can be made using Mitchell et al 's data. Their lowest dose
rate exposure, at 0.006 Gy Min 1, can be assumed to be the upper limit of repair for low
LET radiation. That is, all repairable sub-lethal damage can be assumed to be repaired in
this case. Therefore, using the t for this data as the constants for the photon component
in 4.6.1 gives a predicted response for a combined irradiation where all possible repair of
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SF 0.37 0.1 0.01
Dose/min
0.006 12.52  0.89 29.00  2.1 58.10  4.10
0.012 6.72  0.33 14.26  0.64 25.40  1.10
0.018 6.53  0.31 13.34  0.56 22.90  0.91
0.026 6.06  0.21 12.25  0.35 20.85  0.52
0.045 5.40  0.10 11.14  0.18 19.29  0.28
14.2 3.86  0.29 8.05  0.54 14.08  0.86
Table 4.16: Dose values to produce dierent levels of survival. Calculated from weighted ts to
data taken from Bedford et al[149]. V79 cells irradiated with Cs-133 gamma rays.
SF 0.37 0.1 0.01
Dose/min
0.006 0.310  0.030 0.278  0.027 0.243  0.023
0.012 0.574  0.051 0.565  0.045 0.554  0.041
0.018 0.591  0.052 0.603  0.048 0.615  0.045
0.026 0.637  0.053 0.657  0.053 0.675  0.045
0.045 0.715  0.055 0.723  0.050 0.730  0.046
14.2 1 1 1
Table 4.17: Ratios of (Dose Required)/(Acute Dose Required) for table 4.16
the sub-lethal photon component has taken place. As can be seen from gure 4.38, higher
cell kill is predicted than was observed experimentally. This result suggests that a dose rate
eect is present in the other beam components.
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Figure 4.38: Comparison of V79 survival at 50 mm depth, 10 ppm boron with predictions from
equation 4.6.1. Photon component used is based on very low dose rate data from reference 2.6. All
other components as table 4.7. Solid lines indicate ts from Origin of the LQ function, dotted lines
indicate 95% condence bounds.
4.7 Summary
Survival values found at Birmingham, when irradiating v79 cells with 50ppm boron in an
epithermal beam, are a reasonable match within uncertainties to survival values predicted
from previous cell biology work. Despite the low overall dose rate of 0.042 Gy min 1 at
20mm, this good agreement was found without any allowance for the dose rate eect. This
result suggests that any dose rate eect at this boron concentration is insignicant in the
dose range investigated.
A large systematic error appears to be present in survival results recorded at MIT. The
most likely explanation is that actual boron-10 concentrations in the cell system were lower
than planned. Data has therefore been analysed assuming a boron-10 concentration of 10
ppm. When irradiating cells in the FCB, a dose rate eect was observed at both depths
within the water phantom. However, a large spread in experimental cell survival observed
means that the dierence in tted response was only signicant at 50mm depth.
Comparisons with previously published results suggest that the overall dose rate eect
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observed is too large to be explained solely by the eect on the low LET, photon, component.
This result holds even when the conventional maximum amount of sub-lethal repair in the
photon component is assumed. This implies that some degree of dose rate eect is present
in the higher LET components of the beam.
How the mix of beam components eects the level of eect is not clear. There is a
dierent mixture of components at 20 mm and 50 mm but a comparison between the two is
confounded by the fact that cell survival at the two depths is not signicantly dierent, as
shown in gures 4.39 and 4.40.
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Figure 4.39: V79 cell survival at varying depths in the large water phantom, in the MIT FCB
beam. Full beam dose rate. 10 ppm boron assumed. Solid lines are ts of the LQ function, dashed
lines are the 95% condence intervals for the ts.
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Figure 4.40: V79 cell survival at varying depths in the large water phantom, in the MIT FCB
beam. Reduced beam dose rate. 10 ppm boron assumed. Solid lines are ts of the LQ function,
dashed lines are the 95% condence intervals for the ts.
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4.7.1 Biological Quantication of the Dose Reduction in Attached
Cells
A complication of the large water phantom irradiation rig, when comparing to previous
work, is that with the cells in attachment they are no longer surrounded on all sides by
medium. For work with boron loaded medium this suggests that there is a reduction in the
dose due to boron capture products. In order to quantify the dose reduction eect a series
of cell survival experiments were carried out. These utilised sealable, 0.9 m Mylar based,
glass dishes as shown in gure 4.43. The products of the 10B neutron capture reaction lose
their energy extremely quickly in Mylar but should still deliver a signicant fraction of dose
through a 0.9 m layer. Energies for the boron capture reaction products after passing
through 0.9 m mylar are shown in gures 4.41 and 4.42. These plots were produced by
simulating 105 particles propagating through a layer of ICRU-222 standard Mylar, H8C10O4
using SRIM [72].
A similar protocol to the Birmingham and MIT ask irradiations was followed. 48 hours
prior to irradiation 2 x 105 V79 cells were introduced into the dishes in 2 ml of complete
growth medium, leading to the growth of a cell monolayer on the Mylar base. 16 hours prior
to irradiation the medium was removed and replaced with medium loaded to 50 ppm with
99% 10B enriched boric acid. Immediately prior to irradiation, a second dish without a base
was attached to each of the dishes in which cells had been cultured. Referring to gure 4.43
the `single sided' dishes, equivalent to ask irradiations, had region A lled with boronated
medium and region B lled with normal medium. The `double sided' dishes had both regions
A and B lled with borated medium. The gassing ports, shown sealed with rubber hose,
were not used in this experiment. The samples were then attached in pairs to Perspex rods
to hold them in place at a xed depth of 20 mm within the large water phantom. These were
then irradiated, the Mylar cut out, and the cells cultured in the normal way for a survival
study. Results are shown in table 4.18.
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Figure 4.41: Simulation of the energy spread of 1.47 MeV alpha particles after they have passed
through a 0.9 m mylar layer. Produced using SRIM[72]
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Figure 4.42: Simulation of the energy spread of 0.84 MeV lithium ions after they have passed
through a 0.9 m mylar layer. Produced using SRIM[72]
Single sided Double sided
45 minutes exposure time 0.220  0.003 0.122  0.008
30 minutes exposure time 0.247  0.020 0.153  0.007
Table 4.18: Cell survival fractions from irradiation of V79s, in Birminghams BNCT beam, with
single and double sided boron loading. Data from two separate experimental evaluations
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Figure 4.43: `Jellysh' dishes. Cells were cultivated on the A side of the mylar layer. In `two
sided' irradiations A and B contained borated medium. In `single sided' irradiations A contained
borated medium, B contained normal medium. The gassing ports were not used in this experiment
and were sealed with rubber hose.
Doses in the `jellysh dishes for this experiment were not known precisely at the time of
writing. The necessary MCNP calculation to convert ssion chamber monitor units to dose
at the cell layer had not been carried out. Assuming that the dose response is similar to
that delivered to T25 asks irradiated in the same system allows a useful comparison. Boron
doses required to produce the survival levels shown in table 4.18 were calculated using the
tting data from the T25 ask irradiations described in section 4.6.1. The constants used
were  = 1:226  0:08 , = 0. Solving the linear quadratic tting function for dose, with
 = 0 gives;
Dose =
ln( 1
S
)

(4.7.1)
Where S is survival. Doses calculated this way are shown in table 4.19.
Single sided dose (Gy 1) Double sided dose (Gy 2) Ratio of Single/Double
45 minutes 1.235  0.081 1.72  0.12 0.72  0.07
30 minutes 1.141  0.099 1.53  0.15 0.75  0.1
Table 4.19: Doses estimated from surviving fractions detailed in table 4.18 for two dierent
exposure times
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Monte Carlo calculations carried out by Zamir Ghani [168], detailed in section 4.3.2 on
page 132, suggested a boron dose reduction of 0.77  0.05 for cells in attachment. While
this agrees with the estimated experimental dose reduction, it is important to note that
the data presented here represent a single experimental observation and that the required
dosimetry to fully interpret the results has not been completed.
Further modelling and experimental work in the `jellysh' system is ongoing.
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Chapter 5
CONCLUSIONS
Work presented in this thesis has covered two main areas of radiobiology relevant to BNCT.
The rst was an investigation into synergistic eects when radiations of diering LET are
delivered simultaneously to cells. Previously published work with high LET ions and photons
is inconsistent regarding both degree of synergistic eect and whether any synergistic eect
is seen at all.
A series of experiments were carried out, using a newly constructed irradiation jig built
for the purpose, exposing V79 cells to mixed elds of photons and 238Pu alpha particles.
The motivation was to repeat and extend previous work carried out by McNally et al in a
similar system [1]. Initial exposure using varying doses of alpha particles and 60Co photons
delivered simultaneously found no dierences from a purely additive prediction, based on
the elds given separately. The same result was seen with 2.54 Gy of alpha particles given
simultaneously with X-rays. In the case of a mixed eld with an alpha dose of 3.18 Gy
a signicant synergistic eect was seen, with lower levels of cell survival than would be
expected from the same elds given separately. The level of alpha dose at which McNally et
al observed synergy was lower, with signicant eects being seen with both 2 Gy and 2.5Gy
of alpha particles. The level of synergy eect seen in McNally et al 's results, as a deviation
from predicted survival, was similar to that observed with 3.18Gy of alphas in the present
study. At higher low-LET fractions (>60%) McNally et al observed a larger eect.
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Some published attempts to model synergistic interactions were compared to both Mc-
Nally et al 's and the recent data. It was found that the Zaider-Rossi model [89], using
constants from single eld exposures, was a good t to the data exhibiting synergy but pre-
dicted higher cell kill at the lower alpha dose than was seen experimentally. The same model
was a poor t to McNally et al 's data when the single eld constants were used. When a
non-zero beta constant, based on low LET data, was used the model tted McNally mixed
exposures with 0.5 Gy and 2 Gy of alphas well. Lower cell survival than modelled was seen
in the mixed exposure with 2.5Gy of alphas. Use of the extended Zaider-Rossi model [145]
and the lesion-additively model [155] produced similar results, with no model tting either
data set well at all dose levels.
The second area of uncertainty in BNCT investigated in this report was the dose rate
eect. This is well characterised in single eld, low LET, exposures but not in the mixed
elds encountered in BNCT. A series of experiments were carried out in the MIT FCB at
two dose rates diering by a factor of approximately 15. Cells were exposed at two depths,
20 mm and 50 mm, in a full scatter water phantom. A dierence in response at both of the
two dose rates was observed but was only clearly signicant at the 50 mm depth. Analysis of
the results was complicated by the fact that a large systematic error, thought to be related
to boron-10 concentration, appeared to be present in the results. Analysis, with an assumed
boron-10 concentration of 10 ppm, with reference to previous published work with individual
beam components suggests that the magnitude of the dose rate observed was too large to
be explained solely by a dierence in response of the low LET component.
Further experiments in the Birmingham BNCT beam at 50 ppm boron produced cell
survival levels well matched to predictions based on previous published cell culture work.
The potential impact of these ndings can be explored in the context of clinical BNCT.
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5.1 BNCT Treatment Planning
Treatment planning in BNCT is not a straightforward process. Simplications in computa-
tional approach which are useful in conventional photon therapy and which have historically
been applied in fast neutron therapy are of little use. This is due to the high dependence
of delivered dose on the exact scattering and transport of low energy neutrons [178]. Re-
cent approaches have focussed on probabilistic, Monte Carlo, methods of solving the dose
distribution problem.
Ultimately treatment plans in BNCT are dependent on a number of assumptions and
biologically derived values which have some signicant uncertainties. The rst is that the
boron distribution within various tissues and ultimately within cells must be known with
precision. Historically when calculating eect of boron doses clinically it has been assumed
that boron is distributed uniformly in a tissue of a given type. This has been demonstrated to
be a awed assumption by using various techniques to directly examine boron distribution
in patients. These include positron emission topography (PET) with 18F labelled BPA
[179] and, at a cellular level, Secondary Ion Mass Spectrometry (SIMS) imaging of tumour
explants [180]. The other major assumption, related to the work presented in this report, is
in determining the relative biological eect of the various BNCT dose components.
To determine a treatment dose conversion from a physical absorbed dose, as calculated
by MCNP or similar, and a weighted dose is required. For comparison to standard radiother-
apy this has been handled in BNCT clinical trials via a conversion to 'photon-equivalent-
dose'[181], nominally the dose of photons required to produce the same clinical eect. This
is calculated as;
Dw = (d DRF ) + (dn RBEn) + (dN RBEN) + (10B  CBE) (5.1.1)
Where d, dn and dN are the doses of gamma rays, fast neutrons and nitrogen capture
protons respectively. DRF is the, dose rate dependent, dose reduction factor for photons
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and CBE is the compound biological eectiveness. CBE, as discussed earlier in this report,
is derived from the RBE of the alpha and lithium particles along with the micro distribution
of boron. Historically xed values for the various RBE's have been used.
5.1.1 Impact of Dose Reduction Factor
The DRF factor, in the photon term in equation 5.1.1, is incorporated to account for the
fact that the gamma dose rate in most BNCT treatment beams is considerably lower than
1Gy min 1. This means that, with long exposure times, cell repair is not insignicant.
Rather than direct calculation this factor is arrived at via a somewhat ad hoc methodology
of looking at photon exposures in various in vitro experiments and estimating a level of
reduction in eect on cell survival. For some typical BNCT beams this factor has been
taken as approximately 0.7 [68]. In the MIT FCB it was assumed to be 1, due to the acute
gamma dose rate. Perhaps the factor most applicable to Birminghams Dynamitron beam
would be the one used for early work in the MIT M67 beam, due to their similar gamma
dose rates [182]. This factor was estimated as 0.5, justied by reference to Hall et al 's work
with HeLa cells [183]. It is important to note however, that this 0.5 factor used for the M67
beam was derived with reference to cell data showing dose reduction factors of between 0.3
and 0.7. Dose reduction factors in other beams have similar uncertainties associated with
their derivation.
Typical assumed clinical boron levels, with BPA, are 65g 1 for tumour and 18 g 1
for normal brain tissue. Typical weighting factors are RBEs of 1.0 for photons and 3.2 for
neutrons, CBEs of 1.35 for boron in brain and 3.8 in tumour [173]. These factors can be
used to explore the impact of varying the DRF on doses delivered. Figure 5.1 is a plot of the
Birmingham accelerator beam weighted depth dose curve, in brain, with dierent assumed
values of the DRF. To calculate the impact of this in BNCT treatments, typical BNCT
treatment doses have to be considered.
Maximum BNCT treatment doses are calculated based on dose delivered to healthy brain.
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Figure 5.1: Calculated depth dose curve for the Birmingham beam with dierent assumed values
of the photon Dose Reduction Factor.
Healthy brain radiation tolerance depends on the volume of brain irradiated along with the
dose delivered. Widely quoted tolerance values are taken from Emami et al [184] and are
presented in table 5.1. Any BNCT treatments are likely to be delivered either in a single
fraction or a small number of large fractions. Doses in conventional photon radiotherapy are
instead delivered in a number of smaller doses, typically 2 Gy per treatment. To make use of
the values in 5.1 in BNCT, reference can be made to Biological Eective Dose (BED). The
BED is derived from the linear quadratic function and essentially represents the physical
dose required to produce a given eect if the dose were to be delivered by innitely small
doses per fraction or if the dose were delivered at an extremely low dose rate [185];
BED = nd[1 +
d
(=)
] (5.1.2)
Where n is the number of fractions and d is the dose per fraction. The  /  ratio is
specic to the tissue being considered and gives a measure of repair capacity. As the same
BED in a given tissue type can be achieved through dierent fractionation schedules, the
normal tissue tolerance doses from [184] can be converted to a `single fraction equivalent'
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Volume of brain irradiated TD5=5 (Gy) TD50=5 (Gy)
1/3 60 75
2/3 50 65
3/3 45 60
Table 5.1: Values for healthy brain radiation tolerance taken from [184]. TD5=5 and TD50=5 are
the total doses (TD) producing 5% or 50% incidence of necrosis within 5 years.
for BNCT by setting the BED's as equal, that is;
nPhotondPhoton[1 +
dPhoton
(=)
] = nBNCTdBNCT [1 +
dBNCT
(=)
] (5.1.3)
nPhoton and dPhoton are the number of fractions and dose per fraction. nBNCT and dBNCT
are the number of BNCT fractions and the photon-equivalent BNCT dose per fraction.
Following the approach of Coderre et al [69], the alpha/beta ratio for brain is assumed to
be 2Gy based on the work in reference [186]. This gives an equivalent single fraction dose
for the 1/3 brain TD5=5 quoted in table 5.1 of 14.5 Gy. The equivalent for 3/3 brain TD5=5
is 11.6 Gy.
While this derivation of applicable clinical doses in BNCT is somewhat simplistic, as-
suming this 11.6 Gy-Eq single fraction dose is indicative of a maximum dose that would
be delivered to the healthy brain in BNCT allows the impact on dose delivered, of various
DRF's and other factors, to be explored. In reality the dose prole to healthy brain in
BNCT is extremely complex and varies between patients. To simplify calculations for the
purposes of comparison it is assumed that all dose to tumour is delivered at a xed depth
(32.5mm), and that all dose to healthy tissue is delivered at close to the dose peak (20mm).
This tumour depth was chosen with reference to a recent audit of typical high grade glioma
locations [187] and the healthy tissue depth was chosen as a representative `worst case'.
Using the data from gure 5.1 with the maximum healthy tissue photon-equivalent dose
of 11.6 Gy, and no photon DRF, gives a treatment time of 136 minutes. Dose to tumour
would be 58.7 Gy-Eq. The same treatment time but with a DRF of 0.5 only delivers a
healthy tissue dose of 9.87 Gy-Eq and a tumour dose of 56.9 Gy-Eq. This approximately
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Figure 5.2: V79 cell survival, at 50mm depth in the large rectangular phantom, in MIT's epither-
mal neutron beam at varying dose rates. 10ppm boron assumed. Solid lines indicate tted linear
quadratic functions; constants as in table 4.11 on page 156.
15% shift in healthy tissue dose with DRF, for the same treatment time, suggests that
caution needs to be exercised when applying this factor in treatment planning to avoid
under or over dosing patients. The proportional shift in tumour dose is much smaller, due
to the majority of the weighted dose being contributed by the high-LET components. This
implies that a conservative estimate of the degree of dose rate sparing may be clinically
justiable, as the impact on the therapeutic dose of under-estimation is minor.
The in vitro dose rate work presented in chapter 4 suggests that the dose rate eect seen
in BNCT exposures at low boron concentrations is larger than can be explained solely by
changes in response to the photon component. The tted V79 cell survival curves, at 50
mm depth, are reproduced in gure 5.2. If it assumed that this degree of cell sparing at low
dose will be similar in healthy brain, then these gures can be used to predict the `high dose
rate equivalent' of a dose delivered at low dose rate. The cell responses seen in 5.2 have a
negligible beta component in the LQ t, so for an equivalent biological eect we can write;
LDRDLDR = HDRDHDR (5.1.4)
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Where LDR is the  constant for the low dose rate exposure, DLDR is the dose for the
low dose rate exposure. HDR is the  constant for the high dose rate exposure, DHDR is
the dose for the high dose rate exposure. Solving for DHDR gives;
DHDR =
LDRDLDR
HDR
(5.1.5)
Using the values of LDR=0.4288 and HDR=0.7705 from gure 5.2 and a DLDR of 11.6
Gy-Eq allows us to calculate that giving the maximum healthy tissue dose at low dose rate
is equivalent to giving only 6.5 Gy-Eq at high dose rate. Irradiations at 50 ppm of boron-10
were only carried out at a single, low, dose rate. However, results at this low dose rate
matched predictions from previous cell work, with individual dose components, at high dose
rate. It can therefore be inferred that any dose rate eect at this high boron concentration is
negligible. Consequently the dose to tumour, at low dose rate, would remain at 58.7 Gy-Eq.
These two results raise the possibility that delivering BNCT treatments at low overall
dose rates could have a signicant clinical advantage, with a approximate doubling of the
tumour dose being possible for the same eect on healthy tissue.
The dose rate results presented here are a small data set and have some signicant
issues. The most serious is the uncertainty over the apparent large error in the survival
responses obtained at MIT. With this in mind, drawing rm conclusions is dicult. Future
experiments are likely to use Birmingham's beam, when available, at varying dose rates and
boron concentrations. Initial determinations will essentially repeat the MIT low dose rate
exposures, with 10 ppm of boron-10.
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5.1.2 Impact of Synergistic Eects
To date it has been assumed that the various dose components of diering LET act inde-
pendently; there is no interaction term in equation 5.1.1. The data presented earlier in this
report, along with the historical ndings of McNally et al [1] demonstrate that this is not
always a valid assumption. Irradiation with high and low LET radiation simultaneously can
have a greater eect than is expected from the same doses, of the same radiation, given in-
dependently. The problem is how to treat this in the context of BNCT treatment planning.
Hopewell et al [68] suggest approaching the problem by considering the synergistic eect as
an increase in RBE of the photon component, in the same way the dose rate is treated as
an eective decrease. This may not reect the physical mechanism of the synergistic eect
but it provides a convenient methodology to introduce a synergistic factor. Establishing the
size of this `Dose Enhancement Factor' (DEF) to account for synergy is not straightforward.
It is clear both from the results presented here and by McNally et al [1] that the factor is
dierent at dierent dose levels. This is further emphasised by the failure of Barendsen et
al [38] to observe a synergistic eect at low alpha particle doses.
Despite the dierences between the data for synergistic eects presented by McNally et
al [1] and the data presented here there are enough similarities for some speculative conclu-
sions about impact in BNCT to be drawn. McNally et al showed a strong synergistic eect
with combined 2.5 Gy alpha particle and photon exposures. The more recent data shows a
strong eect with 3.18 Gy of alpha particles and photons. Despite the diering alpha doses
the level of eect, as a fraction of expected survival, seen in the two studies was similar
when the low-LET component of the exposure made up approximately 60% or less of the
total physical dose.
The data for the X-ray only data and the mixed 3.18 Gy plus X-ray curves presented
in section 3.6.2 can be used to calculate values of the DEF for varying mixes. Figure 5.3
shows a plot of the X-ray data vs a curve generated by dividing the mixed eld data by the
corresponding alpha particle only surviving fraction. DEF at any given endpoint can then
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Figure 5.3: Comparison of mixed eld results with 3.18 Gy of alpha particles plus X-rays with
X-ray single eld data. Mixed eld data has been divided by the equivalent alpha particle only,
single eld, survival. The dierence between the curves is therefore the synergistic `enhancement'
eect.
be calculated from the values plotted in this curve, in a similar manner to RBE, that is;
DEF =
X   ray dose
Mixed field X   ray dose (5.1.6)
For the purposes of comparison, a DEF was calculated as a function of low-LET fraction
rather than absolute dose. The DEF at every point in the depth-dose curve could then be
introduced into equation 5.1.1;
Dw = (d DRF DEF ) + (dn RBEn) + (dN RBEN) + (10B  CBE) (5.1.7)
As in the DRF example, a depth dose curve accounting for synergy can then be produced.
DEF at 20 mm depth with 18 ppm of boron was calculated as 1.73. The 11.6 Gy-eq for
healthy tissue, as calculated earlier, therefore becomes 14.2 Gy-eq once synergy is accounted
for. DEF at 32.5 mm depth with 62.5 ppm boron is calculated as 2.12, the corresponding
tumour dose is 62.6 Gy-eq. DRF was assumed to be unity.
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Figure 5.4: Calculated depth dose curve for the Birmingham beam with a synergistic eect assumed
and no dose rate eect
It is unclear how directly applicable the synergy factors used to generate gure 5.4 would
be in a clinical BNCT situation. Implicit in this calculation of DEF is the assumption that
the degree of synergy seen is dependant on the fractions of the dierent LET components
rather than the absolute dose. Both the present study and McNally et al found that the
amount of synergistic eect appeared to vary signicantly with total high LET dose and this
has not been accounted for in the calculations presented. Investigating clinically relevant
high LET doses to tumour, in mixed elds, in cell culture experiments has large practical dif-
culties due to the low survival levels involved. Rather than directly comparable exposures,
more fundamental work understanding the mechanism of synergy will need to be carried
out. Clinical dose strategies can then be based on more sophisticated models informed by
this work.
5.1.3 RBE of High LET Components
Further complications are introduced by the proton and fast neutron dose components. The
RBE of neutrons can vary signicantly with neutron energy, from 1.7 to as high as 6 [188].
Despite this, equivalent dose calculations for BNCT where fast neutron dose is considered as
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the fast neutron component.
a separate factor have tended to use a xed neutron RBE. Similarly proton RBE has been
shown to vary in the approximate range of 1 to 3, depending on energy, by Belli et al [189].
In treatment planning this dose is often combined with the fast neutron dose as a grouped
high LET beam component with a single xed RBE. This is considered a not unreasonable
simplication as the high LET component is generally only of the order of 2 or 3% of the
total physical dose in irradiations where clinically relevant levels of boron are present.
The impact of these RBE uncertainties can be seen in gure 5.5, where the fast neutron
components of the dose have been assigned an RBE of 6.
A further potential uncertainty lies in the use of xed RBE's for all dose components
when deriving photon equivalent doses. As discussed in section 2.1.2, a given RBE is only
valid for a xed dose; RBE decreases as dose is increased. This consideration also applies
to CBE. The widely used CBE value of 3.8 in tumour, quoted in this section and used for
comparison, was taken as an average from experiments described in [94] where CBE was
derived at in vivo survival levels of 0.1, 0.01 and 0.001. Corresponding CBE's were 4, 3.8
and 3.6. The small variation was due to the near linearity of the X-ray curve at these
survival levels. As the doses used were relevant to single dose clinical levels (>10Gy-eq),
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and BNCT tends to be delivered in a single large fraction, it has been assumed that using
a xed average of these values is a reasonable assumption [30].
If a dierent fractionation schedule for BNCT is adopted then uncertainties from the use
of xed RBE's and CBE's will become more of a concern. It is possible that modications of
the BED concept, intended for use in high LET therapy, may be of use in addressing these
issues [190].
5.2 Summary
Based on the work presented in this thesis, both dose rate and synergistic interactions can
make a signicant dierence to the biological eect of a given dose delivered by a BNCT
beam.
In BNCT treatment planning to date dose rate has been treated only via an approximate
factor introduced into the photon component when calculating total photon equivalent dose
delivered. The cell culture work carried out at MIT and presented here demonstrates that
this may lead to an underestimate of the degree of dose rate sparing, particularly in healthy
tissue. Caution needs to be exercised when interpreting this result due to uncertainties
over absolute doses delivered in the MIT beam. However, it is clear that further work is
warranted in this area.
Synergistic interactions have been demonstrated in mixed X-ray and alpha particle elds,
with lower cell survival observed than predicted from individual components. This is im-
portant in BNCT as, if similar levels of interaction are seen in BNCT mixed elds, photon-
equivalent doses change signicantly. There is evidence both from the work presented here
and from previously published work [1][38] that the amount of synergistic eect seen varies
according to high LET dose. There also appears to be a dependance on exact cell growth
conditions.
In general the mechanism of synergy is poorly understood, although recent work on
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DNA damage response in mixed elds is beginning to shed some light on the processes
involved [163]. Direct measurements to quantify synergy in vitro at the high doses involved
in therapy are impractical. Better models to account for the synergistic eect therefore need
to be developed. Simple models to t mixed eld survival data of the type proposed by
Zaider and Rossi [112] are not adequate in isolation for predicting the outcome of mixed
eld exposures. While they provide good ts to some data exhibiting a synergistic eect,
other data is tted poorly. Some improvement can be made through diering treatments of
the constants used but a more complex approach is probably necessary.
Work with track structure models such as LEM has been incorporated into carbon ion
treatment planning codes successfully [191]. Similar models with dose rate and synergy
eects accounted for may be the correct approach for BNCT. Such models will need to be
informed by considerable amounts of further fundamental biology work.
The data presented in this report emphasises the fact that radiobiology in a BNCT
environment is not straightforward. Translation of clinical experiences between facilities,
whether in planning or analysis of outcomes, requires reference to detailed biological work
at both sites. It has been demonstrated that, due to synergistic and dose rare eects, RBE's
calculated for one beam should not be simplistically transferred to another.
5.3 Future Work
Funding has been allocated under the Knowledge Transfer Secondment(KTS) scheme for
a series of experiments that will build on the work presented in this report. The project
will be lead by the Professor of Neurosurgery and involve cooperation with several clinical
scientists based at University Hospital Birmingham. Tissue samples will be acquired during
the surgical debulking of patient tumours. An identical procedure to that used in prior
drug uptake studies[59] will be followed, with a number of small samples being acquired
simultaneously using a side cutting needle. Ethical approval to store and carry out a study
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with patient samples has already been granted (REC reference 05/Q2704/61).
Once samples have been obtained they will be prepared for tissue culture and incubated.
In parallel with this, other samples will be tested for expression of the large neutral amino
acid transporter (LAT1). It is believed from the work published by the Birmingham group
in Cancer Research in 2009[59] that cellular uptake of the candidate drug for BNCT, boron
phenylalanine (BPA), is highly dependent on LAT1 expression.
The bulk tumour samples will be incubated in BPA concentrations which are realistic
for human treatments, and will then receive clinically relevant doses of neutrons. Samples
prepared in parallel will be irradiated with X-rays using the standard hospital radiotherapy
machines. A nal group will receive X-ray irradiation and a `boost' dose of neutrons. This
group is representative of our proposed patient treatment methodology. Damage to the
tumour cells will be evaluated using a H2Ax stain to identify double strand DNA breaks,
following the methodology of Merz et al.
In parallel with this work survival studies will be carried out using cells from the M059K
and M059J cell lines, which are derived from humour tumours.
A study such as this, with greater eect shown in a human tumour system than existing
treatment, is a necessity for clinical trials at Birmingham to proceed. With a suciently
comprehensive in vitro study, with bulk tumour samples, an in vivo animal study will not
be necessary to show ecacy. With recent renovation of the dynamitron completed, and
appropriate medical expertise in place, an eectiveness comparison study remains the last
signicant obstacle to phase one patient trials beginning within the next few years.
Further work will also be carried out using the `jellysh' dish system described on page
168. A comprehensive dose-survival curve for single and double sided boron loading will be
constructed and compared to simulations.
To reduce patient treatment times signicant dynamitron upgrades are planned to in-
crease usable proton beam current from 1mA to 5mA or more. This will require an upgrade
of the target cooling system, currently limited to removing 6kW of heat continuously. A
186
redesign and implementation of a new, modern, ion source is also required. In parallel with
these machine upgrades the beam monitoring and closely related safety systems will be com-
prehensive overhauled and modernised. This involves rewriting the monitoring software in
the latest version of LabView from National Instruments. Outdated data acquisition cards
have been replaced with newer equivalents and the target monitoring thermocouples have
been checked and overhauled.
Once beam upgrades are complete survival experiments similar to those at MIT can be
carried out at a range of dose rates and boron concentrations. This will provide further
valuable data on the dose rate eect in BNCT treatment beams.
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5.4 Publications and presentations arising from this
project
Experimental work detailed in this report has been presented at the Young BNCT investi-
gators meetings at Birmingham in 2007 and Mainz in 2009, where it received an award for
best poster. It was also presented at the Associated for Radiation Research annual meeting
in 2008. A paper was submitted and data presented at the 13th International Congress
for Neutron Capure Therapy, 2008, which received the Fairchild Award. This paper was
published in [192]. Further data was presented at the 14th ICNCT in 2010.
Papers detailing the X-ray, alpha mixed eld work and the BNCT dose rate eect work
are being prepared for publication.
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Appendix A
FORTRAN CHI SQUARED MINIMISATION
PROGRAM
Chi square tting arrives at t parameters by nding values that minimise the value of the
Chi squared statistic;
2 = wi
nX
i=1
yi   ytih (A.0.1)
This chi squared function has a parabolic shape around it's minimum value, as shown in
gure A.1. A FORTRAN program was written which solves for the value of the minimum
of such a parabola.
The program was adapted from one previously written by the author to t a double
exponential to a radioactive decay curve.
program new
implicit none
integer i,j,k,ic/0/,direction/-1/,z
double precision time(500),cnts(500),err(500),line(3),
&test(500),chi(3),chibest,a,inca,
&b,l1,l2,doexp,t/0/,abest,bbest,l1best,l2best,
&incl1,incb,incl2,change/1e10/,dochi,hold(2),
&vary(3),chinew/0/,prev/1e10/
real multi,inc/1/,tolerance
character name*16,choice*1
logical check/.true./,firstloop/.true./,ndone/.true./,
&nfinished/.true./,failed/.false./
C**********************************************************************
C Program body
c**********************************************************************
c get the data file name and load the values into arrays (using getdata
c subroutine)
21 write(6,666)
70 write(6,*) 'Please enter the data file name'
write(6,*) '(including extension, e.g. myfile.csv)'
i
Figure A.1: Plot showing the shape of the Chi squared function around a minimum.
write(6,*)
write(6,*) 'All files must be in comma delimited format.'
write(6,*) '(The example data is stored in data.csv)'
read(*,'(a)',err=70) name
inquire(file=name,exist=check)
if(check) then
call getdata(name,time,cnts,err,ic,failed)
else
write(6,*) 'File does not exist'
goto 70
endif
if(failed) stop
c we went round the loop one too many times so array element=ic is empty
c and we need to discard it
ic=ic-1
c Setup of initial values for increment and 'best' variables
c includes a call to guess subroutine to initialise A,B,lambda1,lambda2
c with sensible starting values
call guess(a,b,l1,l2,cnts,time,ic)
abest=a
bbest=b
l1best=l1
l2best=l2
inca=a/100
incb=b/100
incl1=l1/100
incl2=l2/100
do 40 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
40 continue
chibest=chinew
write(6,666)
write(6,*) 'Initial values:'
write(6,*)'A=',a
write(6,*)'B=',b
write(6,*)'l1=',l1
write(6,*)'l2=',l2
write(6,*)'Initial chi=',chibest
write(6,*)
write(6,*)
c read in the tolerance value - this controls how many times the program loops
90 write(6,*)'Please enter % change to stop iterating at'
write(6,*)'A value of 0.1 is recommended'
read(*,*,err=90) tolerance
ii
if(tolerance.le.0) goto 90
tolerance=tolerance/100
c ********************Iteration loops block starts here***********************
c outer loop ends at 999
do 999,while(nfinished)
c Loop to find parameter A
chinew=0
do 41 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
41 continue
chibest=chinew
c Work out direction of decreasing chi squared
inca=inca*inc
do 2 z=1,2
chinew=0
do 1 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
1 continue
if(chinew.gt.chibest) direction=direction*(-1)
a=a+(inca*direction)
2 continue
inca=inca*direction
c Loop adds increments until chi increases
do 4, while(ndone)
chibest=chinew
chinew=0
do 3 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
3 continue
c Keeps 3 most recent chi squares
hold(1)=chi(2)
hold(2)=chi(3)
chi(3)=chinew
chi(2)=hold(2)
chi(1)=hold(1)
c Find the parabola minimum if there's a chi increase
if(chinew.gt.chibest) then
abest=a-(inca*(((chi(3)-chi(2))/((( chi(3)-
& (2*chi(2)))+chi(1))+0.5))))
ndone=.false.
endif
a=a+inca
4 continue
a=abest
ndone=.true.
chinew=0
c Loop to find parameter B
c set chibest to appropriate (i.e. lowest so far!) value
do 43 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
43 continue
chibest=chinew
c Work out direction of decreasing chi squared
incb=incb*inc
do 6 z=1,2
chinew=0
do 5 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
iii
5 continue
if(chinew.gt.chibest) direction=direction*(-1)
b=b+(incb*direction)
6 continue
incb=incb*direction
c Loop adds increments until chi increases
do 8, while(ndone)
chibest=chinew
chinew=0
do 7 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
7 continue
c Keeps 3 most recent chi squares
hold(1)=chi(2)
hold(2)=chi(3)
chi(3)=chinew
chi(2)=hold(2)
chi(1)=hold(1)
c Find the parabola minimum if there's a chi increase
if(chinew.gt.chibest) then
bbest=b-(incb*(((chi(3)-chi(2))/((( chi(3)-
& (2*chi(2)))+chi(1))+0.5))))
ndone=.false.
endif
b=b+incb
8 continue
b=bbest
ndone=.true.
chinew=0
c Loop to find parameter l1
do 44 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
44 continue
chibest=chinew
c Work out direction of decreasing chi squared
incl1=incl1*inc
do 10 z=1,2
chinew=0
do 9 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
9 continue
if(chinew.gt.chibest) direction=direction*(-1)
l1=l1+(incl1*direction)
10 continue
incl1=incl1*direction
c Loop adds increments until chi increases
do 12, while(ndone)
chibest=chinew
chinew=0
do 11 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
11 continue
c Keeps 3 most recent chi squares
hold(1)=chi(2)
hold(2)=chi(3)
chi(3)=chinew
chi(2)=hold(2)
chi(1)=hold(1)
c Find the parabola minimum if there's a chi increase
if(chinew.gt.chibest) then
l1best=l1-(incl1*(((chi(3)-chi(2))/((( chi(3)-
& (2*chi(2)))+chi(1))+0.5))))
ndone=.false.
endif
iv
l1=l1+incl1
12 continue
l1=l1best
ndone=.true.
chinew=0
c Loop to find parameter l2
do 45 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
45 continue
chibest=chinew
c Work out direction of decreasing chi squared
incl2=incl2*inc
do 14 z=1,2
chinew=0
do 13 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
13 continue
if(chinew.gt.chibest) direction=direction*(-1)
l2=l2+(incl2*direction)
14 continue
incl2=incl2*direction
c Loop adds increments until chi increases
do 16, while(ndone)
chibest=chinew
chinew=0
do 15 k=1,ic
t=time(k)
test(k)=doexp(a,b,l1,l2,t)
chinew=chinew+dochi(test(k),cnts(k),err(k))
15 continue
c Keeps 3 most recent chi squares
hold(1)=chi(2)
hold(2)=chi(3)
chi(3)=chinew
chi(2)=hold(2)
chi(1)=hold(1)
c Find the parabola minimum if there's a chi increase
if(chinew.gt.chibest) then
l2best=l2-(incl2*(((chi(3)-chi(2))/((( chi(3)-
& (2*chi(2)))+chi(1))+0.5))))
ndone=.false.
endif
l2=l2+incl2
16 continue
l2=l2best
ndone=.true.
chinew=0
c decide whether or not to stop looping
change=(prev-chibest)*(100/prev)
if((change.lt.tolerance).and.(change.gt.0)) nfinished=.false.
c this IF statement introduced to combat 'overshooting':
c program tended to get close to optimal value then start increasing chi again.
c I think because of the way previous chi values are stored in the chi array.
c This IF reduces the a incrementing variable until the prog is back on track
if(change.lt.0) then
inc=inc/2
else
inc=1
endif
prev=chibest
999 continue
v
c Write out the results to screen
write(6,*) 'A=',abest
write(6,*) 'Lambda1=',l1best
write(6,*) 'B=',bbest
write(6,*) 'Lambda2=',l2best
write(6,*)'Sum of Chi squared=',chibest
write(6,*)'Chi squared=',(chibest/(ic-4))
write(6,*)
91 write(6,*)'Write results to file?(y/n)'
read(*,601,err=91) choice
if((choice.eq.'y').or.(choice.eq.'Y'))
&call writeout(abest,bbest,l1best,l2best,chibest,ic)
c format statements
601 format(a1)
666 format(///////////////////////////////////////////)
end
c**************************************************************
c START OF FUNCTIONS AND SUBROUTINES
c**************************************************************
c Subroutine to load in the data
c recieves the name variable which contains the filename to be read
c passes back time,cnts,err arrays, ic (number of elements) and failed
c which informs of failed data read
subroutine getdata(name,time,cnts,err,ic,failed)
double precision time(500),cnts(500),err(500),line(3)
integer ic
character name*16
logical failed
open(1,file=name,status='old',err=10)
rewind(1)
do
write(6,*) ic
ic=ic+1
read(1,50,end=20,err=10) line
time(ic)=line(1)
cnts(ic)=line(2)
err(ic)=line(3)
end do
20 close(1)
return
50 format(g12.0,g12.0,g12.0)
write(6,*)
10 write(6,*) 'Something file related is broken!'
write(6,*) 'Most likely, that file is not of the correct'
write(6,*) 'format or is corrupt.'
write(6,*)
write(6,*) 'Failing gracefully(ish).....'
write(6,*)
failed=.true.
end
c**************************************************************
c Function we're using to fit
c takes a,b,l1,l2 for a given value of t
c returns a value for that point
double precision function doexp(a,b,l1,l2,t)
double precision a,b,l1,l2,t
doexp=(a*exp(-l1*t))+(b*exp(-l2*t^2))
return
end
c**************************************************************
c Subroutine to 'guess' starting values
c recieves the cnts,time arrays and ic
c l1 and l2 are set equal to the half life
c A is set to the starting value of counts
c B is set (fairly arbitrarily) to 1/2 A
subroutine guess(a,b,l1,l2,cnts,time,ic)
double precision time(20),cnts(20),a,b,l1,l2
integer i,ic
logical unset/.true./
a=cnts(1)
b=a/2
do 99 i=1,ic
if((cnts(i).le.b).and.(unset)) then
write(*,*) cnts(i),b
vi
unset=.false.
l1=0.693/time(i+1)
write(*,*) time(i+1)
endif
99 continue
l2=l1
return
end
c****************************************************************
c Chi calculation function
c calculates a single chi^2 value from given t,c,e
double precision function dochi(t,c,e)
double precision t,c,e
dochi=((t-c)**2)/(e**2)
return
end
c****************************************************************
c Subroutine to write out the data
c takes in all calculated variables, doesn't return anything
subroutine writeout(abest,bbest,l1best,l2best,chibest,ic)
double precision abest,bbest,l1best,l2best,chibest
character name*12
logical check/.false./
75 write(6,*)'Enter file name:'
write(6,*)'(12 characters maximum)'
read(*,*) name
inquire(file=name,exist=check)
if(check) then
write(*,*) 'Sorry, file exists already'
goto 75
endif
open(2,file=name,status='new',err=76)
rewind(2)
write(2,*) 'A=',abest
write(2,*) 'Lambda1=',l1best
write(2,*) 'B=',bbest
write(2,*) 'Lambda2=',l2best
write(2,*)'Sum of Chi squared=',chibest
write(2,*)'Chi squared=',(chibest/(ic-4))
close(1)
return
76 write(*,*) 'Something file related is broken!'
end
vii
Appendix B
MIXED GAMMA RAY AND ALPHA PARTICLE
CELL SURVIVAL DATA
Data from the mixed eld exposures using the cobalt-60 source are shown in the table
overleaf. Each tabulated survival value represents the mean count from ve Petri dishes.
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Appendix C
MIXED X-RAY AND ALPHA PARTICLE CELL
SURVIVAL DATA
Data for the mixed eld exposures using the X-ray source are presented overleaf. Each
tabulated survival value corresponds to the mean count from ve petri dishes.
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Appendix D
BIRMINGHAM NEUTRON BEAM CELL
SURVIVAL DATA
The data for cells irradiated using the Birmingham dynamitron neutron beam are presented
in this section. All irradiations were carried out with cells loaded with 50g per gram
enriched boric acid. Data for two depths inside the full scatter water phantom are presented;
20mm and 50mm. All survival values represent the mean count from ve petri dishes.
Quoted doses are the combined physical, unweighted, doses from all components.
xii
Plating eciency 0.52 0.06
20mm Depth
Total Physical Dose [Gy] SF Uncertaintity in SF
0.45 1.00E+00 4.00E-02
0.55 3.12E-01 1.84E-02
0.71 3.01E-01 1.46E-02
0.74 1.83E-01 2.04E-02
0.86 2.25E-01 1.78E-02
0.87 2.08E-01 4.95E-03
0.88 1.99E-01 9.79E-02
1.95 4.29E-02 1.84E-02
2.23 3.80E-02 5.11E-03
3.09 4.01E-02 7.50E-03
3.41 2.04E-02 5.79E-04
50mm Depth
Total Physical Dose [Gy] SF Uncertaintity in SF
0.27 4.01E-01 1.08E-02
0.52 4.32E-01 5.39E-02
0.54 2.86E-01 5.43E-02
0.54 3.79E-01 3.73E-02
1.32 1.75E-01 5.53E-03
1.55 2.07E-01 1.87E-02
1.83 8.80E-02 4.04E-03
2.49 4.75E-02 5.95E-03
Table D.1: Birmingham neutron beam cell survival data, cells loaded with 50g per gram enriched
boric acid
xiii
Appendix E
MIT NEUTRON BEAM CELL SURVIVAL DATA
The data for cells irradiated using the MIT FCB, at two dose rates, are presented in this
section. Data for two depths inside the full scatter water phantom, 20mm and 50mm.
Quoted doses are the combined physical, unweighted, doses from all components at the
stated boron level.
Raw data is included for plating eciency comparisons.
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